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Summary 
T cell receptor (TCR) gene therapy is a new therapy for cancer which showed first clinical success but 
at the same time risk factors evolved. After TCR gene transfer the endogenous TCR is simultaneously 
expressed with the transgenic TCR. This can have several consequences. First, the expression and 
functionality of the transferred TCR might be diminished due to competition with the endogenous 
TCR for cell surface expression. Second, the TCR chains can mispair with each other which would lead 
to TCRs with unknown specificities and to a reduced expression and functionality of the transferred 
TCR. Both aspects were analyzed in the first part of this thesis. To do that, dual TCR T cells were 
generated with the particularity that one TCR was inducible in its expression by a doxycycline (Dox)-
regulated vector. First, the TCR expression was characterized in single TCR T cell clones either 
harboring the lymphochoriomeningitis virus-specific P14 TCR or the ovalbumin-specific OT-I TCR. The 
TCR expression was shown to be dependent on the Dox concentration. In dual TCR T cell clones, the 
endogenous TCR (either P14 or OT-I TCR) was constitutively expressed. After induction of second TCR 
expression, the endogenous TCR was still detectable on the cell surface. The induced TCR gained 
functionality whereas the endogenous TCR lost it. One reason was the lower expression level of the 
endogenous TCR. Another reason was the mispairing of TCR chains which was detected by 
fluorescence resonance energy transfer (FRET) technique. The endogenous P14 TCR reduced its 
pairing when the OT-I expression was induced which was not the case for the endogenous OT-I TCR, 
but mispaired TCR dimers were detected in both cell clones. Recently, it was shown that a second 
cysteine bridge in the constant region of the TCR might lead to preferable pairing. Therefore, a 
second cysteine bridge was introduced in the P14 TCR, but no clear benefit could be detected in two 
cell clones in regard of mispairing of TCR chains and functionality of the modified TCR. To assure that 
the observation was not limited to the cell clones, primary OT-I T cells and wild-type T cells were 
analyzed for cysteine-modified TCR expression. In wild-type cells, a tendency but not a significantly 
difference in mispairing could be observed between TCRs with a cysteine bridge or without. 
The second analyzed possible side effect of TCR gene therapy is the insertional mutagenesis by the 
retroviral vector. The vector integration can modify the expression of surrounding genes. So far, 
gene-modified T cells did not show malignant outgrowth in clinical trials. The safety of differentiated 
T cells for TCR gene therapy was analyzed in an animal model. T cell transfer was combined with a 
repetitive stimulation to provide the opportunity for mutations to occur and manifest during cell 
division. OT-I TCR transgenic T cells were transduced with the P14 TCR and were transferred into 
lymphodepleted mice. Recipient mice were pretreated either with 200 mg/kg cyclophosphamide in 
the first experiment or with 100 mg/kg in the second one. The higher dose cyclophosphamide led to 
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toxicity in nine out of 20 animals which could be reduced with the lower dose to three out of 30 
mice. Transferred T cells were regularly stimulated either with P14 or OT-I TCR-specific peptide in the 
first experiment or with a P14 TCR antigen-positive tumor cell line in both experiments. Peptide 
stimulation provided a stronger stimulus, but at the same time kept the transferred T cells on a lower 
level compared to tumor cell stimulation or without a stimulus. Over time, transferred T cells 
increased dramatically in the CD8 T cell compartment of recipient mice, but did not lead to T cell 
lymphomas. The proliferative capacity and the function of transferred T cells were confirmed at the 
end of the experiments after a year or later. The polyclonality of vector integrations could be 
confirmed in peripheral blood of recipient mice of the first experiment by linear amplification-
mediated polymerase-chain reaction (LAM-PCR). As control, one group received green fluorescence 
protein (GFP)-transduced OT-I T cells and a high dose of lymphodepletion. Beside the 
cycloposphamide-related toxicity in three mice no malignancies were observed in the surviving nine 
mice. Also in this experiment, the transferred T cell enriched over time without stimulation. In 
conclusion, TCR gene-modified T cell transfer did not lead to outgrowth of mutated T cell clones even 
not with a repetitive stimulation, but the preconditioning can cause severe side effects. 
Keywords: T cell receptor (TCR), Gene therapy, Regulated TCR expression, TCR mispairing, Insertional 
mutagenesis 
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Zusammenfassung 
T-Zellrezeptor (TZR)-Gentherapie zeigte erste Erfolge in klinischen Studien, jedoch wurden 
gleichzeitig Risikofaktoren deutlich. Nach TZR-Gentransfer wird der endogene TZR ebenfalls 
exprimiert. Das kann verschiedene Konsequenzen haben. Erstens kann die Expression und 
Funktionalität des transferierten TZRs durch die Konkurrenz mit dem endogenen TZR um die 
Oberflächenexpression beeinträchtigt sein. Zweitens können die TZR-Ketten miteinander falsch 
paaren, was zu TZRs mit einer unbekannten Spezifität und zu einer verminderten 
Oberflächenexpression sowie Funktionalität des transgenen TZRs führen würde. Beide Aspekte 
wurden in dem ersten Teil der Arbeit untersucht. Dafür wurden T-Zellen mit zwei TZRs generiert mit 
der Besonderheit, dass die Expression des einen TZRs durch einen Doxicyclin (Dox)-regulierten Vektor 
induzierbar war. Zuerst wurde die Induzierbarkeit der einzelnen TZR-Expression des lmyphozytären 
Choriomeningitis-Virus-spezifischen P14 TZRs oder des Ovalbumin-spezifischen OT-I TZRs untersucht. 
Die TZR-Expression war abhängig von der Dox-Konzentration. In T-Zellkonen mit zwei TZRs wurde der 
endogene TZR (entweder P14 oder OT-I TZR) konstitutiv exprimiert. Nach Induktion der TZR-
Expression blieb der endogene TZR auf der Oberfläche. Während der induzierte TZR Funktionalität 
zeigte, verlor der endogene diese. Ein Grund war das reduzierte Expressionslevel auf der T-
Zelloberfläche. Ein anderer Grund war das falsche Paaren der TZR-Ketten, das mit Hilfe der 
Fluoreszenz-Resonanz-Energietransfer- (FRET-) Technik in beiden T-Zellkonen detektierbar war. 
Zudem verringerte der endogene P14 TZR, jedoch nicht der endogene OT-I TZR, seine 
Paarungseffizienz nach Induktion der Expression des zweiten TZRs. Kürzlich wurde gezeigt, dass eine 
zweite Cystein-Brücke in der konstanten Region des TZRs zu einer besseren TZR-Kettenpaarung führt. 
Deshalb wurde eine Cystein-Brücke in den P14 TZR eingebaut, jedoch führte dies nicht zu einem 
Vorteil in zwei analysierten Zellklonen bezüglich der Falschpaarung und der Funktionalität. Um sicher 
zu gehen, dass die Beobachtung nicht auf die Zellklone beschränkt war, wurden auch primäre OT-I T-
Zellen sowie Wildtyp-T-Zellen analysiert. In den Wildtyp-T-Zellen konnte eine Tendenz aber keine 
signifikanter Unterschied zwischen TZRs mit oder ohne Cystein-Brücke jedoch nach weiterer Codon-
Optimierung beobachtet werden. 
Der zweite untersuchte Risikofaktor der TZR-Gentherapie ist die Insertionsmutagenese durch den 
retroviralen Vektor. Die Vektorintegration kann die Expression der umliegenden Gene beeinflussen. 
Gen-modifizierten T-Zellen zeigten bisher kein malignes Wachstum in klinischen Studien. Die sichere 
Verwendbarkeit von differenzierten T-Zellen für die TZR-Gentherapie wurde in einem Tiermodel, in 
dem T-Zelltransfer mit wiederholter Stimulierung der T-Zellen kombiniert wurde, analysiert. Die 
Stimulierung sollte die Mutationsrate durch Zellteilung erhöhen. Transgene OT-I T-Zellen wurden mit 
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dem P14 TZR transduziert und in lymphodepletierte Mäuse transferiert. Die Empfängermäuse 
wurden entweder mit 200 mg/kg in dem ersten oder mit 100 mg/kg Cyclophosphamid in dem 
zweiten Experiment behandelt. Die hohe Dosis führte zur Toxizität in neun von 20 Tieren, die mit der 
niedrigeren Dosis reduziert werden konnte (drei von 30 Tieren). Transferierte T-Zellen wurden 
regelmäßig mit P14- oder OT-I TZR-spezifischen Peptiden in dem ersten oder mit einer P14 TZR-
Antigen-positiven Tumorzelllinie in beiden Experimenten stimuliert. Die Peptidstimulierung gab einen 
stärkeren Stimulus als die Tumorzellstimulierung, jedoch blieben die transferierten T-Zellen auf 
einem geringeren Level als mit der Tumorzellstimulierung oder ohne eine Stimulierung. Im Laufe der 
Zeit reicherten sich die transferierten T-Zellen in dem CD8-T-Zellkompartiment der Tiere dramatisch 
an, aber entwickelten sich nicht zu T-Zelllymphomen. Die Proliferationskapazität und die 
Funktionalität der transferierten T-Zellen wurden nach einem Jahr oder später bestätigt. Mit Hilfe der 
linear-amplifizierten Polymerasekettenreaktion konnte die Polyklonalität der Vektorintegrationen in 
peripherem Blut von Tieren des ersten Experimentes detektiert werden. Als Kontrolle wurden OT-I T-
Zellen, transduziert mit dem grün-fluoreszierenden Protein (GFP), in Mäuse mit starker 
Lymphodepletion transferiert. Neben der Cyclophosphamid-zugeschriebenen Toxizität in drei 
Mäusen wurde in den überlebenden neun Mäusen keine Malignität beobachtet. Auch hier reicherten 
sich die transferierten T-Zellen ohne Stimulierung an. Es wurde gezeigt, dass TZR-gen-modifizierte T-
Zellen auch nicht durch wiederholte Stimulierung malignes Wachstum aufweisen, jedoch kann die 
Lymphodepletion zu schweren Nebenwirkungen führen. 
Schlagwörter: T‐Zellrezeptor (TZR), Gentherapie, Regulierte TZR‐Expression, TZR‐Kettenpaarung, 
Insertionsmutagenese
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1. INTRODUCTION 
1.1 T CELL BIOLOGY 
T lymphocytes beside B lymphocytes are responsible for the adaptive immunity. T cells recognize 
infected cells or cells which have taken up pathogens by the presentation of fragmented foreign 
protein via peptides loaded by major histocompatibility complexes (MHC) on the cell surface of the 
antigen-presenting cells (APCs). MHC class I molecules are specialized to present peptides originating 
from the cytosol like viral peptides to CD8 T lymphocytes, so called cytotoxic T cells (CTLs) [1,2]. This 
subtype of T cells is specialized to kill virus-infected cells and tumor cells by lysis and cytokine 
secretion. MHC class II molecules present peptides of proteins from intracellular vesicles to CD4 T 
cells which are referred to mostly as helper T cells [3,4]. 
1.1.1 FUNCTION OF T CELLS- FOCUS ON CD8 T CELLS 
Naive T cells migrate through the peripheral blood and lymphoid organs. In the lymph nodes they can 
encounter APCs like mature dendritic cells (DCs), macrophages or B cells. Upon binding of the T cell 
receptor (TCR) and co-receptor CD4 or CD8 to the peptide-MHC, a signal is delivered into the cells. 
For the acquirement of full effector functions and expansion of mature CD4 [5] and CD8 [6] T cells a 
prolonged contact to 3-10 peptide-MHC of APCs and a synapse formation is needed [7]. 
Beside this first signal a second one has to be provided by a co-stimulatory molecule. The strongest 
co-stimulatory effect is given by B7 molecules (B7.1 and B7.2) on the APC which bind to the CD28 
molecule on the T cell. Only with the co-stimulatory signal the T cell is activated without becoming 
anergic. The activated cell enters the cell cycle and produces interleukin-2 (IL-2) and the high-affinity 
version of the IL-2 receptor which boosts the intense IL-2-driven proliferation. Once activated, the T 
cell does not need a co-stimulatory signal when encountering the antigen a second time. Upon 
stimulation a T cell undergoes multiple rounds of cell division and can multiply by 50000 in a week 
[8]. During the expansion time T cells acquire effector functions like cytolytic properties and 
secretion of cytokines. The activated T cell can migrate into infected tissue due to chemotaxis and 
changed adhesion molecule surface expression on the T cell and on tissue cells. The contact to the 
target cell induces a clustering of TCRs, co-receptors and adhesion molecules which is called 
supramolecular adhesion complex (SMAC) [9,10,11]. The SMAC induces a change in the cytoskeleton 
of the T cells which leads to the release of effector molecules at the contact site. The CD8 T cells can 
be bound to several target cells but kills each cell at once after organization of the SMAC. Effector 
molecules for CD8 T cells are cytotoxic molecules like perforin, granzymes, granulysin and FAS ligand 
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as well as cytokines like interferon (IFN)-, tumor necrosis factor (TNF) -α and -β. These molecules are 
produced when a naive T cells sees its antigen the first time and are stored thereafter in lytic 
granules. The effector T cell produces more cytotoxic molecules and cytokines when it encounters 
the antigen again [12]. The successful stimulation of antigen-specific T cells is dependent on co-
signals provided by the inflammatory environment caused by the infection. The TCR avidity 
determines the composition of the resulting effector cell population with high avidity T cells 
presenting the highest numbers. IL-12, type I IFN and IL-2 play an important role for the effector and 
memory cell development. A single antigen encounter is sufficient to drive the differentiation into 
effector and memory T cells but the extent of T cell expansion is dependent on the inflammatory 
signals. The recruitment of CD8 T cells already occurs after 6 - 24 hours (h) after antigen exposure [8]. 
After the expansion and effector phase, most T cells die and few (5 - 10 %) remain and develop into 
memory T cells which provide a life-long protection against the pathogen or related ones. How the 
differentiation exactly takes place is still subject of debate. During the effector phase it is suggested 
that short-lived effector cells can be differentiated from precursor memory effector cells by 
expression of natural killer cell receptors like KLRG1 and IL-7 receptor, respectively [8]. Fully 
differentiated memory T cells can be further differentiated into central and effector memory T cells. 
Central memory T cells are commonly located in lymphoid organs and show strong proliferation upon 
re-exposure to the antigen. Effector memory T cells are mainly located in the peripheral tissue and 
respond immediately with cytokine release upon antigenic restimulation [13]. As shown by Stemberg 
et al. a single T cell can develop into central and effector memory T cells [14]. The memory T cell 
compartment directed against one pathogen is not limited in size but can grow with subsequent 
infections although with some loss of previous immunity provided by effector memory T cells [15]. 
1.1.2 STRUCTURE OF THE T CELL RECEPTOR COMPLEX 
T cells harbor around 40000 TCR molecules on their surface [16]. In the majority of T cells the TCR 
molecules consist of two polypeptides, TCR and TCR chain, which form a heterodimer (Figure 1) 
[17]. Few T cells harbor a TCR consisting of a TCR and TCR chain. In structure the extracellular 
domains of a TCR resembles a Fab fragment of an antibody with a variable immunoglobulin (Ig)-like 
region (v and v) at the N-terminus and a constant Ig-like domain (c and c) region at the C-
terminus. The variable regions are further divided into complementary determining regions (CDR) 1 
to CDR3. CDR1 and 2 are responsible for the binding to the MHC molecule and CDR3 is responsible 
for the peptide-binding. The TCR and  chains are linked by a disulfide bond in the constant region. 
The constant region is followed by a hydrophobic transmembrane region and a short cytoplasmic 
part. Carbohydrates are attached to each variable and constant region which provide hydrogen 
bonds with the other chain. 
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The TCR complex comes to the cell surface together with the CD3 complex which consists of CD3, 
CD3 and two CD3 chains. A homodimer of the CD3 chain is associated intracellular [18]. The CD3, 
 and  proteins have an Ig-like domain in the extracellular part and a single immunoreceptor 
tyrosine-based activation motif called ITAM in the intracellular part. The ITAM can be phosphorylated 
twice by receptor-associated tyrosine kinases of the Src family and can be bound by other tyrosine 
kinases upon phosphorylation. The CD3 protein has only a very short extracellular domain and 
harbors three ITAMs in the intracellular part which are important for TCR signaling. 
The co-receptors CD4 and CD8 stabilize the recognition by binding to the corresponding MHC. The 
sensitivity of CD4 and CD8 T cells is increased by 100-fold by co-receptor-binding to the MHC since 
both co-receptors interact with the tyrosine kinase Lck which enhances the TCR signaling. Whereas 
the CD4 molecule is a monomer comprising of four domains (D1-D4), CD8 is composed of a 
heterodimer of an  and a  chain. Beside the heterodimers also homodimers of the CD8 chains are 
found whose function remain under debate [19]. 
 
Figure 1 Schematic picture of the T cell receptor complex 
TCRα and β chains are depicted in blue, CD3 components in red, the co-receptors CD8 in green and CD4 in 
orange. Both TCR chains are composed of a variable region, a constant region, a hinge with a disulfide bond, a 
transmembrane region and a cytoplasmic tail. Blue diamonds represent carbohydrates bound to TCR chains. 
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The CD3 complex is composed of two , one , one  and two  chains. The intracellular CD3 chains are 
associated with the transmembrane and cytoplasmic domains of the TCR. The CD4 co-receptor is a monomer 
consisting of domains 1-4 (D1-D4). The co-receptor CD8 is composed of an α and a β chain which comprise both 
an extracellular domain, transmembrane region and a cytoplasmic tail. Horizontal lines show disulfide bonds in 
the CD8 receptor, in the TCR and between CD3 chains. Circles with minus and plus signs show charges of 
amino acid residues in the polypeptides. ITAMs are shown in yellow. (Adapted from [20]). 
1.1.3 T CELL DEVELOPMENT 
The diversity of TCR molecules arises from somatic gene rearrangement which is carried out by 
recombination proteins encoded by recombination-activating genes 1 and 2 (RAG-1 and RAG-2) in 
the thymus [21]. TCR gene rearrangement and gene organization resembles that of 
immunoglobulins. The TCR locus consists of V and J gene segments whereas the locus of TCR 
contains additionally D segments. The rearrangement of the TCRand  locus leads to a diversity of 
104 TCRs. The possible TCR output is further increased up to theoretical 1015 TCR combinations by 
adding N-nucleotides and P-nucleotides in the junctional CDR3 regions of TCR and TCR. Practical a 
diversity of 106 - 108 is estimated [22]. 
Precursor T lymphocytes are generated in the bone marrow and migrate into the thymus where they 
further develop (Figure 2). The thymus is organized into two zones: the inner medulla and the outer 
cortex. In both zones specialized epithelial cells, bone-marrow-derived macrophages and dendritic 
cells (DCs) are present. Double-negative (DN) thymocytes which do not express a TCR or a co-
receptor migrate by chemokine signals from the cortico-medullary junction to the outer cortex 
region, the subcapsular zone (SCZ). They start to recombine the TCR locus with the combination of 
D with J gene segments and afterwards that of V and DJ gene segments. Only successful 
rearranged TCR chain will lead to further T cell development. The TCR chain protein is synthesized 
and delivered to the cell surface with an invariant pre-TCR chain and the CD3 complex. TCR signals 
lead to up-regulation of both co-receptors CD4 and CD8 (double-positive (DP) thymocytes). After an 
intense cell expansion, the recombination of the TCR chain locus is started with the combination of 
V and J gene segments. With the fully rearranged and expressed TCR the DP T cells interact with 
peptide-MHC of epithelial cells, first in the cortex later in the medulla. Upon encounter with a 
peptide-MHC of a cortical epithelial cell (TEC) the DP thymocytes are positively selected for proper 
self-MHC molecule binding. A second encounter with a positively selecting TEC is needed for the DP 
thymocytes to further maturate [23,24]. If correctly activated, they maturate to single-positive (SP) 
cells by down-regulation of one of the co-receptors dependent on the type of peptide-MHC 
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encounter they have made. Upon inappropriate binding with high affinity to self-MHC the TCR signal 
leads to apoptosis [25,26]. 
 
Figure 2 T cells mature in the thymus 
Different stages of thymocytes development are shown. The thymus consists of different specialized zones: the 
medulla and the cortex. The T cell progenitors enter the thymus through cortico-medullary junction (CMJ). In 
the cortex and the subcapsular zone (SCZ) they encounter thymic epithelial cortical (TEC), subcapsular (TES) 
cell, macrophages and DCs (not all cell types are shown). In the medulla specialized thymic medullary epithelilal 
(TEM) cells are found. DN, DP, SP: double-negative, -positive, single-positive thymocyte. Picture adapted and 
simplified from [27]. 
DP thymocytes which do not encounter APCs and do not receive positively selecting signals also die 
in the cortex. During the maturation process of positively selected thymocytes the up-regulation of 
the chemokine molecule CCR7 directs them into the medulla [28,29]. The autoimmune regulator 
AIRE is expressed in medullary epithelial cells which leads to expression of tissue proteins [30]. Tissue 
antigens can be presented and tolerance is achieved against these antigens. Also few DCs from the 
skin and blood come to the border of the cortex and medulla in the thymus to present peptides [31]. 
By the described cells, most auto-reactive T cells are deleted. During the positive selection in the 
cortex and the negative selection in the medulla 95 % of the thymocytes die [32,33]. In the periphery, 
naive T cells are kept alive due to low-affinity interaction with self-peptides presented by self-MHCs 
[34]. 
1.2 ADOPTIVE T CELL THERAPY 
Early observations of Ehrlich gave hints that the immune system can provide protection from cancer 
[35]. After inbred mouse strains were available, tumor transplantation experiments were done and 
showed T cell-mediated tumor rejection. The idea of adoptive T cell therapy is based on experiments 
showing that the immunity towards a tumor could be transferred by using the splenocytes of tumor-
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immunized mice [36,37]. Therefore, Burnet and Thomas postulated the theory of 
immunosurveillance saying that the T lymphocytes protect the host from developing tumors [38,39], 
although with spontaneous autochthonous tumors the functional immunity mediated by T cells was 
doubted [40]. Afterwards, it was postulated that T cells cannot respond to spontaneously arising 
tumors but only to virus-induced once [41]. Lately, it was shown that mice transgenic for an inducible 
viral oncogene were not protected from the autochthonous developing tumors and that the T cells 
even get paralyzed in these mice, although this viral antigen could lead to tumor rejection in 
transplantation models [42,43]. The "cancer immunoediting" hypothesis by Schreiber et al. 
postulates that tumor cells are first eliminated by the immune system, but tumor cells which survive 
are “edited” in an equilibrium phase. The evolving variants might than escape the immune system 
[44,45]. 
1.2.1 TUMOR ANTIGENS 
Responsible for the T cell response are the tumor antigens presented by MHC molecules on the 
tumor cell surface [20]. One can divide these antigens into two groups: tumor-specific antigens like 
mutated oncogenes, tumor suppressor genes or viral antigens and tumor-associated antigens (TAAs) 
like differentiation and tumor/testis antigens. Tumor-specific antigens are derived from mutated 
proteins due to point mutations or gene rearrangements which are involved in the cell 
transformation process and are only expressed by the tumor cells. The tumor suppressor p53 [46] or 
the oncogene ras [47] are the most prominent antigens. Viral antigens can lead to cell 
transformation, like proteins E6 and E7 of the human papilloma virus (HPV) in cervical cancer [48], 
latent proteins of the Epstein-Barr virus (EBV) in Burkitt’s lymphoma, post-transplant B cell 
lymphomas, Hodkin lymphomas and nasopharyngeal carcinomas [49,50] or proteins of the human T 
cell lymphotropic virus-1 (HTLV-1) in adult T cell leukemia and lymphomas [51]. TAAs are found in 
many tumor cell types but are also expressed on normal tissue. Differentiation antigens are only 
expressed in specific tissues where certain processes take place like the melanin production in the 
skin, but are therefore shared between tumors and healthy cells. Tyrosinase [52,53], Mart-1/Melan-A 
[54] and gp100 [55,56] serve as tumor-antigens in melanomas. Also in epithelial tissues, 
differentiation antigens are found like the prostate-specific antigen (PSA) in prostate tumors [57,58] 
or the mammaglobulin-A in breast cancer [59]. Over-expressed proteins are another group of TAAs 
found in tumor cells like the receptor Her2/neu in breast and ovarian cancer [60]. Antigens derived 
from proteins which were not correctly posttranslational modified can also serve as tumor antigens 
like the unglycosylated mucin, Muc-1, which is expressed in breast and pancreas cancer [61]. Testis 
antigens are normally only expressed in germ line cells of males but these do not express MHC 
molecules, therefore peptides are not presented on the cell surface [62]. Some tumors like glioma, 
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melanoma and breast cancer aberrantly express tumor/testis antigens to which the melanoma-
associated antigens (MAGE-I and -II) [63], NY-ESO-1 [64] and SSX-2 [65] belong. 
1.2.2 DONOR LYMPHOCYTE INFUSION 
Donor lymphocyte infusions (DLI) are given after bone marrow transplantations to provide patients 
an anti-viral immunity or protection against recurrent leukemia. T cells confer a graft-versus-
leukemia effect (GVL) which is directed against MHC class I and II in HLA-mismatched transplants 
settings or against minor histocompatibility antigens and also mutated antigens in matched 
transplant settings. On the same time, transferred cells might also target healthy tissue which can 
lead to severe graft-versus-host disease (GVHD) [66]. Beside this possible strong side effect, DLI is 
successful in the treatment of chronic myeloid leukemia (CML), but less successful in the treatment 
of acute myeloid leukemia or acute lymphoblastic leukemia (ALL) [67,68]. After allogeneic T cell 
depleted bone marrow or organ transplantation patients are prone to post-transplant 
lymphoproliferative disease (PTLD) which is driven by reactivation of latent viral infections with EBV 
and cytomegalovirus (CMV) or lytic adenovirus infection since endogenous virus-specific T cells had 
been depleted by chemotherapy before transplantation. As successful therapy polyclonal virus-
specific CTLs were generated by ex-vivo stimulation with autologous EBV-transformed 
lymphoblastoid cell lines (LCLs) or CMV-transformed fibroblasts. Firstly shown by Riddell et al. in 
1992, CMV-specific donor lymphocytes committed CMV-specific immune responses after bone 
marrow transplantations [69,70]. Heslop et al. transferred prophylactic EBV-specific T cells into 
immunocompromised patient and could restore EBV-immunity or even treat EBV-positive 
lymphomas [71,72,73]. Also, EBV-positive Hodgkin’s disease [74] and nasopharyngeal carcinoma 
[75,76] were treatable. Newly, it’s possible to generate CTLs bispecific for EBV and adenovirus which 
prevented PTLD and could clear adenoviral infection [77]. Until 2010, 114 patients have received 
EBV-specific CTLs. All 101 patients who received the lymphocytes as prophylaxis did not develop EBV-
related lymphoproliferative disease, and 11 out of 13 with EBV-PTLD went into sustained complete 
remission [78]. 
The generation of CTLs specific for melanoma antigens could be easily derived from tumor-infiltrating 
lymphocytes (TILs) from patients with metastatic melanoma [79]. Melanoma-specific T cells were 
transferred in a number of clinical trials, firstly in 1988, where objective response rates were 
between 31 - 35 %. In later trials with increasing levels of lymphodepletion the objective response 
rate was 49 - 72 % [80]. But transferred T cells also targeted healthy tissue expressing the tumor-
associated antigen which led to vitiligo [81]. 
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Although T cell transfer seems to be feasible for the treatment of PTLD and melanoma, specific T cells 
cannot always be generated. Also, the avidity of the obtained T cells might not be optimal since high-
avidity T cells are deleted in the process of negative selection. The generation of specific T cells takes 
a long time for the identification and expansion. This might not be practical for treatment of every 
patient. Early clinical trials showed short persistence of transferred T cells [82] which could be 
improved by increased lymphodepletion and IL-2 administration [80]. 
1.2.3 TCR GENE THERAPY 
Alternative to the ex-vivo expansion of tumor-reactive T cells is the transfer of tumor antigen-specific 
TCR genes into T cells (Figure 3). This approach is more time-efficient and can be applied to HLA-
matched patients. First TCR gene transfer in mouse splenocytes was done in 1986 by Dembic et al. 
[83] and in human T cells in 1999 [84]. The reactivity of the original T cell clone could be transferred 
to murine or human T cells by the TCR gene transfer. T cells showed cytolytic lysis and cytokine 
release upon coculture with cancer cell lines or peptide-loaded target cells. TCR-transduced T cells 
were investigated in animal models and also used in clinical trials. The first clinical trial was 
conducted by Morgan et al. in which two out of 17 patient showed tumor regression [85]. In this trial, 
a TCR recognizing the tumor-associated Mart-1 antigen was used to transduce autologous PBLs from 
HLA-A*0201-positive patients with metastatic melanomas. TCR transduction efficiencies ranged from 
17 - 67 % (mean 42 %) as measured by TCRvstaining. In patients who received T cells after a rapid-
expansion protocol transferred cells were detectable during the monitored 90 day-period. 13 
examined patients showed increased Mart-1 tetramer staining after adoptive T cell transfer. In the 
two patients with full clinical regression TCR-transduced T cells increased by factor 1400 and 30 in 
the peripheral blood and were kept at high levels one year after transfer with 20 - 70 % of gene-
marked cells. In this trial, the clinical benefit was correlated with increased persistence of TCR-
transduced T cells. Another trial was started using TCRs of higher affinity, again a TCR recognizing 
Mart-1 and a second recognizing the melanoma antigen gp100. The last mentioned TCR was isolated 
from a HLA-A2-transgenic mouse immunized with the peptide. Objective cancer regression was seen 
in 30 % of the patients treated with Mart-1 TCR-transduced autologous PBLs and 19 % in patients 
treated with gp100 TCR-transduced T cells. Unfortunately, it was observed that normal tissues like 
skin, eyes and ears expressing the antigens were also targeted. Some of these patients had to be 
treated with steroids [86]. In a recent clinical trial, a NY-ESO-1-specific TCR was employed for 
autologous T cell transduction. The cancer/testis antigen NY-ESO-1 is expressed in 80 % of synovial 
cell sarcomas and in 25 % of melanomas. Six patients with NY-ESO-1-positive synovial cell sarcomas 
and eleven with NY-ESO-1-positive melanomas were treated. Objective responses were observed in 
four patients with synovial cell sarcomas and in five with melanomas. Two of the melanoma patients 
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went into complete remission and one patient with synovial cell sarcoma showed partial response 
for 18 months [87]. In another study using a murine-derived TCR directed against the human 
carcinoembryonic antigen (CEA), three patients with metastatic colorectal cancer were treated. 
Serum CEA levels decreased in all patients by 74 – 99 % and one patient showed an objective 
regression of metastasis in lung and liver. Besides that, also a transient inflammatory colitis was 
observed in all patients showing the limitations of CEA as a target antigen [88]. One trial had just 
started with renal cell carcinoma patients which received autologous PBLs transduced with a 
modified renal cell carcinoma-specific TCR. The modification was done in the CDR3 region and led 
to improvement of tumor cell recognition [89]. The outcome of the trial is still pending. 
 
Figure 3 Principle of TCR gene therapy 
TCRs are either isolated from TILs or from peripheral T cell clones stimulated with DCs pulsed with antigenic 
peptides or DCs expressing antigenic protein. The TCR genes are cloned into a retroviral vector. By viral 
transduction autologous or HLA-matched T cells receive the new antigen specificity. The TCR gene-modified T 
cells are given to the patient. 
1.2.4 IMPROVEMENT OF TCR GENE THERAPY 
Although first success of TCR gene therapy was made, there are many steps to optimize this 
approach. Very important is the chosen TCR and its cognate antigen. Different points can be 
addressed to improve TCR gene therapy [90]: 
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 The TCR should be of high affinity which would detect low amounts of antigen on tumor cells. 
Also, high-affine TCRs are independent of the co-receptor and would function in CD8- as well as 
CD4-positive T cells which would have a synergistic effect on the anti-tumor activity. 
 Since the transgenic TCR has to compete with the endogenous TCR for CD3 components, cell 
surface trafficking proteins needed for cell surface expression and also for signaling molecules, a 
strong expression is a prerequisite. The expression can be improved by the vector system or 
remodeling of the TCR amino acids or TCR structure. 
 Normally, beside the transgenic TCR also the endogenous TCR is expressed which could form 
mispaired TCR heterodimers with a new unknown specificity (“off-target toxicity”). The prober 
pairing of TCR chains can be improved by TCR chain modifications. 
 The environment in the host can be prepared with lymphodepletion or cytokine injections. This 
would enhance T cell function and persistence and would also have an influence on the tumor. 
 The target antigen is an important issue for TCR gene therapy. It should desirable only be 
expressed on tumor cells but shared between patients. The antigen amount on the tumor cells 
should be high enough for recognition by T cells and should be cross-presented by the 
surrounding tumor stroma. Since such antigens are rare, TAAs have to be evaluated closely, 
especially in respect to on-target toxicity towards healthy cells expressing the antigen. 
Enhancement of TCR expression 
The TCR expression on the cell surface of transduced T cells is an important factor for the redirected 
specificity. The cell surface expression is determined by the TCR itself, CD3-complex recycling in the 
transduced cell and the expression system used for the gene transfer. Optimizations of the TCR and 
the expression system have been intensively examined. Stable transgene expression is obtained by 
usage of lenti- or -retroviral vectors. The promoter activity of the retroviral long terminal repeat 
(LTR) or other promoters can be used for the transcription of the gene. The analysis of a Moloney 
murine leukemia virus (Mo-MLV)-retroviral vector showed that transgene expression driven by the 
LTR, phosphoglycerate kinase (Pgk) or -actin promoter was best in proliferating T cells but 
decreased in resting cells. Only the combination of LTR-driven transgene transcription with a -
interferon (IFN) scaffold attachment region led to enhanced expression in resting T cells [91]. A 
vector with LTRs derived from the myeloproliferative sarcoma virus (MPSV) showed a 75-fold higher 
expression than the Mo-MLV-based vector. Inclusion of a posttranscriptional regulatory element 
(PRE) from the woodchuck hepatitis virus in the MPSV-based vector (MP71) even increased the 
expression level in human T cells [92] by stabilization of the mRNA [93]. For lentiviral vectors several 
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promoters were tested for transgene expression as well. Here, the murine stem cell viral (MSCV) 
promoter performed best in activated PBLs as well as in minimal stimulated PBLs [94]. 
Since the TCR complex comprises two TCR chains, the expression system has to provide transcription 
of two genes. The transcription of the second gene can be driven by an internal promoter which is 
not as efficient as an internal ribosomal entry site (IRES) or a 2A element [95]. The IRES site confers 
coordinated gene expression but the gene downstream of the IRES site has a lower expression level 
[96]. The IRES site can lead to TCR expression [97,98], but in a lentiviral vector it was not sufficient 
[94]. The usage of a 2A element is superior for TCR gene expression [99]. It is used in viruses for the 
translation of a second protein from a long composite polypeptide by a ribosomal skipping 
mechanism and confers good expression of a second gene in retroviral vectors [100,101,102]. With 
the size of 60 nucleotides the 2A linker is much smaller than an IRES site (568 nucleotides) and is 
supposed to provide equal molar ratios of both proteins. The disadvantage of a 2A element is that it 
stays attached to the 5’-gene which could interfere with protein function or could be immunogenic 
but this effect was not observed so far in mice [103] (this dissertation). When used for TCR 
expression multiple studies with -retroviral [99] or lentiviral vectors showed superior expression and 
functionality compared to the usage of an IRES site [94]. Only one study demonstrated better 
performance of transduced T cells with an IRES-linked TCR in vivo [95]. 
Enhanced TCR expression can also be obtained by remodeling the TCR structure and sequence. The 
usage of optimal codons in the gene sequence can improve transgene expression. Since the genetic 
code is redundant, one can choose codons with the most frequently available tRNAs [104]. The usage 
of codon-optimization and the elimination of mRNA instability motifs and cryptic splice sites showed 
increased TCR transgene expression in PBLs [105]. 
As Sommermeyer et al. [106] showed certain TCRs can replace endogenous TCRs on the cell surface 
which would be the best situation for TCR gene therapy. He also showed that two strong TCRs can be 
coexpressed with reduced functionality of the endogenous TCR. The expression level is an important 
issue which might also be influenced by the formation of mispaired TCRs. This leads to a reduction of 
properly paired TCRs and to competition for the CD3 complex. When a murine TCR was expressed on 
human cells it replaced the human TCR [106]. This effect was further studied by Cohen et al. [107] 
who replaced the constant human region of the TCR with the murine one and observed enhanced 
expression of two TCRs in human PBLs. The so-called murinized TCRs showed high level of surface 
expression and increased functionality. Nevertheless, mixed dimers could be formed with TCRs 
harboring a human constant region [108]. The other important point is that the murine constant 
region is foreign for human patients and could induce an immune response. Such an immune 
response against a foreign protein was seen in a clinical trial where gene-modified T cells were 
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rejected by human immunodeficiency virus (HIV) patients [109]. To avoid such an rejection Cohen et 
al. [110] and Sommermeyer [111] could reduce the amount of murine residues to a minimum 
needed for the enhanced expression. 
The enhancement of TCR functional avidity was also achieved by the removal of certain N-
glycosylation sites in the constant regions of different human and murine TCRs which led to an 
increased functional avidity and a better tumor cell recognition compared to the wild-type cells 
[112]. Although the deglycosylated TCRs seem to be superior to wild-type TCRs, still mispairing with 
endogenous TCRs is not excluded. 
For the reduction of mispairing another option is the addition of a second disulfide bridge in the 
constant region by mutating a distinct residue to a cysteine [113]. This second disulfide bridge was 
used to stabilize soluble TCRs for crystallization [114]. It increased properly paired TCR chains, 
enhanced TCR cell surface expression and increased functionality [113]. Here, only one amino acid is 
changed in both chains which reduces the possibility of an immune response upon adoptive transfer. 
Voss et al. [108] found another possibility to mutate the TCR constant region for improvement of 
preferential pairing of TCR chains. By analyzing the crystal structure of a TCR they could determine a 
pair of amino acids in the constant regions which interact in a “knob-into-hole” configuration with 
each other. By mutating these residues the configuration was changed into a “hole-into-knob”. This 
change led to selective pairing of the transduced TCR chains and conserved its function. 
The TCR molecule needs the CD3 complex to be transferred to the cell surface. For signal 
transduction the CD3 chain is responsible. Therefore, chimeric T cell receptors were constructed 
where the part of the constant region downstream of the extracellular cysteine residue which forms 
the disulfide bond was replaced by the CD3 chain [115,116]. These chimeric TCRs did not mispair 
with endogenous TCR chains, were expressed independently of available CD3 components and 
showed functionality. In another approach, the additional transfer of CD3 components together with 
the transgenic TCR conferred as well higher functionality. But the amount of transgenes is not 
practical and mispairing is not avoided in this approach [117]. 
Recently, a new TCR format was developed in which the constant regions were deleted and only the 
variable regions of the TCR are expressed together with the linked Lck tyrosine kinase and CD28 
domain in a stabilized format. This newly modified TCR format showed functionality independent of 
the CD3 complex and the CD4 or CD8 co-receptor and did not lead to mispairing [118]. 
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Preconditioning 
Preconditioning modifies the host environment in favor of transferred cells. Removal of cytokine 
sinks by deleting host cells and providing space in the lymphoid compartment or the administration 
of cytokines can have a positive effect on the persistence and functionality of transferred cells. 
Patients with metastatic melanoma were pretreated with chemotherapy using fludarabine and 
cyclophosphamide and then received in vitro generated TILs combined with IL-2 administration after 
adoptive T cell transfer. Here, an increased response rate of 50 / 47 % was observed [80,119]. As 
shown in an animal model, total body irradiation led to enhanced anti-tumor efficacy of transferred T 
cells. This effect was not only due to deletion of regulatory T cells but also due to increased 
availability of IL-7 and IL-15 [120]. Also, the administration of IL-2 can already increase the 
persistence and the anti-tumor effect of transferred cells as shown with melanoma-specific CD8 T 
cell clones in patients of a phase-I clinical trial [121]. Administration of IL-15 is another option which 
supports the generation of memory T cells. In a nonhuman primate model, it was seen that IL-15 
enriches memory CD8 T cells, CD4 T cells and NK cells. In contrast to IL-2 administration, IL-15 does 
not induce the proliferation of regulatory T cells and only shows transient toxicity [122]. IL-15 
improved anti-tumor efficiency by transferred tumor-/ self-specific T cells as shown in an animal 
model [13]. 
1.3 SAFETY CONCERNS OF TCR GENE THERAPY 
1.3.1 MISPAIRING OF TCR CHAINS 
Mispairing of TCR chains harbors a risk for TCR gene therapy. When polyclonal T cells are used for 
TCR transduction it is not possible to predict mispaired TCRs versions. As shown in an animal model, 
the transfer of TCR-transduced polyclonal wild-type T cells into sublethal irradiated recipient mice 
and administration of high-dose IL-2 led to lethal autoimmunity after two weeks. This severe side 
effect was not seen with the transfer of untransduced T cells, GFP-transduced T cells or TCR 
transgenic T cells. The off-target toxicity could be confirmed to be induced by mixed TCR dimers since 
autoimmunity was also observed when T cells were transduced with only TCRv or TCRv chains 
[123]. The use of T cell clones to minimize possible TCR mispaired versions still can harbor this risk of 
neoreactivity. The TCR-transduction of various virus-specific T cell clones showed new reactivities 
when tested against several LCLs. The newly gained allo-and also auto-reactivities where due to TCR 
mispairing as shown by transfer of TCRv or TCRv chains and were MHC I or MHC II-restricted [124]. 
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1.3.2 RECOGNITION OF SELF-ANTIGENS 
It was already seen that upon transfer of melanoma-specific T cells healthy tissue expressing the TAA 
can be targeted, which is called on-target toxicity [81]. The same observation was made in one TCR 
gene therapy trial using redirected autologous T cells with high-avidity TCRs specific for melanoma 
antigens (MART-1 and gp100) [86]. The targeting led to destruction of melanocytes in the skin, eye 
and ear. Such events were not seen in the clinical trial before, targeting the same melanoma antigen 
but with a TCR of lower avidity [85]. 29 of 36 patients showed a widespread erythematous skin rash 
which was infiltrated by T cells. On day 5, destruction of epidermal melanocytes was already 
observed. As endogenous T cells were depleted at that time by preconditioning, the transferred T 
cells were the source of autoimmunity. Also, cell infiltrates in the eye were observed in several 
patients who had to be treated with steroids. In the infiltrates Mart-1 tetramer-positive T cells were 
found. Hearing loss occurred in some patients. All side effects resolved by time which could be due to 
the loss of transferred T cells or their suppression after treatment with steroids. 
The self-antigen Survivin is expressed on a variety of tumor cells and seemed to provide a good TAA 
for TCR gene therapy. But Survivin-specific TCRs showed to be not useful for TCR gene therapy. After 
TCR transduction of PBLs, they commited MHC-restricted fratricide of T cells in the culture since the 
Survivin-expression was up-regulated in activated T cells [125]. This study showed again the 
limitations of TAAs for TCR gene therapy. 
The recognition of self-antigen can not only be conferred by the transgenic TCR but also by the 
endogenous TCR. T cells harbor a certain avidity to self-antigens which assures their survival in the 
periphery by encountering self-peptide-MHC complexes [34]. Through ligation of the transgenic TCR 
to the tumor antigen the activated T cell could now target self-antigen via its endogenous TCR. That T 
cells can commit both functionalities was shown in transgenic mice harboring T cells with two TCRs 
[126]. T cells could confer anti-tumor response without causing autoimmunity when the tumor 
antigen was highly expressed, whereas the self-antigen was only present in low amounts. But self-
tissue was targeted when the self-antigen was present in high amounts and the transferred T cells 
were either activated through the tumor antigen-specific TCR or the self-antigen-specific TCR [127]. 
In a similar model, it was also shown that TCR-transduced T cells recognizing a self-antigen only 
induced a response when activated by vaccination with this antigen [128]. 
1.3.3 INSERTIONAL MUTAGENESIS 
Retroviral vectors are used for a stable transgene expression which is the result of provirus vector 
DNA integration into the host cell genome. A long time it was believed that the integration occurs 
randomly in the host genome. Mapping of the integration sites of MLV in the human genome 
showed that the virus integrates near transcription start sites of active genes [129] and was mostly 
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located in the first intron [130]. The affected genes are mainly involved in signaling, transcription or 
have kinase activity [130]. The lentiviral HIV integrates into actively transcribed genes, but not near 
the transcription start [129,131]. The virus vector can also have an influence on surrounding genes. 
Its promoter and enhancer regions in the LTRs can drive or enhance downstream or upstream 
adjacent genes. Also gene enhancers can be influenced by the provirus. In self-inactivating (SIN)-
vectors the promoter and enhancer region are minimized to one LTR and have therefore a lower risk 
of insertional mutagenesis. 
That vector integration can indeed lead to a malignant cell transformation in combination with other 
acquired mutations was observed in two clinical trials in France and in England. Patients with the X-
linked severe combined immunodeficiency disease (SCID-X1) don’t develop T cells, NK cells and have 
dysfunctional B cells due to a mutation in the gamma chain (c) of the common cytokine receptors 
for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 which support the development and function of the immune 
system. In these trials, patients were treated with autologous hematopoietic stem cells (HSCs) 
corrected with the c encoding gene IL2RG by retroviral transfer [132,133,134]. Nine out of ten 
patients of the French trial could reconstitute their immune system upon treatment. After around 30 
months, the two youngest patients developed malignant proliferation of T cells and had to be treated 
with chemotherapy. Analysis of vector integration sites in the blood of these patients revealed 
malignant T cell clones with integrations near the cellular proto-oncogene LMO2. The expression of 
the proto-oncogene was dysregulated and probably the cause of malignancy [135]. Two other 
patients developed T cell acute lymphoblastic leukemia (T-ALL) 33 and 68 months after transfer 
[136]. The vector mapping in the third patient showed upstream integration of the oncogene CCND2 
and in the other patient integration in the second intron of LMO2 and near BML1. These genes were 
over-expressed to an abnormal level. The lymphoproliferation in three patients were of an immature 
phenotype and in one patient of a mature phenotype. The transgene IL2RG expression was of 
physiological level in all patients. Also, other chromosomal translocations, mutations of proto-
oncogenes and deletions of suppressor genes were observed in the patients’ blasts cells [136]. In the 
English trial, ten patients were successfully treated with gene-modified autologous HSCs [132,137]. 
One patient developed T-ALL after 24 months and was treated with chemotherapy. Analysis of the 
leukemic cells revealed vector integration near the LMO2 proto-oncogene. LMO2 was over-
expressed in malignant cells. Additional DNA aberrations were found: a gain-of-function mutation in 
NOTCH1, a deletion of the tumor suppressor gene cyclin-dependent kinase 2A (CDKN2A), and a 
translocation of the TCRβ region to the STIL-TAL1 locus [138]. 
Another disease which was treated by gene therapy is the chronic granulomatous disease (CGD). This 
rarely inherited disease is caused by a dysfunctional nicotinamide dinucleotide phosphate (NADPH) 
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oxidase complex which is composed of five subunits. Most cases have mutations in the X-linked 
gp91phox gene encoding for a membrane-spanning subunit. Defects in the NADPH oxidase lead to the 
impairment of antimicrobial activitiy of neutrophils and patients suffer from life-threatening bacterial 
and fungal infections. Until 2010, a total of 12 patients were treated by gene therapy in different 
trials in combination with myelosuppressive pretreatment [139]. Only three patients showed long-
term engraftment with high-levels of gene-modified cells which was promoted by an insertional 
activation of MDS1/EVI1, PRDM16, SETBP1 and resulted in clonal myeloproliferation [140,141]. The 
over-expression of EVI1 was shown to lead to genomic instability resulting in monosomy 7 by the 
impairment of centrosome duplication in two patients [142]. 
The adenosine deaminase-deficient SCID (ADA-SCID) is also treatable by gene therapy. Due to the 
absence of this enzyme, toxic purine metabolites accumulate which lead to impaired lymphocyte 
development, lymphocyte function and immunological unrelated abnormalities. In combination with 
a nonmyeloablative treatment gene-modified HSCs reconstituted T cell development and immune 
function. The administration of polyethylene glycol-modified bovine ADA (PEG-ADA) could be 
discontinued in most of the patients. The selective advantage of gene-modified cells in vivo led to 
success in these trials [143,144,145,146,147]. The analysis of vector integration in HSCs before and 
up to four years after transfer in five patients did not show a clonal selection although integrations 
could be mapped in the proximity of proto-oncogenes like LMO2 and genes involved in growth and 
self-renewal, but repopulating cells led to a highly polyclonal T cell population [148]. 
Recently, a gene therapy trial was started to treat patients with the Wiskott-Aldrich syndrome (WAS) 
which is an X-linked recessive immunodeficiency caused by a mutation in the WAS protein (WASP) 
[149]. The WASP is responsible for the actin polymerization in hematopoietic cells with involvement 
in signaling, cell locomotion and formation of the immunological synapse. The defect leads to 
functional disturbance of T, B, NK cells and their restrained migration resulting in infections, 
autoimmunity and thrombocytopenia. Retrovirally gene-modified autologous HSCs were transfused 
into patients after partial myeloablation. The cells engrafted successfully and a sustained gene 
marking in the myeloid and lymphoid compartment as well as in platelets could be observed 
followed by long-term clinical improvement of the patients. Analysis of vector integration showed 
polyclonality of gene-marked cells with integrations in genes involved in cell growth and immune 
responses in two patients [149]. So far, nine out of ten patients could be successfully treated, but the 
first adverse event occurred in one patient who developed leukemia probably due to insertional 
mutagenesis [150]. 
So far, there is only one clinical study published which used a lentiviral vector for gene-correction of 
HSCs. The X-linked adrenoleukodystrophy (ALD) could be treated with autologous HSCs transduced 
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with a lentiviral vector encoding the ABCD1 gene which product is the ALD protein [151]. The 
deficiency leads to a severe demyelination in the brain. In this trial, two patients were treated and 
demyelination stopped after 14 and 16 months. Polyclonal engraftment was accomplished with 9 
and 14 % gene-marking in the lymphoid compartment as analyzed after 24 and 30 months. 
The described adverse events in patients only occurred in gene therapy trials using retrovirally gene-
modified HSCs. The integration pattern of retroviral vectors clearly influenced the severe side effects 
which were promoted by the in vivo selection advantage of gene-corrected HSCs. So far, the usage of 
gene-modified T cells appears to be safe in patients. Leukemic patients treated with allogeneic stem 
cell transplantation received donor lymphocytes transduced with the suicide gene herpes simplex 
thymidine kinase (HSV-Tk) [152]. The safety mechanism is adopted in this treatment to eventually 
abandon GVHD. Analysis of the transferred T cells showed no clonal outgrowth up to 9 years after 
treatment [153]. Transduced T cells showed stable transgene expression, normal phenotype and 
function. Quantitative analysis revealed that one fifth of the genes nearby the integration site were 
affected in expression without influencing the phenotype. A more detailed analysis of transduced T 
cells in two patients was done and showed no clonal dominance but polyclonality of the transferred 
T cell population [154]. 
In gene-marking studies where T cells were transduced with the truncated NGF receptor (LNGFR) 
and transferred into animals as well as into humans no T cell-related malignancies were observed 
[155]. Even the transduction with the T cell oncogenes LMO2, TCL1 or TrkA did not lead to 
malignant transformation of T cells when transferred into lymphopenic RAG-1-deficient mice 
whereas HSCs were transformed by these oncogenes [156]. But recently, transformation of T cells 
was observed in vitro when the proto-oncogene LMO2 was retrovirally transferred. The evolving T 
cell clone could overgrow competitor T cells in vitro but did not show outgrowth in vivo. Integration 
site analysis revealed proximity of the vector to the IL2RA and IL15RA genes which were over-
expressed. In this study, it was shown that LMO2 can act synergistically with IL-2 in the 
transformation process of T cells [157]. 
 
 
 
1.4 TETRACYCLINE-REGULATED GENE EXPRESSION 
1.4.1 PRINCIPLE OF TETRACYCLINE-REGULATED EXPRESSION SYSTEMS 
In 1992, a regulated expression system was described by Gossen and Bujard [158]. The tetracycline 
(tet)-regulated expression is turned on if tetracycline (Tc) or the derivative doxycycline (Dox) is 
removed from the system which is called Tet-Off (Figure 4). In 1995, Gossen published an expression 
system which was inducible by supply of Dox called Tet-On [159]. Both expression systems can be 
regulated by the amount of Tc or Dox and the expression level is comparable to strong constitutive 
promoters [160]. Most of the elements of the Tet-Off and Tet-On sytems are derived from 
Escherichia coli (E. coli). In these bacteria the Tet repressor protein (TetR) inhibits transcription of the 
genes in the Tn10 transposon by binding to the tet operator sequence (tetO) if Tc is not present. The 
TetR was modified by fusion of its first 207 amino acids with the C-terminal 127 amino acids of the 
Herpes simplex virus type 1 VP16 activation domain which was identified by Triezenberg et al. [161]. 
This converts the former TetR into a Tc-controlled transactivator (tTA) which activates gene 
expression in absence of Tc or Dox. In the Tet-On system, the tTA is mutated in four amino acids and 
called “reverse” Tet repressor (rTetR) which can only activate gene expression in the presence of Dox 
[159]. The Tc-response element (TRE) is composed of seven direct repeats of the tetO followed by a 
minimal CMV promoter which carries deletions in the enhancer regions. The gene is driven by 
activation of TRE-CMV promoter region. 
 
Figure 4 Schematic picture of the Tet-on and Tet-off system 
The transactivator (tTA) (in green) is composed of a tet-repressor sequence (TetR) from E. coli and an activation 
domain VP16 from the Herpes simplex virus type 1. Its expression is constitutively driven by a CMV promoter 
(PCMV in light blue). In the Tet-Off system it can bind to the Tet-responsive element (TRE) (in blue) which is fused 
to a minimal CMV promoter (PminCMV). Transgene expression takes place (in pink). If Dox is added to the system 
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Dox-bound tTA cannot induce the expression anymore. In the Tet-on system the mutated rtTA can only induce 
expression when Dox is bound. 
One difference between Tet-Off and Tet-On systems is that the Tet-On system is only responsive to 
Dox but not to Tc. Dox is compared to Tc more active, concentration from 0.01-1 µg/ml are enough 
compared to 1-2 µg/ml of Tc. These concentrations are below the cytotoxic level for cell culture and 
transgenic animals. The half-life of Dox is 24 h compared to only 12 h of Tc. Dox is therefore the 
preferable antibiotic. 
In comparison to other eukaryotic regulatory elements, the Tet-system is specific in its gene 
regulation, provides higher and faster induction, only shows low background expression and can 
have higher expression levels than achieved with a constitutive promoter. Applications for the 
regulated systems have been established in mammalian, plant, amphibian, insect, and avian cell 
cultures and also in whole organisms like yeast, parasites, flies, amphibians and mammals like mice, 
rats, and nonhuman primates. In transgenic mice, the tTA or rtTA is engineered to be tissue-specific 
expressed and can be crossed to mice which express the tet-regulated gene of interest (for examples 
oncogenes like myc, ras, BCR-ABL1, genes involved in various diseases or cell signaling). Tc or Dox can 
be supplied in the drinking water to mice [162,163]. 
1.4.2 ESTABLISHED VECTORS FOR REGULATION OF GENE EXPRESSION 
In original Tet-systems, the tTA and the gene of interest are provided on separate plasmids. The 
separation on two plasmids confers a tight regulation and high transcription level. Disadvantage is 
that two vectors have to be transferred into one cell which is not achievable for all target cells unless 
the transfer is done one after the other with a subcloning step in between. For primary cells this is 
not convenient [164]. All-in-one vectors which harbor all components of the Tet-system are more 
practical since a single transduction and selection round are sufficient. But these vectors conferred a 
higher background level and regulation of maximal 500-fold, even after clonal selection 
[165,166,167]. There are two types of All-in-one vectors. Either both elements are driven by a 
separate promoter or the transactivator is regulated by a positive feedback loop. In the first case, 
promoter interference can lead to low expression and regulation level and in the second case, a read-
through is needed to start expression which interferes with a tight regulation. The first All-in-one 
vector was a -retroviral vector [168]. Here, the tTA was driven by the simian virus (SV) 40- or JC virus 
promoter and the responsive transgene cassette was either located directly downstream of the tTA 
in opposite direction or located in the U3 region of the 3’-LTR. Last mentioned option leads to a two 
copy provirus, since the U3 region is transferred to the 5’-LTR after reverse transcription. In an auto-
regulatory All-in-one self-inactivating vector, the transgene is driven by a minimal CMV promoter 
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fused to the tandem TRE. The tTA is linked by an IRES site to the transgene. Basal transcription level 
of the promoter leads to minimal transcription of the gene cassette. tTA binds to the TRE sequences 
which leads to stronger transcription. In the presence of Tc, tTA does not bind to the promoter 
anymore and transcription is stopped [169]. Many modifications have been made to the Tet-system. 
The spacing of the tetO sequences could be reduced from 42 to 36 nucleotides which provided a 
better regulation [170]. By applying mutations an improved rtTA could be identified, rtTA25-M2, 
which has a 10-fold higher sensitivity to Dox, higher stability in eukaryotic cells and no background 
expression [171]. It was fused to a minimal domain derived from the transactivation VP16 domain. 
Also, retroviral or adenoviral vectors are available for both elements. There are several variants on 
the market of these systems, providing marker or selection genes, Tags, bidirectional gene 
expression [168] and reduced leakiness. New bidirectional All-in-one vectors were developed by 
Heinz et al. [172] comprising of the rtTA25-M2, new TRE-promoter (Ptet-T2, Ptet-T6, Ptet-T8, Ptet-
T11) and with small alterations of the vector architecture which showed improved transgene 
induction of 220-14000 fold by strongly decreasing the background expression in HT1080 cells as 
measured by luciferase and GFP expression. The vector with the TRE-promoter Ptet-T2 was used for 
TCR expression in this work. 
For the generation of regulated gene expression the insertion site of the Tet-vector is an important 
factor for the proper function. Enhancer and promoter region near the integration sites can lead to a 
background activity of the transgene or the insertion site negatively influences the regulation level of 
the transgene. Therefore, a selection of a cell clone can circumvent this problem. Also, the 
transduction with a low multiplicity of infection (MOI) should be performed [164]. 
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2. OUTLINE OF THIS THESIS 
The aim of this thesis was to determine the safety of TCR gene-modifed T cells. Two different safety 
concerns were approached. The first safety concern concentrated on the expression of two TCRs in 
gene-modified T cells and its consequences. 
For that, an inducible transgene expression system should be analyzed for the suitability of TCR 
expression and its regulation in single TCR T cells. 
Afterwards, a second TCR should be applied for the establishment of dual TCR T cells. The influence 
of the transgenic TCR on the endogenous TCR was to be characterized in terms of 
 surface expression, 
 expression level, 
 functionality, 
 TCR chain mispairing of both TCRs. 
To improve safety of dual TCR T cells by avoiding mispaired TCR chains, a second cysteine bridge was 
applied in the constant regions of the examined TCRs. Its effect was analyzed by measuring the TCR 
surface expression, the functionality as well as the pairing of the TCR chains. 
The effect of the cysteine bridge was to be determined not only in the established cell line clones 
with regulated TCR expression but also in primary transgenic and wild-type cells. 
The second safety issue of TCR gene-modified T cells concerned the stability of the phenotype in vivo, 
since vector transduction harbors the risk of insertional mutagenesis. This risk should be analyzed in 
combination with repeated stimulation of TCR-transduced T cells in vivo. The transferred T cell 
populations was to be analyzed in regard to 
 phenoytype before transfer, 
 activation status after stimulations, 
 functionality, 
 proliferation capacity, 
 vector integrations. 
The recipient mice should be observed for occurring malignancies caused by the T cell transfer. 
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3. MATERIAL AND METHODS 
3.1 MATERIAL 
Table 1 Media 
Medium Content 
CMM  RPMI 1640+GlutaMax1 (Gibco), 10 % heat-inactivated fetal calf serum (FCS, 
PAN Biotech), 100 U/ml penicillin/ streptomycin (Pen/ Strep, GIBCO), 1 mM  
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic-acid (Hepes) pH 7.25 (Sigma-
Aldrich), 1 % sodium pyruvate (Gibco), 1 % non-essential amino acids (Gibco), 
50 µM -mercaptoethanol (Sigma-Aldrich) 
PlatE medium Dulbecco’s modified Eagle’s medium (DMEM, GIBCO), 10 % heat-inactivated 
FCS (Biochrom), 100 U/ml Pen/ Strep, 1 µg/ml puromycin (Sigma-Aldrich), 10 
µg/ml blasticidin (MP Biomedicals) 
T cell medium RPMI 1640+GlutaMax1, 10 % FCS (PAN Biotech), 100 U/ml Pen/ Strep, 10 mM 
Hepes pH 7.25 
LB agar 1.5 % agar (Roth) in LB medium 
LB medium 1 % tryptone, 1 % NaCl, 0.5 % yeast extract (all Roth) 
Soc medium 20 mM glucose, 2 % tryptone, 0.5 yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 
mM MgCl2, 10 mM MgSO4 (all Roth) 
 
Table 2 Buffers 
Buffer Content 
ACK lysis 150 Mm NH4Cl (Merck), 1 mM KHCO3 (Roth), 0.1 mM Na2EDTA (Roth),  
pH 7.5 
ELISA wash 1 x PBS, 0.05 % Tween-20 (Sigma-Aldrich) 
FACS staining 1 x PBS, 0.01 % albumin from bovine serum (BSA, Sigma-Aldrich) 
10 x phosphate-buffered 
salines (PBS) 
80 g NaCL (Merck), 2 g KCl (Roth), 14.4 g Na2HPO4 (Merck), 2.4 g KH2PO4 
(Roth) 
RetroNectin(RN) wash  1 x PBS, 2,5 % 1 M Hepes 
Transfection 1 % Hepes, 1.5 mM Na2HPO4, 270 mM NaCl, 10 mM KCl, pH 6.75 
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Table 3 Interleukine 
Interleukine Concentration used Company 
Human IL-2 (hIL-2) 40 U/ml Chiron 
Recombinant human IL-15 (hIL-15) 10/50 ng/ml Preprotec 
 
Table 4 Peptides 
Peptide 
name 
Amino acid 
sequence 
Presented by Antigen Company 
gp33 KAVYNFATM 
(M is modified 
compared to wild-
type) 
H-2Db lymphochoriomeningitis 
virus glycoprotein  
gp33-41 
Biosynthan 
Ova SIINFEKL H-2Kb Ovalbumin257-264 Biosynthan 
 
Table 5 Reagents 
Reagent cell culture Concentration used Company 
Antibiotic/fungizide mix 200 U/ml Gibco 
Brefeldin A 10 µg/ml Biolegend 
BSA 0.1, 2 % Sigma-Aldrich 
Calcium chloride dehydrate 
(CaCl2) 
2.5 mM Sigma-Aldrich 
Carboxyfluorescein diacetate 
succinimidyl ester (CFSE) 
5 mM stock Invitrogen 
Dimethyl sufloxide (DMSO) 10 % Sigma-Aldrich 
Ethylendiamin-tetraacetat 
(EDTA) 
 Sigma-Aldrich 
Doxycycline (Dox) 1 mg/ml stock Sigma-Aldrich 
Gentamycin 10 µg/ml Gibco 
Sulfuric acid (H2SO4) 2 N Roth 
Ionomycin 1 µM Calbiochem 
Phorbol-12-myristate-13-acetate 
(PMA) 
5 ng/ml Sigma-Aldrich 
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Propidium iodide in PBS 100 ng/µl Sigma-Aldrich 
Protamine sulfate 4 µg/ml Sigma-Aldrich 
RetroNectin CH-296 25 µg/ml TaKaRa Biomedicals 
Trypsin-EDTA 0.05 % Gibco 
Reagent mice work Concentration used Company 
ABX Vet Pack  Scil animal care 
CpG oligodesoxynulceotides (CpG 
ODN) 1826 
10, 50 µg/ml TIB MOLBIOL 
Dulbecco’s PBS (DPBS) 1 x Invitrogen 
Endoxan (Cyclophosphamide) 100, 200 mg/kg Baxter 
Freund’s adjuvant, incomplete 
(IFA) 
100 µl Sigma-Aldrich 
Reagent molecular work Concentration used Company 
Agarose 0.8-2 % Serva 
Ampicillin 100 µg/ml Roth 
Deoxynucleotides (dNTP) 200 µM each Fermentas 
Ethidium bromide 0.5 µg/ml Sigma-Aldrich 
DNA-1 kb  Invitrogen 
Orange G  Sigma-Aldrich 
Reagent LAM-PCR Concentration used Company 
Aqua ad injectabilia (ddH2O)  B Braun, Baxter 
Dynabeads M-280 Streptavidin  Dynal, Invitrogen 
Hexanucleotid mixture  
(Hexa-Nt) 
 Roche 
LiCl 3, 6 M Sigma-Aldrich 
NaOH 0.1 N Roth 
Spreadex EL1200 precast gel  Elchrom Scientific 
Tris-HCL 250 mM; pH 7.5 Sigma-Aldrich 
 
Table 6 Antibodies and Multimeres 
Antibody Fluoro- 
Phore 
Isotype Clone Concentration Company 
HA Biotin Mouse IgG2b, 12CA 0.2 mg/ml Roche 
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HA - Mouse IgG2b, 12CA 0,2 mg/ml Roche 
Mouse CD3 - Armenian hamster 
IgG1 
145-2C11 1 mg/ml BD Pharmingen 
Mouse CD8 FITC, APC Rat IgG2a, 53-6.7 0.2 mg/ml BD Pharmingen 
Mouse CD16/32 - Rat IgG2b 2.4G2  BD Pharmingen 
Mouse CD28 - Syrian hamster IgG2 37.51 1 mg/ml BD Pharmingen 
Mouse CD44 PE Rat IgG2b, IM7 0.2 mg/ml BD Pharmingen 
Mouse CD62L FITC, PE Rat IgG2a, MEL-14 0.2 mg/ml BD Pharmingen 
Mouse CD69 PE Armenian Hamster 
IgG1, 3 
H1.2F3 0.2 mg/ml BD Pharmingen 
Mouse CD90.1 PE, PercP Mouse IgG1, OX-7 0.2 mg/ml BD Pharmingen 
Mouse/Rat 
CD90.1 
FITC, 
Biotin 
Mouse IgG2a, HIS51 0.2 mg/ml 
0.5 mg/ml 
BD Pharmingen 
Mouse CD107 PE Rat IgG2a, 1D4B 0.2 mg/ml BD Pharmingen 
Mouse IFN- APC Rat IgG1, XMG1.2 0.2 mg/ml BD Pharmingen 
Mouse IgG 
(H+L) Fab 
Fragment 
Cy5 Goat  1 mg/ml Jackson 
Immunoresearch 
Mouse v2 APC Rat IgG2a B20.1 0.1 mg/ml Caltag 
Mouse 
v5.1/5.2 
PE Mouse IgG1, MR 9-4 0.2 mg/ml BD Pharmingen 
Mouse 
v8.1/8.2 
PE Mouse IgG2a,  MR 5-2 0.2 mg/ml BD Pharmingen 
Myc - Mouse IgG1 9E10 1 mg/ml Hybridoma 
supernatant 
(ATCC CRL-1729) 
Streptavidin APC   0.2 mg/ml BD Pharmingen 
Tetramer Fluorophore    Company 
H-2Db/KAVYNFATC APC    Beckman Coulter 
H-2Kb/SIINFEKL APC, PE    Beckman Coulter 
 
Table 7 Enzymes 
Enzyme Concentration used Company 
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Fast-Link DNA ligation kit 2 U/µl Epicentre Biotechnologies 
Klenow Enzyme 2 U/µl Roche 
MaximaTM SYBR Green qPCR 
master mix 
 Fermentas 
Phosphatase, alkaline 1 U/µl Roche 
Phusion Taq Polymerase  2 U/µl Finnzymes 
Rapid DNA Ligation Kit 5 U/µl Roche  
Restriction Enzymes 10 U/µl Fermentas 
Restriction enzyme Tsp509I, 
HpyCH4IV 
10 U/µl New England Biolabs 
Taq polymerase 5 U/µl Genaxxon 
 
Table 8 Preparation kits 
Preparation Kit Usage Company 
Cytofix/CytopermTM Kit Intracellular staining BD Bioscience 
EasyPure DNA Purification kit DNA clean up from agarose gel Biozym 
Invisorb Spin Blood Mini kit Mouse blood DNA preparation Invitek 
Invisorb Spin Plasmid Mini Two DNA plasmid preparation Invitek 
Invisorb Spin Tissue Mini kit Mammalian cell DNA preparation Invitek 
MinElute PCR Purification kit Polymerase chain reaction (PCR) 
mix clean up 
Qiagen 
Mouse IFN- ELISA Set Mouse IFN- detection BD Bioscience 
Mouse IL-2 ELISA Ready-SET-GO! Mouse IL-2 detection eBioscience 
Plasmid Maxi, Midi kit DNA plasmid preparation Quiagen 
QuiAmp DNA blood Mini kit Mouse blood DNA preparation Quiagen 
 
Table 9 Plasmids 
Transgene Description Vectors  Cloned by 
OT-I- OT-I TCR chain MP71 Daniel Sommerrmeyer 
OT-I-HA OT-I TCR chain with HA tag 
at N-terminus 
MP71; Tet Simone Reuß 
OT-I- OT-I TCR chain MP71; Tet Daniel Sommerrmeyer, 
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Simone Reuß 
OT-I--P2A-HA 
 
OT-I TCR with HA tag at N-
terminus of TCR chain 
MP71; plSN; Tet Simone Reuß 
OT-I--P2A-
HAco 
Codon-optimized TCR gene MP71 Provided by Prof. Dr. 
Ton Schumacher, 
Simone Reuß 
OT-I--P2A-HA-
cys 
 
 
-cocys 
OT-I TCR with HA tag at N-
terminus of TCR chain; 
Second cystein bridge in 
constant region; 
Codon-optimized 
MP71 Simone Reuß 
P14-DAN P14 TCRchain with two 
myc tags at N-terminus 
MP71 Elisa Kieback 
P14- P14 TCRchain  MP71 Daniel Sommermeyer 
P14--P2A- P14 TCR MP71 Elisa Kieback 
P14--P2A-DAN P14 TCR with two myc tags 
at N-terminus of TCR  
chain 
MP71, plSN, Tet Elisa Kieback, Simone 
Reuß 
P14--P2A-
DANco 
Codon-optimized TCR gene MP71 Provided by Dr. Jehad 
Charo, Simone Reuß 
P14--P2A-DAN-
cys 
 
 
 
-cocys 
P14 TCR with two myc tags 
at N-terminus of TCR 
chain; 
Second cystein bridge in 
constant region; 
Codon-optimized 
MP71, plSN Simone Reuß 
 
Table 10 Primers 
Primer Name Usage Primer Sequence 5’-3’ 
HA-fwd OT-Iv2HA CCA TAT GAC GTC CCA GAT TAC GCG CAG CAG 
CAG GAG AAA CGT GAC CAG C 
HA-rev OT-Iv2HA GTA ATC TGG GAC GTC ATA TGG GTA GCC ATT CAC 
CCC AGC TAG GTG AAG G 
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OT-Iv2-P2A-fwd  OT-Iv2-P2A-fwd AAC TTC TCT CTG TTA AAG CAA GCA GGA GAC GTG 
GAA GAA AAC CCC GGT CCC ATG GAC AAG ATT 
CTG ACA GCA ACG 
v2-NotI-fwd OT-I/P14v2 TTT GCG GCC GCC ATG GAC AAG ATT CTG ACA G 
1. v2-EcoRI-rev  
2. v2-EcoRI-rev 
OT-I/P14v2 
OT-I/P14v2 
CCG GAA TTC TCA ACT GGA CCA CAG CCT CAG 
TTA CTG AAT TCT CAA CTG GAC CAC AGC CTC  
v-cys-fwd Cysteine bridge c CAC TGA CAA ATG TGT GCT GGA CAT G 
v-cys-rev Cysteine bridge c CAT GTC CAG CAC ACA TTT GTC AGT G 
v-NotI-fwd 
 
OT-Iv5/ 
P14v8 
CTG GCG GCC GCC ATG TCT AAC ACT GCC  
v-P2A-rev 
 
OT-Iv5/ 
P14v8-P2A-rev 
TTC CAC GTC TCC TGC TTG CTT TAA CAG AGA GAA 
GTT CGT GGC GCC GCT TCC GGA ATT TTT TTT CTT 
GAC CAT GGC C 
v-cys-fwd Cysteine bridge c ACA GTG GGG TCT GCA CGG ACC CTC AG 
v-cys-rev Cysteine bridge c CTG AGG GTC CGT GCA GAC CCC ACT GT 
Leader-fwd Sequencing CAG CAT CGT TCT GTG TTG TCT 
PRE-rev Sequencing CAT TTA AAT GTA TAC CCA AAT CAA 
-Actin-fwd Real-time PCR ACC CAC ACT GTG CCC ATC TA 
-Actin-rev Real-time PCR CTC AGC TGT GGT GGT GAA GC 
GFP-fwd Real-time PCR ACG TAA ACG GCC ACA AGT TC 
GFP-rev Real-time PCR AAC TCC AGC AGT ACC ATG TG 
M2-fwd Real-time PCR CGG CTG GGA GCA TGT CTA AG 
M2-rev Real-time PCR GTC GGT ATC GAA GGC CTG AC 
Neo-fwd Real-time PCR GGA TTG CAC GCA GGT TCT CC 
Neo-rev Real-time PCR CGG CCA CAG TCG ATG AAT CC 
v2-fwd Real-time PCR CAT GAC CAG CAT CAG GTG AG 
v2-rev Real-time PCR CAG TCA ACG TGG CAT CAC AG 
LC1 Linker cassette GACCCGGGAGATCTGAATTCAGTGGCACAGCAGTTA
GG 
LC3 Linker cassette-Tsp509I AATTCCTAACTGCTGTGCCACTGAATTCAGATC 
LC5 Linker cassette-HpyCH4IV CGCCTAACTGCTGTGCCACTGAATTCAGATC 
LCI-fwd Linker-fwd GAC CCG GGA GAT CTG AAT TC 
LCII-fwd Linker-fwd GAT CTG AAT TCA GTG GCA CAG 
LTRa-bio-rev 5’LTR-rev, biotinylated TGC TTA CCA CAG ATA TCC TG 
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LTRb-bio-rev 5’LTR-rev, biotinylated ATC CTG TTT GGC CCA TAT TC 
LTRII-bio-rev 5’LTR-rev, biotinylated GAC CTT GAT CTG AAC TTC TC 
LTRIII-rev 5’LTR-rev TTC CAT GCC TTG CAA AAT GGC 
 
Table 11 Handling material 
Material Volume/Size Company 
Cell strainers 40 µm BD Flacon 
Cryo-tubes 2 ml Greiner 
Culture flasks 25 cm2, 75 cm2, 150 cm2 BD Flacon 
Culture flasks 150 cm2 Techno Plastic Products 
FACS tubes  BD 
Filters 0.2, 0.45 µm Whatman 
MaxiSorp plates 96-well Nunc 
Microcon YM-30 30 kDa nominal molecular weight 
limit 
Millipore 
Needle 0.4 x 20 mm, 27 G B Braun 
PCR tubes 100 µl NeoLab 
Pipettes  5, 10, 25 ml  
Plates, flat bottom 6-, 24-well Greiner 
Plates, round & flat bottom 96-well Corning Costar 
Polystryene tubes 15 ml Greiner 
Syringes 2, 5, 10, 30, 50 ml B Braun 
Tips 10, 200, 1000 µl Eppendorf 
Tips, filtered 10, 200, 1000 µl Sorenson BioScience 
Tubes 0.5, 1.5, 2 ml Eppendorf 
Tubes 15, 50 ml BD Falcon 
 
Table 12 Equipment 
Equipment Description Company 
Biofuge Pico Centrifugation Heraeus 
Centrifuge 5810R Centrifugation Eppendorf 
Centrifuge 5804R Centrifugation Eppendorf 
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Centrifuge 6K10 Centrifugation Sigma 
Centrifuge 3K12 Centrifugation Sigma 
Cryo-container Freezing cells Nalgene 
Electrophoresis chamber Agarose gel electrophoresis Bio-Rad 
FACSAria flow cytometer Cell sorting BD 
FACSCalibur flow cytometer Cell analysis BD 
FACS Lyse/Wash Assitant Red blood cell lysis BD 
Gel documentation system Ultraviolet light (UV) gel analysis PeqLab 
Gel electrophoresis apparatus 
SEA 2000 
Electrophoresis Elchrom Scientific 
GeneRay UV-Photometer DNA measurement Biometra 
HERA cell 240 incubator 37 °C, 5 % CO2, 95 % humidity Kendro Laboratory 
Products 
Horizontal shaker KS 260 basic Shaker IKA 
Lumi-Imager F1 UV light gel analysis Roche 
Microscope Inverted micrscopy Olympus 
NanoDrop DNA measurement Thermo Scientific 
Neubauer chamber Cell counting  
Power Pac Universal Electrophoresis, power supply Bio-Rad 
7300 Real-time PCR system PCR Applied Biosystems 
Scil Vet abc Murine blood cell counting Scilvet 
Thermocycler PCR Biometra 
Vortex Genie 2 Vortexing Bender & Hobein AG 
µQuant Enzyme-linked immune-sorbent 
assay (ELISA) 
BioTek 
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3.2 METHODS 
3.2.1 CELL CULTURING AND CELL PREPARATION 
58 cells derived from the T cell lymphoma BW5147 were cultured in T cell medium. Cells were diluted 
1:5 in fresh medium three times a week. PlatE cells derived from the 293T cell line expressing gag-pol 
and ecotrophic env genes [173]. Cells were cultured in DMEM and 10 % inactive FCS and used for 
ecotrophic virus production. MC57gp33high clone 1 expresses a fusion gene of gp33 and GFP and is 
derived from MC57gp33low fibrosarcoma cells treated with 200 nM 4-hydroxytamoxifen [174]. Cells 
were grown in DMEM with 5 % FCS. Adherent cells were trypsinated with 0.05 % trypsin-EDTA in PBS 
for 5 minutes (min) at 37 °C and then taken up 1:10 diluted in fresh medium. Murine splenocytes 
were cultured in CMM. 
Freezing and thawing of cells 
Frozen cells were kept at -80 °C or in liquid nitrogen in cryo-tubes. For freezing, cell lines were taken 
up in 500 µl T cell medium with 20 % FCS and 10 % DMSO, primary cells in 500 µl FCS and 10 % DMSO 
and then slowly cooled down to -80 °C in a cryo-container for 24 h. For thawing, cyro-tubes were 
shortly incubated at 37 °C; cells were washed with medium and taken up in medium for culturing. 
Cell counting 
Cells were counted in a 1:10 or 1:4 dilution with 10 µl cells, 30 µl (10 µl) trypan blue and 60 µl (20 µl) 
PBS in a Neubauer chamber. 
Preparation of splenocytes, lymphnodes and bone-marrow 
The spleen was cut out and smashed in a cell strainer with a plunger. Cells were washed through the 
cell strainer with 20 ml PBS and if needed, a second cell strainer was used. After centrifugation for 5 
min at 400 g and 4 °C, cells were resuspended in 3 ml ACK lysis buffer and incubated for 3 min. 20 ml 
PBS was added and cells were centrifuged for 5 min at 400 g and 4 °C. The cells were washed a 
second time with PBS and then resuspended in CMM medium and activated as mentioned below. 
Lymphnodes (LN) were pooled and smashed in a cell strainer with a plunger. If necessary, red blood 
cells were lysed with ACK lysis buffer. Lymphnode cells were resuspended in PBS. 
Bone-marrow (BM) was prepared by flushing the femur and tibia bones with PBS supplemented with 
1 mM EDTA and 2 % FCS. Red blood cells were lysed with ACK lysis buffer. Cells were resuspended in 
PBS. 
36 
 
3.2.2 DNA TRANSFECTION BY CALCIUM PHOSPHATE PRECIPITATION 
PlatE cells (1 x 106) were plated in 3 ml per well in a 6-well plate 24 h before transfection to obtain  
80 % confluency of the cells. 18 µg of the transgene vector DNA was mixed in 150 µl destilled water 
(dH2O) containing 15 µl calcium chloride dihydrate (2.5 mM). 150 µl of transfection buffer was added 
in drops during vortexing the DNA-water-CaCl2 mix to generate DNA-calcium-phosphat-complexes. 
The transfection mixture was incubated for 15 min at room temperature (RT) and then added in 
drops on the plated cells. After 6 h incubation, the medium was carefully replaced by fresh medium. 
48 h later, viral supernatant was harvested and filtered through a 0.45 µm filter. A second harvest of 
virus supernatant was done 24 h later. 
3.2.3 VIRAL TRANSDUCTION 
For transduction with viral particles, cells were seeded on RN-coated plates. For coating, 400 µl RN 
(25 µg/ml) was used per well on a 24-well plate and 1 ml on a 6-well plate. Coating was done for 2 h 
at RT. Afterwards; wells were blocked with 2 % BSA for 30 min at RT. Wells were washed with RN 
wash buffer. 
Transduction of cell lines (58 cells) 
1 x 105 cells were plated in a RN-coated 24-well plate per well and ml. 1 ml viral supernatant was 
added as well as 4 µg/ml protamine sulfate. The plate was spinoculated for 90 min at 800 g and  
37 °C. The transduction was repeated 24 h later in the same way by replacing 1 ml with fresh viral 
supernatant. 
Transduction of murine splenocytes 
Freshly prepared splenocytes were activated for 24 h with 1 µg/ml anti-CD3 antibody, 0.1 µg/ml anti-
CD28 antibody and 40 U/ml hIL-2. They were seeded in 3 ml CMM with 2 x 106 cells /ml per well in a 
RN-coated 6-well plate. The next day, 3 ml viral supernatant was added per well supplemented with 
4 µg/ml protamine sulfate, 1 µg/ml anti-CD3 antibody, 0.1 µg/ml anti-CD28 antibody and 40 U/ml 
hIL-2. The 6-well plate was spinoculated for 90 min at 800 g and 37 °C. After 24 h, 3 ml was replaced 
with fresh viral supernatant supplemented with protamine sulfate and hIL-2 and the plate was again 
spinoculated. After spinoculation, 2 ml fresh medium with hIL-2 was added. For in vitro assays, 
splenocytes were washed and counted the next day. 1 x 106 cells /ml were seeded in fresh CMM 
medium with 10 ng/ml hIL-15 and analysis was done after two days. For the OT-I+P14 I and OT-I+GFP 
experiment in vivo, cells were transferred into mice 24 h after the last transduction. For the OT-I+P14 
II experiment, cells were washed after the second transduction and resuspended in fresh CMM 
medium supplemented with 50 ng/ml rhIL-15. Three days later, cells were transferred into mice. 
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Determination of virus titer 
For the safety analysis of transduced T cells in vivo the virus titer was determined by transducing 58 
cells. GFP-virus was diluted 1:200 and P14 TCR-virus 1:100 in 2 ml and supplemented with 4 µg/ml 
protamine sulfate. The RN-plate was spinoculated. After 72h, the cells were analyzed for GFP or TCR 
expression, respectively. The calculation of the virus titer was as followed:  
Virus titer/ ml = number of cells * GFP/P14-TCR-positive cells * dilution factor * division factor / 
volume 
The division factor is 2 since cells had to divide for virus infection. 
3.2.4 FUNCTIONAL ASSAYS 
In a 96-well plate 1 x 105 effector cells and 1 x 105 peptide-loaded target cells were added in a 
volume of 200 µl. As a positive stimulation control 5 ng/ml Phorbol-12-myristate-13-acetate (PMA) 
and 1 µM Ionomycin was added. The negative control included target cells without peptide. Peptides 
were added directly to the coculture. After 4 or 24 h incubation at 37 °C, the supernatant was 
harvested for cytokine secretion analysis by enzyme-linked immune-sorbent assay (ELISA) or cells 
were harvested for intracellular cytokine staining, respectively. Experiments were repeated at least 
once. 
Determination of secreted IL-2 or IFN- 
Mouse IL-2 and IFN- were measured by an ELISA according to the manufacturer’s manual but half of 
the volumes were used. A 96-well plate was coated with purified anti-mouse IL-2 or IFN- antibody in 
1 x coating buffer (50 µl/ well) over night at 4 °C. Wells were washed three times with 300 µl ELISA 
wash buffer. Wells were then blocked with 100 µl 1 x assay diluent diluted in dH2O for 1 h at RT. After 
the blocking step and a washing step as mentioned above, 50 µl of the cocultivation supernatant and 
standard dilutions of recombinant mouse IL-2 (200, 100, 50, 25, 12.5, 6.25 pg/ml) or mouse IFN- 
(2000, 1000, 500, 250, 125, 62.5 pg/ml) in 50 µl 1 x assay diluent were added in doublets and the 
plate was incubated for 2 h at RT. The plate was washed five times with 300 µl/ well ELISA wash 
buffer. For IL-2 detection, 50 µl of the detection antibody (biotinylated anti-mouse IL-2) diluted in 1 x 
assay diluent was added and incubated for 1 h at RT. After washing, 50 µl of streptavidin-horseradish 
peroxidase diluted in 1 x assay diluent was added and incubated for 30 min at RT. For IFN- 
detection, biotinylated anti-mouse IFN- and streptavidin-horseradish peroxidase was added in 50 µl 
1 x assay diluent and incubated for 1 h at RT. The wells were washed again and then 50 µl of the 
substrate (1 x tetramethylbenzidine solution) was added. Incubation was done in the dark, and the 
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time of reaction was individually decided by judging the developing colour of the standard wells but 
was maximally 15 min. 50 µl 2 N H2SO4 solution stopped the reaction, and the plates were measured 
with the µQuant at 450 nm and 570 nm for background absorption. Values of 570 nm and the blank 
value were subtracted from values of 450 nm. A standard curve was drawn with the titrated standard 
protein concentrations and 450 nm-values. Unknown concentrations were calculated with help of 
the standard curve. 
3.2.5 ANTIBODY-STAINING AND FLOW-CYTOMETRIC MEASUREMENT 
Cell staining for fluorescence activated cell sorting (FACS) analysis 
0.5 - 1 x 106 cells were harvested and resuspended in 50 µl FACS buffer with 0.5-1 µl antibody. The 
staining was done for 15 - 30 min at 4 °C. The stained cells were washed twice in FACS buffer and if 
necessary stained with a secondary antibody. The stained cells were analyzed with the FACSCalibur. 
Quantification of TCR chains 
To quantify TCR chains on the cell surface the Qifikit® from DAKO was used. Cells were stained with 
primary antibodies. Afterwards, they were stained with 1 µl anti-mouse IgG-FITC antibody in 50 µl 
FACS buffer. In parallel, 50 µl of set-up beads and of calibration beads were washed in 3 ml FACS 
buffer and then stained with 1 µl anti-mouse IgG-FITC antibody in 50 µl FACS buffer. After washing 
twice, the stained cells and beads were measured with the FACSCalibur. The stained set-up beads 
and unstained cells were used to adjust the photomultiplier tube (PMT) voltage to see the positively 
and negatively FITC-labeled fractions. Calibration beads were measured with excluding debris and 
doublets in the forward scatter versus side scatter. Without changing the settings the samples were 
measured afterwards. For the calculation of the antigen density per cell a calibration curve was 
determined. The mean fluorescence intensity (MFI) of the bead populations was determined with 
help of FloJo software and plotted against the antibody-binding capacity (ABC) of each bead 
population as indicated in the manufacturer’s manual (Table 13). The MFI of the samples were 
determined and the antigen density was calculated with help of the equation of the calibration 
curve. The MFI of negatively stained cells was used for calculation of the background antibody 
equivalent (BAE) and subtracted from the ABCs of the samples. The experiment was repeated once. 
Table 13 Antibody-binding capacity of bead populations 
Calibration Bead ABC 
B 1600 
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C 10000 
D 49000 
E 184000 
F 543000 
DAKO Qifikit® REF K0078 LOT 00046689  
FRET analysis 
This technique is used to analyze the regional proximity of two molecules by labeling these with 
suitable fluorophores. One fluorophore serves as donor which transmits its energy after excitation to 
a nearby acceptor fluorophore which gets excited by non-radiative energy. Prerequisite for this 
energy transfer is the proximity of 10 nm of donor and acceptor molecule. The donor fluorophore 
emits light of a different wave length after this energy transfer which can be measured (Figure 5). 
For FRET analysis, unstained cells were measured for calculation of the background MFI, single 
stained cells with the donor fluorophore and acceptor fluorophore for the determination of the 
correction factors S1-S4 and double stained cells for the calculation of the FRET efficiencies. For the 
FRET measurement, cells were stained with PE-labeled anti-TCRv chain antibodies and primary Tag 
antibodies (anti-Myc or anti-HA) in combination with an anti-mouse IgG-Cy5-labeled secondary 
antibody. The PE-fluorophore served as the donor molecule whereas the Cy5-fluorophore functioned 
as acceptor molecule. The cell clones were cultured with the indicated Dox concentrations and 24 h 
later stained for the above mentioned combinations. The stained cells were analyzed using a 
FACSCalibur without compensation. The FACS files were then analyzed with the FRET software Aflex, 
and FRET efficiencies were calculated. The same correction factors and the -factor of 1 were used 
for all analyzed measurements. Stainings were repeated several times. 
 
Figure 5 Jablonski Diagramm 
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Donor and acceptor energy levels are shown. S0: the unexcitated status of the fluorohore electrons, S1: 
excitated status of the fluorohore electrons. Donor fluorophore electrons can transmit energy in a non-
radiated form to nearby acceptor fluorophore electrons. Diagram was adapted from the Olympus website. 
IFN--/CD107-staining 
Antibody against CD107 as well as Brefeldin A (10 µg/ml) and GolgiStopTM (1 µl/200 µl) was directly 
added to the cocultivation which was incubated for 4 h at 37 °C. Stimulated cells were harvested and 
stained first for surface antigens as described above. Then, intracelluar staining for IFN- was done 
with the Cytofix/CytopermTM kit. Cells were resuspended in 100 µl Cytofix/Cytoperm supplemented 
with 1 µl GolgiStopTM and incubated for 30 min at 4 °C. Cells were washed twice with 100 µl 1 x 
Perm/Wash buffer. Then IFN- antibody was added in 50 µl Perm/Wash buffer to the cells and cells 
were incubated for 20 min at 4 °C. After washing twice with 100 µl Perm/Wash buffer, cells were 
resuspended in 100 µl FACS buffer. 
3.2.6 GENERATION OF TCR EXPRESSING CELL CLONES 
The 58 T cell line was used for TCR expression since it does not express an endogenous TCR. To test 
functionality of MHC class I-restricted TCRs it was engineered to express the CD8 receptor. For the 
generation of cell clones, 1 x 106 transduced cells were stained with an antibody directed against the 
relevant antigen (TCR chain) as mentioned above. If necessary, the TCR expression was induced by 
adding 1 µg/ml Dox to the cell culture 24 h before the staining. Stained cells were resuspended in 
500 µl PBS with 10 % FCS, 200 U/ml antibiotic/fungizide mix and 10 µg/ml gentamycin and given 
through a cell strainer into the sterile FACS tube. 96-well round-bottom plates were prepared with 1 
x 103 irradiated unstained cells in 200 µl T cell medium with 200 U/ml antibiotic/fungizide mix and 10 
µg/ml gentamycin. Before, cells were irradiated with 63 gray and washed twice with T cell medium. 
The single cell sorting of positively stained cells was performed with the FACSAria and one cell was 
added per well. After approximately 14 days, 100 µl medium was replaced with fresh T cell medium 
in wells with growing clones. 3 days later, 100 µl cell suspension was transferred into a new 96-well 
plate and used for antibody staining. Positively stained cells were expanded in culture for further 
analysis. 
3.2.7 ANIMAL EXPERIMENTS 
C57BL/6N mice were purchased from Charles River or Janvier. B6.PL-Thy1a/CyJ mice were purchased 
from The Jackson Laboratory. This mouse strain is congenic for the T cell marker Thy1a (Thy1.1= 
CD90.1), and T cells can be differentiated from T cells of C57BL/6 mice which have the congenic 
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marker CD90.2. B6.PL-Thy1a/CyJ mice were bred to OT-I/Rag-/- mice (originating from C57BL/6-
Tg(TcraTcrb)1100Mjb/J) to obtain OT-I/CD90.1/Rag+/- mice. Mice of the first generation which 
expressed both CD90.1 and CD90.2 and of the second generation which only expressed CD90.1 were 
used for donor cell preparation. Breeding and experiments were done in the animal facility of the 
Max Delbrück Center for Molecular Medicine, Berlin, Germany. Animal experiments were officially 
approved and permitted by the institute and the regional authority. 
Adoptive T cell transfer 
Cells were washed twice in DPBS and counted. 5 x 106 cells in 200 µl DPBS were injected 
intravenously into the tail vein, vena caudalis mediana, with a 0.4 x 20 mm needle. 
Stimulation in vivo 
The MC57gp33high tumor cell line was trypsinated and washed twice with DPBS. 3 x 106 cells in 300 µl 
DPBS were injected subcutaneously with a 0.4 x 20 mm needle, 150 µl on each side. 
Peptide (50 or 10 µg) and CpG ODN 1826 (50 or 10 µg) was mixed with 100 µl incomplete Freund’s 
adjuvant (IFA) and adjusted to a volume of 200 µl with DPBS. To obtain a homogenous mixture a 
syringe with a 0.6 x 20 mm needle was used. 200 µl was injected subcutaneously, on each side 100 µl 
with a 0.4 x 20 mm needle. 
Blood withdrawal and blood processing 
Blood was taken with a Goldenrod animal lancet (MEDIpoint) from the Vena facialis which is located 
in the submandibular area without anesthesia. 50 - 100 µl blood was taken for DNA preparation with 
the QuiAmp DNA blood Mini kit or Invisorb Spin Blood Mini kit according to the manufacturer’s 
manuals. Elution of the DNA was done in 200 µl dH2O. For flow cytometry staining, 30 - 50 µl blood 
was incubated with 30 - 50 µl PBS and 0.3 - 0.5 µl antibody and anti-CD16/CD32 for FC-receptor 
blocking for 20 min in the dark at RT. Blood was either lysed with help of the FACS lysis /wash 
assistant or by adding 500 µl ACK lysis buffer. After 30 min incubation with ACK lysis buffer, cells 
were washed with 2 ml PBS and resuspended in 200 µl PBS. 
In vivo proliferation 
5 mM carboxyfluorescein diacetate succinimidyl ester (CFSE) stock solution was diluted 1:500. 1 x 107 
cells were resuspended in 900 µl PBS. 100 µl of CFSE was added to the cells (CFSE final: 1 µM), and 
cells were incubated for 15 min at 37 °C. CMM medium was added, and cells were washed. Cells 
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were resuspended in medium and incubated for 30 min at 37 °C. After washing with DPBS, cells were 
counted and CFSE-labeling was analyzed by FACS measurement. 3 x 106 cells in 200 µl DPBS were 
injected into the mouse tail vein. Stimulations were done right after as described above. After 4 days, 
spleens were processed and stained for CD90.1. CFSE dilution was measured by FACS on CD90.1-
positive cells. 
3.2.8 RETROVIRAL VECTORS 
Tetracycline-regulated vector system 
The used retroviral vector for inducible gene expression is a MLV SIN vector, where part of the U3 
region of the 3’-LTR, which harbors promoter and enhancer functions, was deleted. This region is 
transferred to the 5’-end of the provirus during the reverse transcription process in the host cell and 
drives viral gene expression. In the tet-regulated vector transgene expression is driven by the T2-
modified minimal CMV promoter (T2) which was constructed to harbor a tetO heptamer binding 
sequence (tetO7) (Figure 6). The M2 transactivator gene expression is constitutively driven by the 
human Pgk promoter in reverse direction to the transgene. When Dox binds to the M2 
transactivator, it can bind to the tetO heptamer sequence of the CMV minimal promoter and 
transcription of the transgene is initialized. The tet-regulated vector was provided by Rainer Löw 
from the Euffets GmBH and from Niels Heinz from the lab of Christopher Baum at the Medical School 
Hannover [172]. 
 
Figure 6 Schematic picture of the tet-regulated retroviral vector 
SIN-LTR: deletions in Mo-MLV-3´-LTR: border (-448/-412; -74/-1, TATA-box mutated in core promoter); , +: 
Psi-binding signal for packaging of viral RNA into the viral particles; SA, SD: splice acceptor, splice donor; PRE: 
posttranscriptional regulatory element of the woodchuck virus; modified "atg" of ´X´-protein; M2: reverse 
transactivator; M2 variant; hPgk: human phosphoglycerate kinase promoter; tetO7: tet-operator heptamer, wt-
DNA-sequence, 36 nt spacing from core to core, asymmetric operator fusion points; TCR: T cell receptor gene in 
the formation of TCRv chain-P2A-TCRv chain; CTE: constitutive transport element of the simian retrovirus 
type 1; hghpA: human growth hormone polyA signal. 
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MP71 retroviral vector 
The MP71 retroviral vector contains LTRs of the MPSV and a PRE of the woodchuck hepatitis virus. It 
also contains a modified mRNA splice site [92]. 
LXSN retroviral vector 
The LXSN retroviral vector contains the promoter-enhancer elements of the Mo-MLV LTR which drive 
transgene expression. The SV40 promoter drives neomycin resistance [175]. 
3.2.9 T CELL RECEPTORS 
The P14 TCR is specific for the lymphochoriomeningitis virus glycoprotein peptide gp33-41 (gp33) 
(KAVYNFATM) in a H2-Db-restricted manner. It consists of the P14v2 and P14v8 chain. The OT-I 
TCR is specific for the H2-Kb-restricted peptide ova257-264 (ova) (SIINFEKL) of the antigen ovalbumin 
and harbors the OT-Iv2 and OT-Iv5 chain. TCRs were cloned as a transgene into the tet-regulated 
vector, LXSN vector or MP71 vector in the formation of TCRv chain linked by a P2A element of the 
porcine teschovirus which then enables expression of the followed TCRv chain. 
Since the OT-I and P14 TCR harbor a TCRv chain of the same family, the antibody directed against 
the TCRv chain cannot distinguish between the OT-Iv2 and the P14v2 chain in dual TCR T cells. 
Therefore, the TCRv2 chains were tagged with a short sequence at the N-terminus of the protein. 
The P14v2 chain was tagged with two Myc sequences (EQKLISEEDL EQKLISEEDL) by Elisa Kieback 
and the OT-Iv2 chain with the HA sequence (YPYDVPDYA). The additional sequences do not 
interfere with protein functionality and do not disturb the proper pairing of the corresponding TCRv 
chains. These modifications made it possible to distinguish the TCRv chains by staining with 
antibodies directed against the Tags. 
3.2.10 MOLECULAR CLONING OF GENES 
Gene cloning by polymerase chain reaction 
Polymerase chain reactions (PCRs) were conducted as stated in Table 14 and run as noted in Table 
15. Annealing temperature was adjusted to the used primers. 1 µl 5 x loading buffer was added to 5 
µl PCR reaction and the mixture as well as 8 µl of DNA-1 kb marker was applied on a 1 % agarose gel 
which was prepared with 0.5 µg/ml ethidium bromide. The gel was run at 120 V and bands were 
visualized by ultraviolet light (UV). PCR reaction products were purified using the MinElute PCR 
Purification kit and DNA was eluted in 10 µl elution buffer. 
44 
 
Table 14 PCR reaction mix 
Reagents Concentration used Volume (µl) 
Phusion polymerase buffer (Finnzymes) 10 x 5 
dNTPs 200 µM each 1 
Primer fwd 20 pmol/µl 1 
Primer rev 20 pmol/µl 1 
Phusion polymerase (Finnzymes) 2 U/µl 1 
Template DNA 100 ng  
dH2O  ad 50  
 
Table 15 PCR cycles 
Cycle number Time and temperature 
1 5 min 95 °C 
2-35 1 min 95 °C, 45 s 58-64 °C, 45 s 72 °C  
36 10 min 72 °C 
Hold 4°C 
 
PCR products were annealed as stated in Table 16 and Table 17 and amplified in following PCR cycles 
(Table 15) by adding 2 µl of 20 pmol/µl primer fwd and rev. 
Table 16 Annealing reaction 
Reagents Concentration used Volume (µl) 
Phusion polymerase buffer (Finnzymes) 10 x 10 
dNTPs 200 µM each 2 
PCR product 1  4 
PCR product 2  4 
Phusion polymerase (Finnzymes) 2 U/µl 2 
dH2O  ad 100  
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Table 17 Annealing cycles 
Cycle number Time and temperature 
1 5 min 95 °C 
2 1 min 95 °C 
3 Cool down from 95 °C - 45 °C, 5 °C in 30 s 
4 1 min 72 °C 
2-4 5 x 
Hold 4 °C 
 
PCR reaction product was purified with MinElute PCR purification kit and DNA was digested with 
restriction enzymes NotI and EcoRI. DNA was eluted in 32 µl dH2O and 4 µl restriction buffer and 2 µl 
of each restriction enzyme was added. Digestion was done for 1 h at 37 °C. DNA was precipitated 
with 10 fold volume of 100 % ethanol by centrifugation at maximal speed at 4 °C. After washing with 
2 fold volume 70 % ethanol, the dried DNA was dissolved in 10 µl dH2O. 
The MP71 vector DNA (4 µg) was digested as mentioned above and cohesive ends of the DNA were 
dephosphorylated with alkaline phosphatase to prevent re-ligation of vector DNA. To 40 µl digestion 
mix 6 µl 10 x dephosphorylation buffer, 53 µl dH2O and 1 µl alkaline phosphatase was added and the 
mixture was incubated for 1 h at 37 °C. After 30 min, again 1 µl alkaline phosphatase was added. 
Vector DNA was analyzed by agarose gel electrophoresis. Under UV light the correct band was cut 
out and purified using the EasyPure DNA purification kit. 
DNA concentrations of PCR fragment and vector DNA were estimated on a 1 % agarose gel with help 
of a DNA marker. For ligation, the ratio of vector and fragment size was calculated and a molar ratio 
of 1:3 was used with 100 ng vector DNA. In a 20 µl ligation mix, 10 µl 2 x ligation buffer, 4 µl 5 x 
ligation buffer, 1 µl rapid ligase, DNA and dH20 was added and incubated for 5 min at RT. 10 µl of 
ligation mix were given to 100 µl chemically prepared competent Mach1TM E. coli (Invitrogen) and 
incubated for 20 min on ice. Heat shock was done with the bacteria for 45 seconds at 42 °C. After 
incubation for 1 min on ice, 1 ml Soc medium was added to the bacteria and the mix was incubated 
for 1 h at 37 °C and 220 rpm. Bacteria were plated on a LB agar plate supplemented with 100 µg/ml 
ampicillin. The plate was incubated over night at 37 °C. 
Bacterial colonies were isolated and incubated in 3 ml LB medium over night at 37 °C. Plasmid DNA 
was prepared using the Invisorb Spin Plasmid Mini Two kit according to the manual. Control digestion 
was done with purified DNA. DNA was sequenced using primers Leader-fwd and PRE-rev by the 
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company Eurofins MWG Operon. Correct plasmid DNA (100 ng) was transformed in Mach1TM E. coli 
as described above. A colony culture was set up for a Maxi DNA preparation. The quality of plasmid 
DNA preparation was checked by control enzymatic digestion. 
In Table 18 plasmids are listed which were generated as described above by PCR with stated primers. 
Table 18 Plasmids generated by PCR 
Generated plasmid Template DNA PCR1, PCR2, PCR3 Annealing PCR 
MP71-OT-IHA MP71-OT-I v2-NotI-fwd, HA-rev v2-NotI-fwd, 1. v2-
EcoRI-rev MP71-OT-I HA-fwd, v2-EcoRI-rev 
MP71-OT-I--P2A-
HA 
MP71-OT-I v-NotI-fwd, v-P2A-rev v-NotI-fwd, v2-
EcoRI-rev MP71-OT-IHA OT-Iv2-P2A-fwd, v2-
EcoRI-rev 
MP71-OT-I-cys-P2A-
HAcys 
MP71-OT-I--P2A-
HA 
v-NotI-fwd, v-cys-rev v-NotI-fwd, v-
EcoRI-rev 
MP71-OT-I-- P2A- v-cys-fwd, v-cys-rev 
 HA   
MP71-OT-I-- P 2A-
HA 
v-cys-fwd, v-EcoRI-
rev 
MP71-P14-cys-P2A-
DANcys 
MP71-P14--P2A-
DAN 
v-NotI-fwd, v-cys-rev v-NotI-fwd, v-
EcoRI-rev 
MP71-P14--P2A-
DAN 
v-cys-fwd, v-cys-rev 
MP71-P14--P2A-
DAN 
v-cys-fwd, v-EcoRI-
rev 
 
Gene cloning by enzymatic digestion 
The cloning of genes into the pLXSN vector and the Tet vector was done by enzymatic digestion as 
shown in Table 19. For generating the Tet vectors (Tet) an intermediate plasmid with the M2 
promoter (M2) was used in a first cloning step. Afterwards, the transgene with the M2 promoter 
cassette was excised and inserted into the final Tet vector. 
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Table 19 Plasmids generated by enzymatic digestion 
Generated Plasmid Template Plasmid Cut with Target 
Plasmid 
Cut with 
pLSN-OT-I--p2a-HA MP71-OT-I--P2A-HA NotI, EcoRI; 
Klenow-Fillin 
pLSN Hpa1 (blunt) 
pLSN-P14--P2A-DAN MP71-P14--P2A-
DAN 
NotI, EcoRI; 
Klenow-Fillin 
pLSN Hpa1 (blunt) 
M2-OT-I--P2A-HA MP71-OT-I--P2A-HA NotI, EcoRI; 
Klenow-Fillin 
M2 Bsp1407I, NcoI; 
Klenow-Fillin 
M2-P14--P2A-DAN MP71-P14--P2A-
DAN 
NotI, EcoRI; 
Klenow-Fillin 
M2 Bsp1407I, NcoI; 
Klenow-Fillin 
Tet-OT-I--P2A-HA M2-OT-I--P2A-HA NotI, XhoI Tet NotI, XhoI 
Tet-P14--P2A-DAN M2-P14--P2A-DAN NotI, XhoI Tet NotI, XhoI 
M2-OT-I- MP71-OT-I- NotI, EcoRI; 
Klenow-Fillin 
M2 Bsp1407I, NcoI; 
Klenow-Fillin 
M2-OT-HA MP71-OT-I-HA NotI, EcoRI; 
Klenow-Fillin 
M2 Bsp1407I, NcoI; 
Klenow-Fillin 
Tet-OT-I- M2-OT-I- NotI, XhoI Tet NotI, XhoI 
Tet-OT-HA MP71-OT-I-HA NotI, XhoI Tet NotI, XhoI 
 
Digested DNA which did not have the same overhangs as the target plasmid was filled up with the 
Klenow enzyme. Digested DNA was precipitated with ethanol and dissolved in 16.6 µl H2O, 0.4 µl 
dNTP, 2 µl Klenow puffer and 1 µl Klenow enzyme. The reaction was incubated for 10 min at RT and 
for 20 min at 37 °C. Target plasmid was filled up to 100 µl with H2O for dephosphorylation reaction 
and purified after agarose gel electrophoresis with the EasyPure DNA purification kit. Insert-DNA was 
purified by ethanol precipitation or after agarose gel electroporesis. 
3.2.11 DETERMINATION OF VECTOR COPY NUMBER INTEGRATION BY REAL-TIME PCR 
The determination of the number of integrated vectors per cell was performed by means of real-time 
PCR. Vector specific primers (Table 10) were used to detect the proviral DNA, and normalisation was 
done with detection of the housekeeping gene β-actin. A calibration curve of detected DNA was done 
with titrated plasmid in untransduced cells. For all samples, 10 ng DNA was used and vector-specific 
and -actin detection was done in triplets ,and the PCR was repeated once. 20 µl of the MaximaTM 
SYBR Green qPCR master mix was used, and 5 µl of DNA was added. The PCR was run with the 7300 
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Real-time PCR system. CT values were determined with help of the system software. In the 
calibration curve CT values (CT-actin- CTplasmid) were calculated and plotted against copy number in a 
log scale. CT values were calculated for the samples (CT-actin- CTvector) and solved for the copy 
number with help of the equation of the calibration curve. For the calculation it was assumed that 
one cell contains 6,81 pg DNA. The copy number integration was calculated per cell and the 
transduction efficiency was taken into account. For the Tet vector cell clones a factor of 1 was taken 
for the transduction efficiency since ~100 % TCR-positive cell clones were used. 
3.2.12 LINEAR AMPLIFICATION-MEDIATED PCR 
Linear PCR 
Linear amplification-mediated (LAM) PCR was performed after the protocol by Schmidt et al. [176] 
and done in the lab of Prof. von Kalle, NCT, Heidelberg. The LAM-PCR protocol was developed for the 
determination of vector integration sites in the target genomic DNA (Figure 7). 
 
Figure 7 LAM-PCR 
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Experimental set-up of the LAM-PCR. Adapted from [176]. Blue quadrates represent the beads. In brown Biotin 
bound to DNA is shown. 
100 ng DNA was used in a volume of 50 µl for a linear PCR with 5’-biotinylated primers which bind in 
the 5’-LTR. After the first run, 0.25 µl Taq polymerase was added to each tube and a second round of 
PCR cycles was done (Table 20, Table 21). 
Table 20 Linear amplification mix 
Reagents Concentration used Volume (µl) 
Taq polymerase buffer (Quiagen) 10 x 5 
dNTPs 200 µM each 1 
Primer LTRa-bio-rev 0.5 pmol/µl 0.25 
Primer LTRb-bio-rev 0.5 pmol/µl 0.25 
Taq polymerase (Genaxxon) 5 U/µl 0.5 
Genomic DNA 100 ng  
ddH2O  ad 50  
 
Table 21 PCR cycles 
Cycle number Temperature 
1 5 min 95 °C 
2-51 1 min 95 °C, 45 s 60 °C, 90 s 72 °C  
52 10 min 72 °C 
Hold 4 °C 
 
Magnetic capture 
Magnetic beads were prepared. 20 µl per reaction was taken and put on a magnet. Supernatant was 
taken, and beads were diluted in 40 µl PBS with 0.1 % BSA. The washing step was repeated once. 
Then, beads were washed with 20 µl 3 M LiCl and resuspended in 50 µl 6 M LiCl. Beads were mixed 
with 50 µl PCR reaction mixture and incubated over night at RT and 300 rpm. 
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dsDNA synthesis 
The PCR-bead mix was washed with 100 µl ddH2O on the magnet and then resuspended in 20 µl 
Hexa-Nt priming mix. The reaction was done for 1 h at 37 °C (Table 22). 
Table 22 Hexanucleotid priming 
Reagents Concentration used Volume (µl) 
Hexa-Nt 10 x 2 
dNTPs 200 µM each 0.5 
Klenow enzyme 2 U/µl 1 
ddH2O  16.5  
 
80 µl ddH2O was added to the reaction and put on the magnet. Supernatant was withdrawn and 
samples were washed with 100 µl ddH2O. 
Enzymatic digestion of DNA 
The DNA was then digested with either HypCH4IV or Tsp509I restriction enzyme in a 20 µl reaction 
volume for 1 h at 37 °C (Table 23). 
Table 23 Enzymatic digestion 
Reagents Concentration used Volume (µl) 
Restriction buffer 10 x 2 
Enzyme 10 U/µl 0.4 
ddH2O  17.6 
 
Ligation of the linker cassette to the DNA 
DNA-bead mix was washed with 80 µl and 100 µl ddH2O as described above. In a 10 µl volume a 
linker cassette was ligated to the digested DNA. The ligation was performed for 5 min at RT (Table 
24). 
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Preparation of the linker cassette 
The linker cassette had to be prepared in advance. 40 µl of LC1 (100 pmol/µl), 40 µl of LC2 (100 
pmol/µl), 10 µl of MgCl2 (100 mM) and 110 µl of annealing buffer (Tris-HCL (250 mM; pH 7.5)) was 
mixed and incubated for 5 min at 95 °C. The reaction mixture was then cooled slowly to 4 °C. After 6 -
24 h, 300 µl ddH2O was added and the mixture was transferred to a Microcon-30 column which was 
centrifuged for 12 min at 15000 g and RT. The reversed column was placed on a new 1.5 ml tube and 
centrifuged for 3 min at 1000 g and RT. The dropped-down volume was adjusted to 80 µl with ddH2O. 
The linker cassette was frozen in aliquots of 10- 20 µl each and only used once. 
Table 24 Ligation 
Reagents Concentration used Volume (µl) 
Ligation buffer 10 x 1 
ATP 10 mM 1 
Ligase 2 U/µl 1 
Linker cassette n.d. 2 
ddH2O  5 
 
Denaturation of DNA 
The DNA was washed with 90 µl and 100 µl ddH2O on the magnet and then denaturated with 5 µl 0.1 
N NaOH for 10 min at RT and 300 rpm on a horizontal shaker. 
Nested PCRs 
The denaturated DNA was placed on the magnet and 2 µl of the supernatant which contained single-
stranded unbiotinylated DNA was used for a nested PCR with primer LCI-fwd and LTR-bio-rev (Table 
25, Table 26). 
Table 25 Nested PCR 
Reagents Concentration used Volume (µl) 
Taq polymerase buffer (Quiagen) 10 x 5 
dNTPs 200 µM each 1 
Primer LCI-fwd/LCII-fwd 16.67 pmol/µl 0.5 
Primer LTRII-bio-rev/LTRIII-rev 16.67 pmol/µl 0.5 
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Taq polymerase (Genaxxon) 5 U/µl 0.5 
Denaturated DNA  2/1 
ddH2O  40.5  
 
Table 26 PCR cycles of nested PCR 
Cycle number Temperature 
1 5 min 95 °C 
2-35 1 min 95 °C, 45 sec 60 °C, 90 s 72 °C  
36 10 min 72 °C 
Hold 4 °C 
 
20 µl beads were prepared as described above, except that they were taken up in 20 µl 6 M LiCl. 
Beads were mixed with 20 µl of the PCR reaction mixture and incubated over night at RT and 300 
rpm on a horizontal shaker. After incubation, DNA was washed with 60 µl and 2 x 100 µl ddH2O on 
the magnet and denaturated with 20 µl 0.1 N NaOH for 10 min at RT and 300 rpm on a horizontal 
shaker. 1 µl of the supernatant was used for a second nested PCR with primers LCII-fwd and LTRIII-
rev as stated in Table 25 and Table 26. For analysis 5 µl of the PCR reaction was mixed with loading 
buffer and run on an agarose gel or spreadex gel. 
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3.3 COMPANIES 
Table 27 Companies 
Company City, Country 
Applied Biosystems by Life 
Technologies 
Carlsbad, USA 
ATCC Manassas, USA 
Baxter Unterschleissheim, Germany 
BD Bioscience Heidelberg, Germany 
BD Falcon Franklin Lakes, USA 
BD Pharmingen Heidelberg, Germany 
Beckman Coulter Krefeld, Germany 
Bender & Hobein Zurich, Switzerland 
Biochrom Berlin, Germany 
Biolegend Fell, Germany 
Biometra Goettingen, Germany 
Bio-Rad Munich, Germany 
Biosynthan Berlin, Germany 
BioTek Bad Friedrichshall, Germany 
Biozym Hessisch Oldendorf, Germany 
B Braun Melsungen, Germany 
Calbiochem by Merck Darmstadt, Germany 
Caltag Laboratories Karlsruhe, Germany 
Charles River Sulzfeld, Germany 
Chiron Marburg, Germany 
Corning Costar Munich, Germany 
Chiron Marburg, Germany 
Dako by Biozol Eching, Germany 
eBioscience San Diego, USA 
Elchrom Scientific Cham, Switzerland 
Epicentre Biotechnologies Madison, USA 
Eppendorf Hamburg, Germany 
Eurofins MWG Operon Martinsried, Germany 
Fermentas St. Leon-Rot, Germany 
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Finnzymes Lafayette, USA 
Genaxxon Ulm, Germany 
Gibco Karlsruhe, Germany 
Greiner Bio-One Frickenhausen, Germany 
Heraeus Buckinghamshire, UK 
Invitek Berlin, Germany 
Invitrogen by Life Technologies Darmstadt, Germany 
Jackson Immunoresearch West Grove, USA 
Kendro Laboratory Products Langenselbold, Germany 
MEDIPoint New York, Germany 
Merck Darmstadt, Germany 
Millipore Schwalbach/TS., Germany 
MP Biomedicals Illkirch Cedex, France 
Nalgene Rochester, USA 
NeoLab Heidelberg, Germany 
New England Biolabs Ipswich, USA 
Nunc Langenselbold, Germany 
PAN Biotech Aidenbach, Germany 
Peprotech Hamburg, Germany 
Quiagen Hilden, Germany 
Roche Diagnostics Mannheim, Germany 
Roth Karlsruhe, Germany 
Scil animal care Viernheim, Germany 
Serva Heidelberg, Germany 
Sigma-Aldrich Taufkirchen, Germany 
Sorenson BioScience Salt Lake City, USA 
TaKaRa Biomedicals Otsu, Japan 
The Jackson Laboratory Bar Harbor, USA 
Techno Plastic Products Trasadingen, Switzerland 
Thermo Scientific Karlsruhe, Germany 
TIB MOLBIOL Berlin, Germany 
Tree Star Ashland, USA 
Whatman Middlesex, UK 
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4. RESULTS 
4.1 SAFETY ANALYSIS OF T CELLS EXPRESSING TWO TCRS 
4.1.1 CHARACTERIZATION OF THE TETRACYCLINE-REGULATED TCR EXPRESSION 
For the safety analysis of TCR gene-modified T cells a model was established in which the regulation 
of TCR expression was possible. The influence on the endogenous TCR by different amounts of 
transgenic TCR molecules should by analyzed. The regulated TCR-transgene expression was 
conferred by a tet-regulated vector. 
TCR expression could be induced 
Clones of 58 cells were generated either expressing the P14 or the OT-I TCR in a tet-regulated 
fashion. The inducibility of the TCR gene expression was analyzed by adding different Dox 
concentrations. Cells were analyzed by staining of the TCR chains with TCR- and TCR-antibodies  
24 h later (Figure 8A). A clear TCR-positive population appeared with 0.01 µg/ml Dox (58+P14tet: 17 
± 7 %; 58+OT-Itet: 9 ± 6 %). For 58+P14tet TCR-positive cells increased from 60 ± 1 % with 0.05 µg/ml 
Dox to 88 ± 9 % with 0.1 µg/ml Dox which already indicated maximal TCR expression (Figure 8A, 
white bars). The clone 58+OT-Itet had an increase in TCR-positive cells from 55 ± 9 % to 69 ± 16 % 
with 0.05 to 0.1 µg/ml Dox. With 0.5 µg/ml Dox, the 58+OT-Itet cells clearly reached its maximal TCR 
expression with 86 ± 5 % TCR-positive cells (Figure 8A, black bars). When comparing the two cell 
clones 58+P14tet cells showed slightly more TCR-positive cells with 1 µg/ml (91 ± 7 %) than 58+OT-
Itet cells (88 ± 7 %). 
The expression level of the transgenic TCR was determined by the mean fluorescence intensity (MFI) 
of both TCR chains. TCR expression level was only slightly over background with 0.01 µg/ml Dox but 
was well detectable with 0.05 µg/ml Dox. It increased from 0.05 to 1 µg/ml Dox differently for each 
TCR chain in both cell clones (Figure 8B and C). In 58+P14tet cells the P14v2 chain increased in its 
expression level as measured by MFI between 0.05 and 0.1 µg/ml Dox from 9 ± 1 to 19 ± 6 and the 
P14v8 chain from 12 ± 4 to 24 ± 9 (Figure 8B). Whereas the MFI of the P14v2 chain did not further 
increase, the P14v8 chain did increase to 38 ± 11 with 0.5 µg/ml Dox. The MFI of the OT-I TCR 
chains in the 58+OT-Itet cells had an increase between 0.05 and 0.1 µg/ml from 7 ± 1 to 13 ± 5 for 
OT-Iv2 chain and from 9 ± 1 to 17 ± 4 for the OT-Iv5 chain (Figure 8C). The OT-Iv2 chain increased 
further in its MFI with 0.5 µg/ml Dox to 21 ± 7 but did not further increase with 1 µg/ml Dox (22 ± 6). 
The OT-Iv5 chain showed higher MFI of 22 ± 5 and 32 ± 8 for 0.5 and 1 µg/ml Dox, respectively. The 
expression level as measured by the MFI of the TCR chain stainings indicated for both cell clones the 
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lowest expression level with 0.05 µg/ml Dox. Although the TCR and TCR chains should be 
expressed equally on the cell surface, differences in MFI were detected which might be due to 
properties of the antibodies used. 
 
Figure 8 Characterization of tet-inducible P14 and OT-I TCR expression 
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Cells were incubated for 24 h with different concentrations of Dox. The TCRv chains were stained with anti-
v5-PE for the OT-I TCR and anti-v8-PE for the P14 TCR. TCRv2 chains were stained with an APC-labeled 
antibody. A: Percentages of TCRv2 and TCRv chain-positive cells are shown of 58+P14tet and 58+OT-Itet 
cells. B: left side: MFI of each TCR chain of 58+P14tet cells, right side: representative TCR staining of 58+P14tet 
cells incubated without or with 1 µg/ml Dox. C: left side: MFI of each TCR chain of 58+OT-Itet cells, right side: 
representative TCR staining of 58+OT-Itet cells incubated without or with 1 µg/ml Dox. 
High TCR expression was obtained already after 13 hours in 58+P14tet cells or 15 hours in 58+OT-
Itet cells and was lost again after 72 hours 
Cells were analyzed for the time needed to express the TCR on the cell surface after induction with 1 
µg/ml Dox. Cells were taken after indicated hours for TCR staining. After 3 h, first TCR expression 
could be detected (Figure 9). After 8 h, 58+P14tet cells already showed 89 ± 3 % TCR-positive cells 
which increased to 95 % after 13 h and 97 ± 2 % after 24 h. In 58+OT-Itet cells, high TCR expression 
was reached after 13 h with 88 %. It slightly increased to 95 ± 3 % TCR-positive cells after 15 h and 93 
± 3 % after 24 h. Therefore, maximal TCR expression was reached after 13 h or 15 h in 58+P14tet cells 
or 58+OT-Itet cells, respectively. After deprivation of Dox the TCR expression was lost after 72 h in 
both cell clones. 
 
Figure 9 Percentage of TCR-positive cells after different time points of Dox treatment 
Cells were incubated for different hours with 1 µg/ml Dox and then stained for TCR chains. Staining was done 
with anti-v2-APC for both v TCR chains, anti-v8-PE for the P14 TCR and anti-v5-PE for the OT-I TCR. 
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TCR expression conferred functionality corresponding to percentage of TCR-positive cells 
The induced TCR expression was tested for functionality. The 58 cell line is a hybridoma originating 
from a CD4 T cell and is therefore capable of IL-2 secretion. The OT-I and P14 TCR are originated from 
CD8 T cells and only function in combination with the co-receptor CD8. The CD8 chain is sufficient 
for these TCRs to maintain their functionality, therefore the CD8 chain was introduced into the 58 
cells used in this work. 
Cell clones were incubated with stated Dox concentrations to induce different amounts of TCR 
expression. 10 µM of cognate peptide, gp33 or ova, was loaded on irradiated splenocytes as APCs 
which were cocultured with the cell clones 58+P14tet and 58+OT-Itet, respectively. The amount of 
secreted IL-2 increased mostly with the Dox concentration (Figure 10) due to the induced TCR 
expression of both cell clones (see Figure 8A). First TCR expression was seen with 0.01 µg/ml Dox in 
Figure 8A which is also indicated by IL-2 secretion of 58+P14tet cells in this experiment, whereas 
58+OT-Itet cells already secreted IL-2 with 0.005 µg/ml Dox. In 58+P14tet cells, IL-2 secretion 
increased thereafter until treatment with 0.5 µg/ml Dox. The IL-2 amount in 58+OT-Itet cells 
increased only subtle. In conclusion, induced P14 TCR expression led to slightly higher IL-2 secretion 
when treated with high concentrations of Dox whereas the level of IL-2 secreted by 58+OT-Itet cells 
did not further increase with more than 0.01 µg/ml Dox. As a control unloaded splenocytes (w/o) 
were used which did not trigger IL-2 secretion. The maximal stimulus was given by PMA and 
Ionomycin (Max) which led to high amounts of secreted IL-2. 
 
Figure 10 Inducible TCR expression resulted in Dox-dependent IL-2 secretion 
Cell clones were cocultivated with irradiated splenocytes loaded with 10 µM peptide (gp33 for P14 TCR and ova 
for OT-I TCR) and different concentrations of Dox as indicated. As control no peptide (w/o) or an unspecific 
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stimulus with PMA and Ionomycin (Max) was added. Supernatant was taken 24 h later and employed in an 
anti-mouse IL-2 ELISA. Max values were 728 ± 6 pg/ml IL-2 for 58+P14tet cells and 740 ± 76 pg/ml IL-2 for 
58+OT-Itet cells. 
4.1.2 DUAL TCR EXPRESSING T CELLS 
In TCR gene therapy, T cells which already express an endogenous TCR are transduced with a 
therapeutic TCR. To analyze the properties of those T cells the two TCR-tet-regulated cell clones were 
transduced with a second TCR representing the endogenous one. The 58+P14tet clone was 
transduced with the OT-I TCR and the 58+OT-Itet clone with the P14 TCR. As a transfer system the 
LXSN vector was chosen. This vector supports a constitutive TCR expression level which allows 
simultaneous inducible TCR expression. The inducible TCR represents here the transgenic TCR. Cell 
clones transduced with the LXSN vector were taken for further analysis after subcloning. The cell 
clones were named as 58+OT-I+P14tet and 58+P14+OT-Itet (Table 28). 
Table 28 Designation of Dual TCR expressing T cells 
Cell designation TCR expression 
Endogenous 
(Constitutive) 
Inducible 
(Transgenic) 
58+OT-I+P14tet OT-I P14 
58+P14+OT-Itet P14 OT-I 
 
After second TCR induction both TCRs were coexpressed on the cell surface 
The generated cell clones were incubated with different amounts of Dox and 24 h later analyzed for 
constitutive and induced TCR expression by flow cytometry. In the 58+OT-I+P14tet clone, the 
transgenic P14 TCR could be induced with 1 µg/ml Dox in up to 96 % cells as measured by TCR- and 
-positive cells. At the same time, the endogenous constitutive OT-I TCR stayed on the cell surface of 
all cells (Figure 11A). In the 58+P14+OT-Itet clone, the inducible OT-I TCR expression was measured 
on 87 % cells whereas the endogenous P14 TCR surface expression was slightly reduced from 99 % 
down to 93 % TCR-positive cells with 1 µg/ml Dox (Figure 11B). 
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Figure 11 Induction of TCR expression led to coexpression with the endogenous TCR 
After 24 h with Dox, A: 58+OT-I+P14tet; B: 58+P14+OT-Itet cells were taken for staining of the induced and the 
endogenous TCR. The sequential staining was done with anti-HA antibody for the OT-Iv2 chain and anti-Myc 
antibody for the P14v2 chain, the tag primary antibodies were then labeled with anti-mouse IgG-Cy5. Finally, 
the TCRv chains were stained with anti-v5-PE for the OT-I TCR and anti-v8-PE for the P14 TCR. 
Inducible TCR expression effected the expression level of the endogenous TCR 
Although the percentage of cells expressing the endogenous TCR did not change, when the inducible 
TCR came to the surface, the expression level of the endogenous TCR chains partially changed (Figure 
12). The induced TCR of both cell clones increased in its TCR chain fluorescence intensity with 
increasing Dox concentration, although between 0.1 and 1 µg/ml Dox no difference was seen (Figure 
12 upper row). In the 58+OT-I+P14tet clone, the endogenous OT-Iv2 TCR chain decreased but not 
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the v5 TCR chain. In the 58+P14+OT-Itet cells, both endogenous P14 TCR chains were reduced in 
their expression level as determined by their mean fluorescence intensity (MFI) (Figure 12 lower 
row). 
 
Figure 12 Inducible TCR expression lowered the MFI of endogenous expressed TCR chains 
TCR stainings from Figure 11 were analyzed as histograms for each TCR chain. 
Quantification of endogenous TCR chains showed a reduction of surface expression level 
The reduced surface TCR expression level of the endogenous TCRs after induction of the tet-
regulated TCR was analyzed in more detail. The staining shown in Figure 11 and Figure 12 was biased 
by the used antibodies and different fluorophores. To obtain equal conditions for the staining of all 
TCR chains primary antibodies were used which were then labeled with a FITC-labeled secondary 
antibody directed against the murine IgG region. For the quantification of the FITC-signal beads with 
different amounts of IgG were labeled with the FITC antibody. The measured MFI were correlated to 
the antibody-binding capacity (ABC) of the beads as stated by the manufacturer (Figure 13A). With 
help of a calibration curve (Figure 13B) the antigen density per cell was determined with the 
measured MFI of each TCR chain. 
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Figure 13 FITC-labeled beads for quantification of FITC fluorescence intensity 
A: Histogram of FITC-labeled beads. Indicated numbers show antibody-binding capacity per bead (ABC) as given 
by the manufacturer. B: MFI of the gated bead populations plotted against the ABC values in a calibration 
curve. 
The endogenous TCRs (in blue) of both cell clones were reduced in surface expression when the 
inducible TCR expression was induced, although differences between Dox concentrations were only 
subtle (Figure 14). The amount of the endogenous OT-I TCR chain molecules in 58+OT-I+P14tet cells 
was 1830 ± 480 for the OT-Iv2 chain and 1910 ± 210 for the OT-Iv5 chain without Dox (Figure 14A). 
The total amount of the induced P14 TCR chains was more (P14v2: 1670 ± 460 and P14v8: 1850 ± 
560) as for the OT-I TCR (OT-Iv2: 940 ± 360 and OT-Iv5: 820 ± 130) with 1 µg/ml Dox. By setting the 
antigen density of the endogenous TCR chains without Dox as 100 % the decrease of each TCR chain 
on the cell surface could be calculated in percentage. In the 58+OT-I+P14tet clone, the OT-Iv2 chain 
was decreased by 49 % and the OT-Iv5 chain by 57 % with 1 µg/ml Dox. In the other cell clone, the 
endogenous P14 TCR had 4360 ± 1080 of P14v2 chain molecules and 3200 ± 440 P14v8 chain 
molecules on the cell surface (Figure 14B). The amount of the P14 TCR chains stayed at higher levels 
(P14v2: 1600 ± 780 and P14v8: 1970 ± 400) as compared to the induced OT-I TCR (OT-Iv2: 1280 ± 
680 and OT-Iv5: 830 ± 50). In 58+P14+OT-Itet cells, the P14v2 chain was stronger decreased (63 %) 
as the P14v8 chain (39 %) when the antigen density without Dox was set as 100 %. The quantified 
staining confirmed the results of the staining presented in Figure 12 but here, the reduction of the 
TCR  chains was also seen. 
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Figure 14 Quantified TCR staining of TCR chains showed a reduction of cell surface expression of 
the endogenous TCR 
After 24 h Dox, A: 58+OT-I+P14tet; B: 58+P14+OT-Itet cells were taken for staining, either with anti-v-Biotin, 
anti-v-Biotin, anti-Myc or anti-HA-Biotin. In a second staining step, cells were labeled with anti-IgG-FITC. TCR 
chain amounts were calculated with help of a calibration curve determined by staining of calibration beads. 
Background staining with each antibody was subtracted. The reduction of the endogenous TCR chains was 
calculated in percentage by setting the ABC values without Dox as 100 %. 
Functionality of the endogenous TCR was lost when the expression of the second TCR was induced 
To analyze the functionality of the dual TCR T cells cocultivations with peptide-loaded splenocytes 
were done. The peptide amounts were titrated from 10-5 M to 10-9 M. The cell clones were 
simultaneously incubated with a low (0.05 µg/ml) and a high Dox concentration (1 µg/ml). In 58+OT-
I+P14tet cells, the induced P14 TCR led to IL-2 secretion which was according to TCR-positive cells 
higher for 1 µg/ml as for 0.05 µg/ml Dox (Figure 15A). At the same time, the endogenous OT-I TCR 
led to a reduced secretion of IL-2 when the P14 TCR expression was induced with 0.05 µg/ml and was 
even more reduced with 1 µg/ml Dox. For both TCRs the amount of IL-2 secreted was titrated by the 
peptide concentrations. In 58+P14+OT-Itet cells, the inducible OT-I TCR led to IL-2 amounts according 
to TCR-positive cells with the low and high Dox supply (Figure 15B). The IL-2 amount was according to 
the peptide concentration from 10-7 to 10-10 M. With both Dox concentrations the endogenous P14 
TCR lost its function and did hardly lead to IL-2 secretion after stimulation. 
The endogenous TCR had a reduced functionality in 58+OT-I+P14tet cells and even lost its 
functionality in 58+P14+OT-Itet cells, although TCR expression was still observed on the cell surface 
as shown before in both cell clones. 
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Figure 15 IL-2 secretion analysis showed functionality loss of the endogenous TCR when the 
expression of the second TCR was induced. 
A: 58+OT-I+P14tet; B: 58+P14+OT-Itet cells were cocultivated with irradiated splenocytes loaded with indicated 
peptide concentrations (gp33 for P14 TCR and ova for OT-I TCR). Indicated Dox concentrations were added to 
the coculture. As control no peptide (w/o) was added. Supernatant was taken 24 h later and employed in an 
anti-mouse IL-2 ELISA. 
4.1.3 TCR CHAIN INTERACTIONS 
The lost functionality of the endogenous TCR led to the question why surface expression, although 
reduced in expression level, was still detectable on the cell surface of both cell clones. We 
hypothesized that the TCR chains of the one TCR could form a TCR dimer with the chains of the other 
TCR. The mispaired TCR dimers could be another reason beside the reduced surface expression for 
the loss of functionality of the endogenous TCR. To investigate this hypothesis FRET measurements 
were done in collaboration with Zolt Sebestyén (Erasmus University Rotterdam, Netherlands). 
On dual TCR T cells mispaired TCR dimers could be detected by FRET 
FRET measurements were done with the cell clones 58+OT-I+P14tet and 58+P14+OT-Itet without and 
with Dox. All possible combinations were stained when the expression of the second TCR was 
induced: P14v2 and P14v8 for the correct pairing of the P14 TCR, OT-Iv2 and OT-Iv5 for the 
correct pairing of the OT-I TCR, OT-Iv2 and P14v8 for a mispaired TCR dimer and P14v2 and OT-
Iv5 for the second possible mispaired TCR dimer. For all combinations FRET efficiencies could be 
calculated. In 58+OT-I+P14tet cells, the FRET efficiency of the constitutively expressed OT-I TCR did 
not change when P14 TCR expression was induced (without Dox: 34 ± 5 %, with Dox: 32 ± 8 %) 
(Figure 16A). The induced P14 TCR had a lower FRET efficiency (23 ± 8 %) as the OT-I TCR but which 
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was as high as the mispaired TCR combination of OT-Iv2 chain and P14v8 chain (23 ± 8 %). The 
FRET efficiency of the second mispaired TCR dimer of P14v2 and OT-Iv5 was the lowest (12 ± 7 %). 
In the other cell clone, the constitutive P14 TCR dropped in its FRET efficiency when the second TCR 
was induced in its expression (without Dox: 35 ± 3 %, with Dox: 19 ± 6 %) (Figure 16B). The FRET 
efficiency for the induced OT-I TCR was 25 ± 6 % which was also here similar to the mispaired TCR 
combination of OT-Iv2 chain and P14v8 chain (21 ± 8 %) The second mispaired TCR version of 
P14v2 and OT-Iv5 had a lower FRET value (12 ± 3 %). The detected mispaired TCR dimers in both 
cell clones and the reduced FRET efficiency of the endogenous P14 TCR in 58+P14+OT-Itet cells 
explained the lost or reduced functionality of the endogenous TCRs. 
 
Figure 16 Mispaired TCRs could be detected by FRET 
58+OT-I+P14tet cells (A) and 58+P14+OT-Itet cells (B) are shown without (black bars) or with 1 µg/ml Dox 
(white bars) after 24 h. All possible TCR chain combinations were measured. The staining was done as 
described in Figure 11. 
Mispaired TCR dimers could be confirmed by tet-inducible single TCR chain expression in a T cell 
clone 
To verify the FRET measurements shown in Figure 16 cell clones were constructed which expressed 
the endogenous P14 TCR and either the OT-Iv2 or the OT-Iv5 chain as inducible transgenic TCR 
chain. TCR expression was determined without and with Dox by TCR staining and FRET efficiencies 
were calculated. When the OT-Iv2 chain expression was induced the P14 TCR-positive cell 
population decreased from 96 % to 76 % which was due to the partial loss of P14v2 chain 
expression (Figure 17A, left). Also, the MFI of P14v2 chain was decreased as seen in the histogram 
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(Figure 17A, right). The induced OT-Iv2 chain formed a double-positive TCR cell population of 89 % 
with the P14v8 chain which even had an increased MFI in this situation. These FACS stainings 
showed that the P14v2 chain was displaced by the OT-Iv2 chain. In the other cell clone, the 
expression of the OT-Iv5 chain was turned on by Dox. Here, the P14 TCR surface expression 
dropped from 96 % to 46 % TCR-positive cells (Figure 17B, left). The regulated OT-Iv5 chain formed 
a double-positive cell population of 59 % with the P14v2 chain. Therefore, the P14v8 chain was 
partially replaced by the expression of the OT-Iv5 chain which was also indicated by the lower MFI 
of the P14v8 chain shown in the histogram. For the P14v2 chain there was no difference in MFI 
seen in these cells (Figure 17B, right). 
 
Figure 17 Induction of only one TCR chain led to mispaired TCR dimers with the constitutive P14 
TCR chains 
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A: TCR staining of 58+P14+OT-Iv2tet and B: 58+P14+OT-Iv5tet after 24 h TCR induction with 1 µg/ml Dox. C: 
FRET efficiencies of 58+P14+OT-Iv2tet without (black bar) or with 1 µg/ml Dox (white bar) and of 58+P14+OT-
Iv5tet without (dark blue bar) and with 1 µg/ml Dox (light blue bar). TCR staining was done as described in 
Figure 11. 
FRET measurements showed that the FRET efficiency of the endogenous P14 TCR was clearly reduced 
when the OT-Iv2 chain was induced (from 27 ± 8 % to 10 ± 4 %) but only slightly when the OT-Iv5 
chain came to the cell surface (from 27 ± 8 % to 26 ± 3 %) (Figure 17C). The mispairing of the OT-Iv2 
chain with the P14v8 showed a FRET efficiency of 16 ± 4 % and mispairing of the P14v2 chain with 
the OT-Iv5 resulted in a FRET value of 28 ± 5 %. These results indicated that the OT-Iv2 chain had a 
higher potential to pair with the P14v8 as the corresponding P14v chain. But both inducible OT-I 
TCR chains could reduce the percentage of P14 TCR-positive cells. 
4.1.4 TCR WITH A SECOND CYSTEINE BRIDGE IN THE CONSTANT REGION 
Mispairing of TCR chains can lead to severe problems if it occurs in a clinical setting. A new unknown 
reactivity arises which could lead to autoimmunity. Besides that it diminishes the functionality of the 
therapeutic TCR. As shown by Kuball et al., the modification of the constant region by introducing 
cysteines which form a cysteine bridge between the constant region of both TCR chains lead to 
preferential pairing of the TCR chains and an increase in cell surface expression of the modified TCR 
[113]. Since we clearly detected mispairing between the OT-I and P14 TCR chains, it was tested if 
introduction of an additional cysteine bridge could diminish the observed mispaired TCR versions. 
The setting of induced OT-I TCR and endogenous expressed P14 TCR was chosen because the P14 
TCR chain pairing was strongly impaired by the induced OT-I TCR. The P14 TCR chains were modified 
with a cysteine in both constant regions and cell clones were generated. 
Depending on the TCR induction rate the P14cys TCR was lost on part of the cells 
Two 58+P14cys+OT-Itet cell clones were chosen for detailed analysis. In the first analyzed clone 7, 
the OT-I TCR was induced to a lower percentage (57 %) (Figure 18A). The P14 TCR with the second 
cysteine bridge (P14cys) was not affected by the OT-I TCR, neither in percentage of TCR-positive cells 
nor in the MFI. The second chosen clone 9 showed an induction of the OT-I TCR in 96 % of the cells. 
The high OT-I TCR expression led to a reduction of P14cys TCR-positive cells from 96 % to 68 % and 
also resulted in a strongly decreased MFI of the P14v2 chain and a fewer decreased MFI of the 
P14v chain (Figure 18B). Here, a partial replacement of the P14cys TCR was observed, which was 
not the case in the described clone with endogenous P14 TCR without a cysteine bridge. 
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Figure 18 Characterization of 58+P14cys+OT-Itet clones 
A. TCR stainings of 58+P14cys+OT-Itet clone (cl.) 7 and B: cl. 9 after 24 h induction with 1 µg/ml Dox. The 
staining was done as described in Figure 11. 
Functionality of the endogenous P14 TCR is lost despite of the second cysteine bridge in its 
constant region 
To test the functionality of the cysteine-modified P14 TCR a cocultivation was done with irradiated 
splenocytes which were loaded with different amounts of gp33 or ova peptide. The 58+P14cys+OT-
Itet cl. 7 and 9 were simultaneously incubated with Dox. Secreted IL-2 was measured 24 h later by an 
ELISA. The induced TCR showed IL-2 secretion, and the IL-2 amount was depending on the peptide 
concentration in both cell clones (Figure 19). On the other side, the constitutively expressed P14 TCR 
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with the cysteine bridge in cl. 7 and cl. 9 did not maintain its functionality as already seen for the P14 
TCR without the cysteine bridge. Thus, the additional disulfide bond did not rescue the functionality 
of the P14 TCR. 
 
Figure 19 IL-2 secretion analysis showed functionality loss of the endogenous P14 TCR when the 
second TCR was induced despite of the cysteine bridge 
A: 58+P14cys+OT-Itet cl. 7; B: 58+P14cys+OT-Itet cl. 9 were cocultivated with irradiated splenocytes loaded 
with indicated peptide concentrations (gp33 for P14 TCR and ova for OT-I TCR). 1 µg/ml Dox was added to the 
coculture. As control no peptide (w/o) was added. Supernatant was taken 24 h later and employed in an anti-
mouse IL-2 ELISA. 
The second cysteine bridge in the TCR constant region did not prevent mispairing 
FRET analysis was done to see if one can detect a difference between the pairing behavior of the P14 
TCR with or without a cysteine bridge. Both cell clones of 58+P14cys+OT-Itet cells were stained for 
their TCR chains. The cl. 7 showed a small reduction of the P14cys TCR FRET efficiency when the OT-I 
TCR expression was induced (from 20 ± 5 % to 15 ± 4 %) (Figure 20A). The mispairing of the P14v2 
chain and the OT-Iv5 chain reached a FRET efficiency of 15 ± 6 %, whereas the TCR dimer of OT-Iv2 
and P14v8 had a lower one (10 ± 6 %). The induced OT-I TCR showed pairing with 26 ± 4 %. The 
reduction in FRET efficiency of the P14cys TCR was stronger in cl. 9 (from 25 ± 6 to 11 ± 5 %) (Figure 
20B). The mispaired TCR dimers had different FRET values compared to cl. 7 (P14v2/OT-Iv5: 6 ± 3 
%; OT-Iv2/P14v8: 19 ± 3 %). The induced OT-I TCR showed a similar FRET efficiency as in cl. 7 (25 ± 
7 %). In both cell clones, mispaired TCR chain combinations could be detected. Therefore, the 
cysteine bridge did not diminish the mispaired TCR dimers between the P14 and the OT-I TCR.  
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The two clones showed different reduction of the P14 TCR FRET efficiency when the transgenic OT-I 
TCR was expressed. As seen in the TCR stainings of Figure 18 this effect was related to the amount of 
induced TCR expressed. In cl. 7 OT-I TCR was only inducible in 46 % of the cells and the pairing of the 
P14 TCR was not as drastic reduced as in cl. 9 in which OT-I was induced in 90 % of the cells. 
 
Figure 20 Cysteine bridge of the P14 TCR did prevent mispairing of TCR chain combinations 
58+P14cys+OT-Itet cl. 7 (A) and cl. 9 (B) are shown without or with 1 µg/ml Dox after 24 h. All possible TCR 
chain combinations were measured. The sequential staining was done as described in Figure 11. 
Different copy number integrations of the endogenous TCR correlated with FRET efficiencies 
To further analyze the shown effect that the pairing of the P14 TCR independent of the cysteine 
bridge was impaired when the OT-I TCR expression was induced the copy number of integrated 
vectors of all cell clones was determined by real-time PCR. 
Indeed, there was a different copy number for the endogenous TCR found in 58+OT-I+P14tet (16.2), 
58+P14+OT-Itet (5.2), 58+P14cys+OT-Itet cl. 7 (11.4) and 58+P14cys+OT-Itet cl. 9 (5.4) which might 
influence the FRET efficiencies of the endogenous TCR, simply because different amounts were 
available when the transgenic TCR was induced (Table 29). In cell clones with a lower number of 
copies of the endogenous TCR gene, the TCR chains were eventually easier displaced. But, T cell 
clones were mostly still over 90 % positive for the endogenous TCR chains, and FRET efficiencies 
should be independent of TCR molecule amounts. 
The copy number of the induced TCR was the same (1 copy per cell) for all clones except for 
58+P14cys+OT-Itet cl. 9 which was 2.6 copies per cell. In 58+P14cys+OT-Itet cl. 7 the copy number of 
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the endogenous TCR expressing vector was 11.4 which might explain the low induction of the 
expression of the OT-I TCR. 
Table 29 Vector copy number integration 
Vector 58+OT-I+P14tet 58+P14+OT-Itet 58+P14cys+OT-Itet cl.7 58+P14cys+OT-Itet cl.9 
Endogenous TCR 
(pLSN) 
16.2 ± 0 5.2 ± 0 11.4 ± 0 5.4 ± 0 
Transgenic (Tet) 1.1 ± 0.001 0.9 ± 0.001 1.1 ± 0.002 2.6 ± 0.001 
 
4.1.5 ANALYSIS OF DUAL TCR PRIMARY T CELLS 
So far, cell lines expressing two TCRs were analyzed. To broaden the analysis primary cells were used 
to determine the influence of the cysteine bridge on the P14 TCR. Transgenic OT-I cells were 
transduced with the MP71 vector encoding the P14 or the P14cys TCR. TCR stainings were 
undertaken to determine the transduction and FRET efficiencies between the P14v2 chain and 
P14v8 or OT-Iv5 TCR chains. The FRET efficiency between OT-Iv2 chain and the TCRv chains 
could not be done, since the transgenic OT-Iv2 chain does not harbor the HA tag. 
P14 TCR transduced cells showed similar gp33 tetramer binding and FRET efficiencies independent 
of a second cysteine bridge in the constant region 
Primary OT-I T cells transduced with the P14 or P14cys TCR were stained with the gp33-tetramer for 
P14 TCR expression and with the ova-tetramer for the OT-I TCR expression. OT-I+P14 cells showed 77 
% gp33-tetramer binding and OT-I+P14cys 81 % (Figure 21A). The expression level as determined by 
MFI of gp33-tetramer-positive cells did not reveal differences between the transduced cells. All cells 
still bound the ova-tetramer (OT-I+P14 95 % and OT-I+P14cys 94 %). 
The staining used to calculate the FRET efficiencies are shown in Figure 21B. In OT-I+P14 cells 87 % 
were P14v2- and P14v8-positive, in OT-I+P14cys 88 % were positive. FRET efficiencies between 
these two TCR chains was 9 ± 3 % for OT-I+P14 and 12 ± 2 % for OT-I+P14cys cells (Figure 21C). In the 
second possible FRET staining OT-I+P14 cells were 81 % and OT-I+P14cys cells 83 % positive for 
P14v2 and OT-Iv5. The staining with P14v2 and OT-Iv5 showed a low correlation between the 
two TCR chains. FRET efficiencies of these stainings were 5 ± 3 % for both cell populations. As seen 
for the cell line clones, there was not a clear advantage of the P14 TCR with the second cysteine 
bridge than without. Only the FRET efficiency of P14v2 and P14v8 was slightly higher for OT-
I+P14cys but this was not significantly different. 
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Figure 21 Transduction and FRET efficiencies of OT-I+P14 and OT-I+P14cys cells 
A: TCR stainings of P14 TCR-transduced or untransduced OT-I splenocytes labeled with anti-CD8-FITC and gp33-
tetramer-APC or ova-tetramer-APC. MFI values of gp33-tetramer-positive cells are given in black and bold in 
the middle of the FACS dot plot. B: FRET stainings were done as described in Figure 11. C: FRET efficiencies of 
stainings in B. 
P14 TCR and P14cys TCR transduced OT-I cells showed same functionality 
The functionality of P14 TCR-transduced OT-I cells was tested to see if the P14 TCR with the cysteine 
bridge has an advantage. Transduced and untransduced cells were incubated with irradiated 
splenocytes loaded either with gp33 or ova peptide, and the supernatant was tested for IFN-. All cell 
populations showed reactivity down to 10-11 M peptide (Figure 22). No differences could be seen 
between cell populations incubated with gp33 peptide or with ova peptide. The functional assay 
confirmed the results of the TCR stainings and FRET measurements. 
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Figure 22 IFN- secretion of primary OT-I cells transduced with the P14 or P14cys TCR was not 
different 
Transduced T cells were cocultivated with irradiated splenocytes loaded with indicated peptide concentrations 
(A: ova for OT-I TCR and B: gp33 for P14 TCR). Supernatant was taken 24 h later and employed in an anti-mouse 
IFN- ELISA. 
In wild-type cells differences in FRET efficiency could be detected between different TCR formats 
The obtained results indicated that the second cysteine bridge in the constant region did not prevent 
mispairing of the P14 TCR with the OT-I TCR chains. To exclude that this situation only holds true for 
this setting primary wild-type cells were transduced with different TCR formats of the P14 and the 
OT-I TCR (with and without the second cysteine bridge in non- and codon-opitmized TCRs). As 
expected TCRs encoded by codon-optimized DNA yielded higher transduction rates as shown by 
TCR and TCR staining, but differences between cys-formats could not be confirmed (Figure 23A). 
Only the OT-Icys TCR had a higher expression rate of 30 % than the OT-I TCR which was due to a 
higher virus titer. Calculated FRET efficiencies revealed a tendency between the P14 TCRs (Figure 
23B). With TCR optimization the FRET efficiency increased. Also for the OT-I, OT-Icys, OT-Ico TCR this 
increase could be seen, but no differences was caclulated between the OT-Ico and OT-Icocys TCR. 
Therefore, the cysteine bridge might only have an effect on certain TCRs and formats, but the 
differences in FRET efficiencies were not significant. 
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Figure 23 Primary C57BL/6 cells transduced with the P14 or OT-I TCRs revealed small differences 
in TCR pairing behavior 
A: C57BL/6 splenocytes were transduced with different formats of the P14 and OT-I TCR and transduction rates 
were determined by staining as described in Figure 11. B: FRET efficiencies of stainings in A. 
Only with a small amount of antigen differences in functionality between different TCR formats 
could be detected 
Small differences in FRET efficiencies between TCR formats could be detected. To see if these 
differences also apply to functionality of the transgenic TCR a cocultivation of equilibrated numbers 
of TCR-positive cells with peptide-loaded splenocytes was done. Only for 10-12 M and 10-12.3 M 
peptide different amounts of IFN- could be seen in the order of optimization (Figure 24). These 
small differences could also be due to the different transduction rates despite of usage of 
equilibrated TCR-positive cell numbers. 
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Figure 24 IFN- secretion of primary C57BL/6 cells transduced with the P14 or OT-I TCRs was only 
different for small amounts of antigen 
Transduced C57BL/6 splenocytes were cocultivated with irradiated splenocytes loaded with indicated peptide 
concentrations (A: gp33 for P14 TCR and B: ova for OT-I TCR). Supernatant was taken 24 h later and employed 
in an anti-mouse IFN- ELISA. 
 
76 
 
4.2 SAFETY ANALYSIS TCR GENE-MODIFIED T CELLS IN VIVO 
The second part of the dissertation deals with the long-term analysis of TCR-transduced T cells in 
vivo. Vector transduction leads to integration into the cell genome which results in changes at the 
integration site, like changed expression of surrounding genes or disruption of genes. Potentially 
changed expression of genes involved in the regulation of the cell cycle could lead to an advantage of 
proliferating cells or survival of cells. This potential risk was combined with a regularly stimulation of 
transduced T cells. Stimulation of T cells leads to proliferation and mutated cells might have a 
proliferation advantage. In the following described experiment OT-I T cells were transduced with the 
P14 TCR and transferred into non-myeloablative treated mice. In the recipient mice the transferred 
cells were stimulated either with gp33 peptide, ova peptide, each combined with an adjuvant, or 
with a gp33-positive tumor cell line. The experiment was repeated once with a milder non-
myeloablative treatment and stimulation was done with the gp33-positive tumor cell line. One 
control experiment was carried out with adoptive transfer of GFP-transduced OT-I T cells into 
lymphodepleted mice but without stimulation of transferred cells. 
4.2.1 CHARACTERIZATION OF TCR- AND GFP-TRANSDUCED OT-I SPLENOCYTES BEFORE 
ADOPTIVE TRANSFER 
OT-I splenocytes were highly transduced with the P14 TCR or with GFP 
OT-I splenocytes were transduced with the MP71 vector encoding the P14 TCR. Transduced cells and 
recipient mice of the first experiment were named as OT-I+P14 I whereas of the second experiment 
OT-I+P14 II. Tetramer staining of the P14 TCR was done 72 h after transduction. OT-I+P14 I cells were 
highly transduced with 73 % and OT-I+P14 II with 49 % gp33-tetramer-positive cells (Figure 25A). 
Transduction of OT-I T cells with the MP71 vector encoding GFP led to 66 % GFP-positive cells (Figure 
25A). 
The activation status of the OT-I+P14 I cells was analyzed by the activation marker CD44, the early 
activation marker CD69 and the homing marker CD62L and compared to naive splenocytes which 
revealed an activated phenotype with up-regulated CD44 and CD69 and down-regulated CD62L 
(Figure 25B). 
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Figure 25 Transduced OT-I splenocytes showed P14 TCR or GFP expression and an activated 
phenotype 
A: Tetramer stainings showing transduction efficiency of OT-I splenocytes transduced with P14 TCR stained 
with anti-CD8-FITC and gp33-tetramer-APC. As control untransduced OT-I cells are shown. GFP-transduced OT-I 
cells are shown as a histogram. B: Activation status of OT-I+P14 I cells (filled histogram) compared to naive 
CD8-positive OT-I cells (black line). Staining was done with anti-CD62L-PE, -CD69-PE, -CD44-PE. Naive cells were 
gated on CD8-positive cells stained with anti-CD8-APC. 
P14 TCR-transduced and GFP-transduced OT-I T cells harbor high virus copy number integrations 
To determine the copy number of integrated provirus per cell Real-time PCR was done with DNA 
from transduced cells. P14v2- and GFP-specific primers were used to detect the proviral DNA and a 
calibration curve with P14 plasmid DNA was done for calculations (Figure 26). The transduction rate 
measured by TCRv2 and TCRv8 staining or the GFP expression was taken into account. As already 
indicated by the transduction efficiencies OT-I+P14 I cells had a higher copy number of 3.8 than OT-
I+P14 II cells (1.2 copy number) (Table 30). OT-I+GFP-transduced cells had 7.7 copy numbers of 
provirus per cell. Since the transgene vector with GFP is smaller as the vector with the P14 TCR the 
virus titer was higher (5.7 and 9 x 106/ml for 1st and 2nd GFP virus harvest versus 2-6 x 106/ml for P14 
TCR virus harvests as measured on 58 cells) which led to a higher copy number integration per cell. 
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Figure 26 Calibration curve of diluted plasmid DNA and DNA samples detected by real-time PCR 
CT values were plotted against the copy number of plasmid DNA used in a Real-time PCR with P14v2-specific 
primers. DNA cell samples analyzed resulted in CT values in range of the calibration curve, here shown for 
average values. 
Table 30 Vector copy number integration 
Cells OT-I+P14 I 
(v2+/v8+) 
OT-I+P14 II 
(v2+/v8+) 
OT-I+GFP 
(GFP+) 
Transduction efficiency (%) 81 60 66 
Copy number integration per 
transduced cell 
3.8 ± 0.5 1.2 ± 0.003 7.7 ± 001 
4.2.2 ADOPTIVE TRANSFER OF TCR AND GFP GENE-MODIFIED T CELLS 
For the long-term analysis of TCR-transduced T cells recipient mice were lymphodepleted before 
transfer to ensure the prober engraftment of transferred T cells. For lymphodepletion the 
chemotherapy agent cyclophosphamide was chosen. This agent is a nitrogen mustard alkylating 
substance and given as a prodrug which is converted in the liver. Recipient mice were pretreated 
intraperitoneal with 200 mg/kg cyclophosphamide [177] in the experiment with OT-I+P14 I and OT-
I+GFP cells and with 100 mg/kg cyclophosphamide in the experiment with OT-I+P14 II cells one day 
before adoptive transfer. Mice were either 10 or 12 weeks old in the first or second experiment, 
respectively. 5 x 106 T cells were intravenously transferred. 
Peptide-stimulated transferred cells showed a higher activation status than gp33 tumor cell-
stimulated or unstimulated transferred cells 
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One day after transfer, mice of the first experiment were stimulated either with ova peptide (4 mice) 
gp33 peptide (10 mice) or with a tumor cell line presenting the gp33 peptide (gp33 tumor cells) (5 
mice). The tumor cell line does not grow in immune-competent mice. The peptides were combined 
with CpG ODN 1826 and IFA. One mouse was left unstimulated. The OT-I+GFP transferred T cells 
were left unstimulated (12 mice). In the second experiment transferred T cells were either left 
unstimulated (15 mice) or were stimulated with the gp33-positive tumor cell line (14 mice). 
Blood was taken on day 7 or day 4 after stimulation in the OT-I+P14 I- or OT-I+P14 II-experiment, 
respectively. The activation status was analyzed by staining for the congenic marker CD90.1 of 
transferred T cells, the activation marker CD44 and the homing molecule CD62L which is down-
regulated upon activation. Compared to unstimulated or tumor cell-stimulated cells peptide-
stimulated cells were stronger activated shown by the higher down-regulation of CD62L (Figure 27). 
 
Figure 27 Activation status of transferred cells after first restimulation 
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OT-I+P14 I: Blood cells were stained with anti-CD90.1-biotin/streptavidin-APC, anti-CD44-PE and anti-CD62L-
FITC. OT-I+P14 II: Blood cells were stained with anti-CD90.1-PercP, anti-CD44-PE and anti-CD62L-FITC.The dot 
plot of CD44 against CD62L is gated on CD90.1-positive cells. 
All transferred cells were CD44-positive due to the in vitro activation for viral transduction. As control 
blood of a naive OT-I mouse is shown. In unstimulated mice, 66 % or 3 ± 1 % cells down-regulated 
CD62L in the first or second experiment, respectively (Table 31). Tumor cell-stimulated cells were 72 
± 6 % or 43 ± 23 % CD62L-negative in the OT-I+P14 I- or OT-I+P14 II- experiment, respectively. The 
ova peptide-stimulated cells were 95 ± 3 % and the gp33 peptide-stimulated cells 84 ± 14 % CD62L-
negative. Differences in the CD62L-down-regulation between the first and second experiment could 
be due to the different amount of cyclophosphamide used in these mice. 
Table 31 Down-regulation of CD62L in stimulated mice 
CD90.1: CD44+/CD62L- (%) OT-I+P14 I  
Day 8 
OT-I+P14 II 
Day 4 
Naive mice 
Stimulation 
Without 66 (n=1) 3 ± 1 (n=3) 10 ± 2 (n=2) 
gp33 tumor cells 72 ± 6 (n=2) 43 ± 23 (n=3)  
gp33 peptide 84 ± 14 (n=6)  
ova peptide 95 ± 3 (n=3) 
 
Toxicity was observed in recipient mice due to cyclophosphamide treatment 
The time point of death and its reasons of individual mice are listed inTable 32 as well as the last 
measured percentage of transferred cells. In the experiment OT-I+P14 I surviving mice were killed 
individually (indicated as autopsy in Table 32) whereas in OT-I+GFP and OT-I+P14 II surviving mice 
were killed on day 450 or day 365, respectively. 
Between day 30 and 86 after T cell transfer of OT-I+P14 I cells the animal facility was closed due to a 
suspicion of mouse hepatitis infection. During this time 6 out of 20 mice died and could not be 
analyzed (Table 32). Since the reason for the early death could not be clarified at this time point, the 
surviving mice were further analyzed. The control group receiving OT-I+GFP cells started at a later 
time point. Here 3 out of 12 mice died early (day 48, 75, 112). Death of mice was mainly due to the 
cyclophosphamide concentration and the young age of mice at the time point of adoptive transfer 
which led to early toxicity with symptoms like teeth problems or outgrowth of untransduced OT-I 
cells in two mice with OT-I+GFP cells (70 % and 98 % CD8: CD90.1-positive, 0.4 and 0.03 % CD8: 
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CD90.1/GFP-positive). Late toxicity occurred around day 200 which might have been caused by a not 
well enough reconstituted immune system. Three mice died during peptide injection (Handling). 
Toxicity could be limited by reducing the cyclophosphamide concentration in the second experiment 
(OT-I+P14 II). Here, one mouse in the unstimulated group and three mice in the stimulated group 
died due to early or late toxicity. One mouse was sacrificed shortly before the end of the experiment 
(day 314) because of sore skin lesions but this mouse had lost the transferred cells (Late toxicity). A 
second mouse killed on day 209 had a bowel obstruction. 
Table 32 Overview of recipient mice and cause of death 
Experiment Stimulation  Death due to Day after T cell 
transfer 
 
Transferred T cells 
CD8: CD90.1+ (%) 
OT-I+P14 I  without Autopsy 460 60 
gp33 tumor cells Early toxicity >86 26, 30 
Autopsy/  
Old age 
410, 557, 557 66, 85, 30 
gp33 peptide Early toxicity >86 4, 16, 5 
Late toxicity 262, 310 7, 14 
Autopsy/  
Old age 
480, 546, 546 29, 28, 41 
Handling 151 1, 5 
ova peptide Early toxicity >86 7 
Late toxicity 213  20 
Autopsy 416 39 
Handling 34 3 
OT-I+GFP without Early toxicity 48, 75, 112 12, 70, 98 
OT-I+P14 II without Late toxicity 216 7 
gp33 tumor cells Early toxicity 121 0 
Reason 
unkbown/  
Late toxicity 
209, 314 34, 0 
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Transferred OT-I+P14 cells persisted in most of the recipient mice 
Blood analysis of recipient mice showed that the transferred T cells persisted over time in most of 
the mice (Figure 28). CD8 cells from the peripheral blood were analyzed for CD90.1 expression and 
TCRv8 chain expression of the transduced P14 TCR. On day 8 after transfer, T cells had an expansion 
peak due to homeostatic proliferation and also due to the stimulation. In the first experiment, the 
ova peptide-stimulated group had the highest percentage with 58 ± 10 % CD90.1 of CD8 cells, 
followed by the gp33 tumor cell-stimulated group with 53 ± 12 %, then the unstimulated mouse with 
43 % and the gp33 peptide-stimulated group with 40 ± 11 % (Figure 28A). The gp33 peptide-
stimulated group had a higher percentage of cells which had down-regulated CD62L than the gp33 
tumor cell-stimulated group on day 8 after transfer but had a lower proliferation peak of transferred 
cells. In the second experiment, OT-I+P14 II blood was taken on day 4 after stimulation and analyzed 
for transferred cells. Transferred T cells persisted and enriched over time (Figure 28B) with the 
exception of two mice in the unstimulated group and four mice in the tumor cell-stimulated group. In 
these mice transferred T cells persisted below 0.5 % of CD8 T cells. The first expansion peak in the 
second experiment was lower than for the OT-I+P14 I with 8 ± 2 % in the unstimulated group and 11 
± 6 % CD90.1 of CD8 T cells in the gp33 tumor cell-stimulated group. The difference was due to the 
lower concentration of cyclophosphamide used for the non-myeloablative treatment. 
Transferred T cells declined thereafter until the next stimulation which led to a small increase in both 
experiments. The increase was seen after most of the stimulations in the first and after all 
stimulations in the second experiment. Since the blood was always checked on day 7 after 
stimulation in OT-I+P14 I mice, the expansion peak might have occurred before which could also 
depend on the type of stimulation (peptide versus tumor cell line). The analysis on day 4 after 
stimulation in OT-I+P14 II mice always revealed an increase of transferred cells. After stimulations 
the cells normally declined again. 
Overall, the transferred T cells enriched over time in the CD8 T cell compartment which became 
vigorous from day 200 on (Figure 28A and B). In OT-I+P14 I mice, the unstimulated mouse had 
enriched the transferred T cell up to 60 % on day 416 and the gp33 tumor cell-treated mice up to 44 
± 26 % (three mice) on day 501. Although peptide stimulation led to a higher down-regulation of 
CD62L, cells did not increase in percentage which might have been due to activation-induced cell 
death. The transferred T cells in the peptide-stimulated mice stayed on a lower level, for gp33 
peptide- 31 ± 9 % on day 416 (three mice) and for ova peptide stimulation 39 % on day 416 (one 
mouse) (Figure 28A). Similarly, in the OT-I+P14 II experiment in unstimulated mice 28 ± 10 % and in 
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tumor cell-stimulated mice 58 ± 18 % CD90.1-positive cells of CD8 T cells were found on day 365 after 
adoptive transfer. 
Analysis of v8-positive and v8-negative cells revealed that the transduced and untransduced cells 
kept the ratio over time in the gp33 peptide-, gp33 tumor cell-stimulated or unstimulated group 
(Figure 28A lower figures). In the ova peptide-stimulated group, the proportion of untransduced cells 
increased a little since here also untransduced cells were addressed by the stimulation. In the second 
experiment, the ratio of transduced to untransduced transferred cells also stayed the same with 
mainly over 90 % v8-positive cells of CD90.1 cells shown as CD90.1/v8-positive cells (Figure 28B 
lower figure). 
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Figure 28 Transferred OT-I+P14 cells persisted long-term in recipient mice 
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Blood of recipient mice was checked on time points with symbols. A: OT-I+P14 I. Cells were stained anti-CD8-
APC, anti-CD90.1-FITC, and anti-v8-PE. B: OT-I+P14 II. Cells were stained with anti-CD8-APC, anti-CD90.1-
PercP, and anti-v8-FITC. Red arrows indicate stimulation time points, for A: day 1, 34 (only #2 and #4), 99, 151, 
207, 255, 305, 401, for B: day 1, 66, 115, 167, 216, 265, 314. 
Transferred OT-I+GFP cells persisted in recipient over time 
The OT-I+GFP mice were bled every 50 days and every second 50 days after 7 days again as done 
with OT-I+P14 I mice. After a small expansion peak of 13 ± 3 % CD90.1-positive of CD8 T cells which 
was not as vigorous as for OT-I+P14 I mice the transferred cells declined until day 100 (Figure 29). 
After day 100, cells enriched slowly as seen in OT-I+P14 I and II mice. At the end of the experiment on 
day 450, they made up 28 ± 8 % of the CD8 T cells. On day 8 after transfer 11 ± 3 % and on day 450 
17 ± 12 % of cells were GFP/CD90.1-positive. In regard to CD90.1-positive cells the percentage of 
transduced GFP-expressing cells declined from 86 ± 20 % to 53-62 % of CD90.1-positive cells until the 
end of the experiment on day 450 (Figure 29). 
 
Figure 29 OT-I+GFP cells persisted long-term in recipient mice 
Blood of recipient mice was checked on time points with symbols. Cells were stained with anti-CD8-APC and 
anti-CD90.1-PercP. Number of mice was 12 on day 8 and 9 mice from day 100 on. 
Peptide-stimulated transferred T cells showed a stronger activation status than gp33 tumor cell-
stimulated or unstimulated T cells over time 
Upon activation the CD62L is down-regulated and rises again with memory formation or after 
repetitive stimulation. Memory T cells are differentiated into effector memory T cells and central 
memory T cells which differ in CD62L expression. Effector memory T cells are CD62L-negative and 
central memory T cells are CD62L-positive. Both types of memory T cells are present in the peripheral 
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blood. The CD62L expression was analyzed on transferred T cells after three stimulation rounds in 
OT-I+P14 I mice. CD8-gated cells were checked for CD90.1 and CD62L expression (Figure 30). 
 
Figure 30 Upon stimulation transferred T cells showed down-regulated CD62L expression which 
is up-regulated thereafter again 
A: Examples shown once after stimulation (day 213) and before the next stimulation round (day 305, ova 
peptide: day 401). Cells were stained with anti-CD8-APC, anti-CD90.1-FITC, and anti-CD62L-PE. Cells were gated 
on CD8 and in the first histogram CD90.1-positive cells are shown. These were analyzed for CD62L expression 
shown in the second histogram. 
After the third stimulation, tumor cell stimulation led to a down-regulation of CD62L expression in 60 
± 25 % of the cells, whereas gp33 peptide- and ova-peptide stimulation led to a down-regulation in 
95 ± 4 % and 98 ± 1 % of the cells, respectively (Table 33). Analyzed samples of two chosen time 
points, just before stimulation, showed that the tumor cell- and gp33 peptide-stimulated group 
increased its CD62L expression again but 52 ± 27 % or 58 ± 25 %, respectively, stayed CD62L-
negative. In case of the two ova peptide-stimulated mice 95 ± 5 % cells stayed CD62L-negative. The 
tumor cell stimulation, as already shown on day 7 after the first stimulation in vivo, was not as strong 
as peptide stimulation as shown by weaker CD62L down-regulation. During the memory phase this 
group showed a higher CD62L expression as the ova-stimulated group but similar to gp33-stimulated 
mice. This property confers to a central memory phenotype. 
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Table 33 Activated phenotype of transferred T cells 
CD90.1: CD62L- (%) After stimulation 
Day 213 
Before stimulation 
Day 305/401 Stimulation 
without (naive mice) 10 ± 3 (n= 2)  
gp33 tumor cells 60 ± 25 (n= 3) 52 ± 27 (n= 6) 
gp33 peptide 95 ± 4 (n= 5) 58 ± 25 (n= 6) 
ova peptide 98 ± 1 (n=2) 95 ± 5 (n= 2) 
 
In OT-I+P14 II mice, peripheral blood cells were regularly checked for CD62L- and CD44 expression. 
After each stimulation CD62L-negative cells increased indicating the stimulation effect on the 
transferred cells by tumor cell stimulation (Figure 31). Blood of unstimulated mice was also analyzed 
for CD44 and CD62L expression, but here CD62L-negative cells decreased over time indicating 
memory formation of transferred cells. 
 
Figure 31 Analysis of CD62L expression over time in transferred T cells 
Peripheral blood cells were stained with anti-CD8-APC, anti-CD90.1-PercP, anti-CD62L-FITC, and anti-CD44-PE. 
Cells were gated on CD8, then on CD90.1 and finally analyzed for CD44-positive and CD62L-negative cells. Red 
arrows indicate stimulation time points. 
4.2.3 EX VIVO ANALYSIS OF TRANSFERRED T CELLS 
Transferred T cells were able to bind P14 TCR-specific gp33-tetramer 
To make sure that v8-positive transferred T cells still bound P14 TCR-specific gp33-tetramer, 
peripheral blood of OT-I+P14 I mice was analyzed on day 262. Transferred cells stained positive for 
gp33-tetramer (Figure 32). Blood of the unstimulated mouse was 62 % positive for gp33-tetramer, of 
gp33 tumor cell- or peptide-stimulated mice were 76 ± 3 % or 74 ± 4 % positive, respectively (Table 
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34). The ova-stimulated cells bound 31 % of gp33-tetramer which was less than for the other groups. 
This correlated with the v8 TCR chain expression which was lower for the ova-stimulated 
group/mouse. In OT-I+P14 II mice, splenocytes were analyzed at the end of the experiment for gp33-
tetramer binding. Here, unstimulated cells bound 80 ± 11 % and tumor cell-stimulated cells bound 74 
± 19 % tetramer (Table 34). Between these groups no significant difference was detected. 
 
Figure 32 Transferred T cells bound gp33-tetramer 
A: Peripheral blood of one mouse is shown per group on day 262 of OT-I+P14 I mice and spleen cells of OT-
I+P14 II mice. Blood of OT-I+P14 I mice was stained with anti-CD8-PE, anti-CD90.1-FITC, gp33-tetramer-APC and 
splenocytes of OT-I+P14 II mice with anti-CD8-FITC, anti-CD90.1-PercP, and gp33-APC. First histogram shows 
CD90.1-positive cells gated on CD8. CD90.1-positive cells are gated in the dot plot against gp33-tetramer (gp33-
tetr.). 
Table 34 GP33-Tetramer-binding of transferred T cells 
CD90.1: gp33+ (%) OT-I+P14 I  
peripheral blood 
OT-I+P14 II 
spleen Stimulation 
Without 62 (n= 1) 80 ± 11 (n= 12) 
gp33 tumor cells 76 ± 3 (n= 3) 74 ± 19 (n= 10) 
gp33 peptide 74 ± 4 (n= 4)  
n.s. 
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ova peptide 31 (n= 1)  
Transferred T cells were present in blood, spleen, LN and BM 
After day 365, OT-I+P14 II mice were sacrificed. Lymphoid organs were analyzed for transferred cells. 
In all lymphoid organs, blood, spleen, LN and BM, the transferred T cells were found at similar levels 
and were highly positive for P14v8 and OT-Iv5-TCR chains (Figure 33A).  
Transferred T cells in lymphoid organs were also analyzed for CD62L- and CD44 expression. Cells of 
the unstimulated group were mainly CD62L- and CD44-positive (Figure 33B). Cells from mice which 
were stimulated with gp33 tumor cells were significantly lower in CD62L expression in the blood, 
spleen and in the bone-marrow due to the stimulation. 
 
Figure 33 Transferred cells were found in lymphoid organs 
Blood, splenocytes, LN and BM were prepared on day 368-371 and stained with anti-CD8-APC, anti-CD90.1-
PercP, and A: anti-v5-PE and anti-v8-FITC or B: anti-CD44-PE and anti-CD62L-FITC. Cells were gated first on 
CD8, then on CD90.1-positive cells and were finally analyzed for positive v5- and v8-expression (A) or 
positive CD62L- and CD44 expression (B). 
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Transferred T cells still showed proliferation capacity at the end of the experiment upon adoptive 
transfer into second recipients 
Since transferred T cells were regularly restimulated in vivo, proliferation capacity was tested at the 
end of the experiment. Mice were sacrificed and splenocytes were labeled with CFSE. Labeled cells 
were transferred into second recipients and stimulated as in the first recipients. After 3 - 4 days, 
splenocytes of second recipients were stained with anti-CD90.1 and analyzed for CFSE labeling which 
is diluted upon proliferation. The gp33 peptide- and gp33 tumor cell-stimulated cells showed a clear 
CFSE dilution upon transfer into second recipient and restimulation (Figure 34A). Transduced OT-
I+P14 II T cells, which were not used for adoptive transfer into first recipients, were cryopreserved 
and could be compared to OT-I+P14 II T cells from first recipients (three mice per group) for their 
proliferation capacity in parallel. Transduced T cells before first adoptive transfer and T cells from 
unstimulated first recipient mice showed a background proliferation of 39 or 41 ± 6 %, respectively, 
without stimulation in the second recipient (Figure 34B). For T cells from tumor cell-stimulated mice, 
the background proliferation was significantly lower with 6 %. Upon stimulation in the second 
recipient, 91 % of OT-I+P14 II T cells before first adoptive transfer, 75 ± 20 % of T cells from 
unstimulated first recipient and 45 ± 18 % of gp33 tumor cell-stimulated first recipient mice 
proliferated. In comparison, T cells from mice which were left untreated showed a similar 
proliferation capacity as OT-I+P14 II T cells before adoptive transfer. T cells from stimulated first 
recipients showed a lower proliferation capacity in second recipients upon restimulation, but the 
difference was not significant. These results showed clearly that, although multiple times stimulated, 
that the transferred T cells were still able to proliferate upon stimulation and were not exhausted by 
the chosen stimulation methods. 
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Figure 34 Transferred T cells proliferated upon transfer and stimulation in second recipients 
Splenocytes of second recipients were stained with anti-CD90.1-PercP. Cells were gated on CD90.1-positive 
cells and are shown in an overlaid histogram for CFSE. Filled histograms are cells from unstimulated second 
recipients, black line from stimulated recipients. Grey numbers on histogram indicate percentage of the CFSE-
populations of unstimulated cells. Black numbers indicate CFSE-populations of stimulated cells. OT-I+P14 I: 
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Splenocytes taken on day 557 after transfer. OT-I+P14 II: Splenocytes taken on day 368-371. B: Summarized 
results of OT-I+P14 II with three mice per group. Transduced T cells before first transfer were cryopreserved 
until this assay. 
Transferred T cells secreted IFN- and degranulated CD107α 
At the end of the experiment with OT-I+P14 II mice, transferred T cells were analyzed for the 
cytokine secretion capacity by staining of IFN- as well as their degranulation capacity by staining of 
CD107. Splenocytes from OT-I+P14 II mice were incubated for four hours with gp33, ova or no 
peptide as well as anti-CD107-antibody. Afterwards, intracellular staining was done for IFN-. 
Splenocytes secreted IFN- as well as degranulated CD107α upon stimulation with gp33 or ova 
peptide (Figure 35). As example CD107α-/IFN--stainings from splenocytes of one mouse of each 
group are shown (Figure 35A). Splenocytes from mice which were left unstimulated were positive for 
CD107α/IFN- with 37 ± 13 % when stimulated with gp33 peptide, with 47 ± 13 % when stimulated 
with ova peptide and with 13 ± 10 % without peptide (Figure 35B). Splenocytes from mice which 
were stimulated with gp33 tumor cells were 44 ± 15 % positive for CD107α/IFN- when stimulated 
with gp33 peptide, 43 ± 16 % when stimulated with ova peptide and 3 ± 8 % without peptide. 
Between both groups no significance difference could be detected, only without in vitro peptide 
stimulation the background secretion of CD107α/IFN- of splenocytes from unstimulated mice was 
higher as from stimulated mice. 
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Figure 35 Transferred T cells were still functional at the end of the experiment 
Splenocytes were incubated with 1 µM of ova, gp33 peptide or without (no), anti-CD107-PE, Brefeldin (10 
µg/ml) and Golgi-Stop (0.5 µl/200 µl) for 4 h. Cells were stained with anti-CD90.1-PercP and intracellular 
staining was done with anti-IFN--APC. Cells were gated on CD90.1. A: Dot plots of CD107- against IFN--
expression of two mice are shown. Upper row: splenocytes from a mouse which was left unstimulated 
(without), lower row: splenocytes from a mouse which was stimulated with gp33 tumor cells. B: Bar diagram 
shows summarized results of the CD107-/IFN--stainings of splenocytes from mice which were left 
unstimulated (12 mice) or which were stimulated with gp33 tumor cells (10 mice). 
LAM-PCR revealed polyclonality of the transduced T cells over time 
LAM-PCR is used to detect the integration site of the provirus in the cell genome. The analysis was 
undertaken with DNA from all collected time points and done with two restriction enzymes for the 
experiment with OT-I+P14 I transferred T cells (Figure 36) and OT-I+GFP transferred T cells (data not 
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shown). The experiments were carried out in the lab of Christof von Kalle in Heidelberg. Gel 
electrophoresis showed multiple bands of different size ranging from 100-500 bp (Figure 36A-C). 
Since the 5’-LTR and 3’-LTR are equal in the provirus, an internal control is also amplified from the 3’-
LTR into to the proviral sequence. For the restriction enzyme HpyCH4IV the internal control band has 
a size of 512 bp if it is cut at the first restriction site. Shortly after, there are two more restriction sites 
for HpyCH4IV which would lead to band sizes of 525 and 576 bp. Two bands were visible around 500 
bp which were seen in all samples representing the internal control bands. For each sample 100 ng 
was used but band intensities were different between samples which was due to the different 
percentages of transferred cells in the mice on different time points. Smears indicated many 
integrations sites. Specific bands did not increase with time, but disappeared again. LAM-PCR 
experiments of some samples were done at a later time point (Figure 36D-E). Here, LAM-PCR did not 
give raise to multiple distinct bands but only to a DNA smear and one single band. Reason for that 
were contaminations with the MP71 plasmid which disturbed the amplification of integration sites. 
Instead, a plasmid band of a size of 90 bp which had an advantage during the amplification 
procedure over larger sequences was amplified. In the first LAM-PCR, this contaminated plasmid 
band was also visible but nevertheless other sequences could be well amplified. Optimization of the 
DNA preparations to avoid plasmid contaminations was done in the OT-I+P14 II experiment, but 
LAM-PCR experiments are still ongoing. LAM-PCR products will be sequenced in the future. 
Nevertheless, the first and also partly the second LAM-PCR experiments showed that multiple 
integration sites were present in the analyzed DNA samples which suggest that in none of the mice a 
monoclonal outgrowth could be observed. DNA of the control experiment OT-I+GFP was also 
analyzed by LAM-PCR but here, also the plasmid contamination dominated the amplification so that 
other bands were rarely visible or only as a smear (data not shown). 
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Figure 36 LAM-PCR of analyzed blood DNA revealed polyclonal integrations sites 
LAM-PCR with the restriction enzyme HpyCH4IV is shown. A-C: Spreadex gels - first LAM-PCR experiment. D-E: 
2% agarose gels- second LAM-PCR experiment. Second LAM-PCR experiment was performed on a later time 
point. 100-bp marker was loaded. On spreadex gels 5 µl and on agarose gel 10 µl of PCR products was loaded. 
In the second LAM-PCR experiment few samples of the first LAM-PCR were repeated. Numbers above brackets 
indicate mouse numbers, and beside the stimulation method is indicated. gp33: gp33 peptide-stimulation, ova: 
ova-peptide stimulation, gp33 tumor: gp33-tumor cell stimulation. 
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5. DISCUSSION 
5.1  INDUCIBLE TCR EXPRESSION AND DUAL TCR T CELLS 
5.1.1 INDUCIBILITY OF THE ANALYZED TET-SYSTEM 
The TCR complex has a complex structure and biology. The inducibility of the TCR expression is not 
easily comparable to proteins like luciferase or GFP. The TCR complex consists of two polypeptides 
which have to be folded in the endoplasmatic reticulum (ER) and associate there with the CD3 
complex which also consists of multiple polypeptides. Therefore, the TCR expression in the Tet-
system does not only depend on the induction but also on the prober association with the CD3 
complex. The fold-induction which is used as a characteristic term for tet-regulated gene expression 
of indicator genes like luciferase or GFP is not useful for tet-regulated TCR surface expression. The 
vector used in this work had a 220-fold induction of GFP and luciferase in HT1080 cells [172]. The cell 
system used in this analysis does not harbor an endogenous TCR in the first place. But TCR expression 
on the cell surface is limited by the amount of CD3. When all available CD3 complexes are occupied, 
there is no further increase of TCR expression. Also, one has to take into account that the TCR/ CD3 
complexes are cycled between the cell surface and endosomes [178,179,180]. 70 - 85 % of the TCR/ 
CD3 complexes are on the cell surface while 15 - 30 % are found inside the cell. The cycling time is 
about 100 min and a TCR is recycled approximately nine times in resting cells before it is degraded 
[181]. The screening of cell clones showed different expression patterns (data not shown). Some 
clones did not show good TCR expression but others were > 90 % TCR-positive after Dox induction. As 
also seen for other transgenes, the different expression patterns can be due to different copy 
numbers of the vector per cell and also depend on the integration site [164]. In case of TCR 
expression, other properties of the cell clone could have an influence like the CD3 availability, the 
protein folding and recycling machinery. 
The inducibility of the TCRs P14 and OT-I in the shown 58 cell clones was similar. A small TCR-positive 
population of 10- 20 % was visible with 0.01 µg/ml Dox which increased to around 60 % with 0.05 
µg/ml Dox. The 58+P14tet clone reached the maximal TCR expression with less Dox (0.1 µg/ml) than 
the 58+OT-Itet clone (0.5 µg/ml). With higher Dox concentrations the differences in TCR-positive cells 
were small if not absent. The expression levels, studied by the MFI, were the lowest with 0.05 µg/ml 
Dox. The increase of the expression level was different between the TCR chains which might also 
have been due to the properties of the used antibodies. Also, the cell number and the fitness of the 
cells could influence the inducibility and titration. Although the experimental set-up was 
standardized with usage of the same cell concentrations, variations were seen between experiments. 
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The functionality of the TCR-positive cells was partially titrated with different Dox concentrations, 
but also here variability was seen between experiments. IL-2 secretion of 58+P14tet cells increased 
until a concentration of 0.5 µg/ml Dox, although the maximal TCR expression was already reached 
with 0.1 µg/ml Dox. The functionality of the 58+OT-Itet cells was not further increased with more 
than 0.01 µg/ml Dox, but maximal TCR expression was shown to be obtained only with 0.5 µg/ml 
Dox. For the functionality assay only one experiment was shown, whereas for the TCR expression 
summarized results were shown which probably causes the discrepancies to the functionality data. 
In case of dual TCR T cells, it was possible to generate T cell clones which were over 90 % TCR-
positive after induction and kept at the same time the endogenous TCR expression. The induction 
properties with different Dox concentrations were similar to the Tet clones expressing a single TCR. 
With 0.05 µg/ml Dox around 70 % cells were TCR-positive. With higher concentrations the 
percentage was between 80- 90 % for the induced OT-I TCR and 85-98 % for the induced P14 TCR 
depending on the experiment. The expression level as determined by the MFI was lowest with 0.05 
µg/ml Dox and with higher Dox concentrations hardly distinguishable. The differences in expression 
level were more prominent for the TCRv chains than for the TCRv chains, probably due to the two-
step antibody staining which led to an enhancement of the signal and therefore, to an enhancement 
of MFI differences. 
Although the functionality of the induced TCR was seen in dual TCR T cells, the functionality of the 
endogenous TCR was lost or reduced even with a low concentration of 0.05 µg/ml Dox. The reason 
for this could be intrinsic factors of the 58 cell line or others as discussed below. With the here 
described Tet vector, it was not possible to analyze the correlation of TCR amount on the cell surface 
and function, since the expression level was only lower when only part of the cells expressed the TCR 
(with 0.05 µg/ml Dox). With higher Dox concentrations differences were too small or absent. 
Labrecque et al. [16] have genereated a transgenic mouse with a constitutively expressed OT-Iv5 
chain and a regulable OT-Iv2 chain by a Tet-off system. After treatment of mice with Tetracycline 
(Tc), blood was taken on day 4 and stained for CD8 or CD4 and OT-Iv2. A strong decrease of 
expression level was seen which further decreased to baseline level on day 14. With help of 
calibration beads TCR molecules were quantified. The transgenic mouse had 20000 TCR molecules on 
the cell surface without Tc. After treatment with different doses of Tc (5, 10 and 400 µg/ml) for two 
weeks, stably reduced expression levels of the OT-Iv chain was measured corresponding with 5000-
6000, 500-1000, 0-200 with stated Tc concentrations, respectively. The functionality of these 
different T cell populations was dose-dependent of Tc. 1100 TCR molecules were enough to trigger 
proliferation in 7 % (2 % background) of the cells after immunization with 0.1 µg peptide. With 450 
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TCR molecules they saw proliferation in 40 % of the cells after immunization with 100 µg peptide. In 
these transgenic mice, it was possible to determine the functionality of T cells dependent on the TCR 
density on the cell surface. Although the inducible TCR expression in the presented cell system 
conferred a lower TCR level with a low Dox concentration (0.05 µg/ml), this effect was concomitant 
with the lower percentage of cells expressing the TCR. 
5.1.2 TCR AMOUNT AND TCR PROPERTIES 
The avidity of T cells is reduced when the expression level of the transduced TCR is lower than in the 
original clone. This can be due to a less efficient expression of one or both TCR chains because of 
several reasons or mispairing with endogenous TCR chains. It was clearly shown that the T cell avidity 
is proportional to the expression level of the TCR [16,182]. 
That the surface expression level of the transgenic TCR depends on the endogenous TCR was shown 
by several investigators. Heemskerk et al. saw that a transgenic TCR is expressed on different levels 
depending on the T cell clone used for transduction [183]. This effect was independent of the 
expression system. As Sommermeyer et al. [106] showed, certain TCRs can replace endogenous TCRs 
on the cell surface. The P14 TCR could replace the endogenous TCR of B3Z cells as shown by TCRv 
chain staining and functional analysis. The expressional and functional loss was also the case when a 
human CMV-specific T cell clone was transduced with the melanoma-specific gp100-TCR. When using 
the same expression system by using retroviral transduction of human Jurkat76 cells, which do not 
harbor an endogenous TCR, it was also shown that the strong gp100 TCR replaces a weak renal cell 
carcinoma-specific TCR. On the other hand, two strong TCRs could be coexpressed as shown for a 
melan-A-specific T cell clone transduced with the gp100 TCR and also shown in double-transduced 
Jurkat76 cells. 
A study using combinations of 16 different TCR chains and 15 different TCR chains showed that 
each TCR chain combination had a different capacity to be expressed on the cell surface. This was 
analyzed in  T cells where mispairing with TCR and  chain could be excluded. Expression level was 
solely dependent on the competition for the CD3 complex with TCR and  chains. This analysis 
showed that the competence to associate with the CD3 complex was dependent on the variable 
region, only 5 amino acids in the CDR3 region could make a difference [183]. 
In the analyzed cell system the P14 and OT-I TCR could be coexpressed. The percentage of cells 
positive for the endogenous TCR was not or only slightly reduced (Figure 11) but the expression level 
as measured by MFI was reduced after TCR induction in both cell clones (Figure 12). The 
quantification of the TCR chains (Figure 13) revealed that the 58+OT-I+P14tet had less TCR molecules 
of the endogenous OT-I TCR on the cell surface (OT-Iv2: 1830 ± 480, OT-Iv5: 1910 ± 210 molecules) 
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than the 58+P14+OT-Itet of endogenous P14 TCRs (P14v2: 4360 ± 1080, P14v8: 3200 ± 400 
molecules). Normally, on primary mouse T cells 40000 TCR molecules are found [16]. The low 
amounts of TCRs seen here must be a property of 58 cells. In 58+OT-I+P14tet cells, the endogenous 
OT-I TCR was equally reduced in its TCR chains (OT-Iv2 by 49 %, OT-Iv5 by 57 %) whereas the 
transgenic P14 TCR was equally induced. In the second clone, the endogenous P14 TCR chains were 
reduced to different amounts, the P14v2 by 63 % and the P14v8 by 39 %, but stayed with more 
molecules on the cell surface as the induced OT-I TCR molecules. The different reduction of 
endogenous TCR chain molecules correlate with the measured FRET values. The endogenous OT-I 
TCR did not drop in its FRET efficiency after second TCR expression but the endogenous P14 TCR. 
Since the molecule amount of the P14v2 without Dox had a high standard deviation the calculated 
reduction of 63 % might not be correct. Nevertheless, in the FACS histogram of Figure 12 it was also 
seen that the P14v2 chain was strongly decreased in its MFI. Also, by the cell clones with only one 
inducible OT-I TCR chain it was apparent that the P14v2 chain was strongly decreased in its MFI 
when the OT-Iv2 chain was induced which again led to a drop of FRET efficiency of the P14 TCR. The 
replacement of P14v2 by the OT-Iv2 might be therefore the main reason that FRET efficiency of 
the P14 TCR decreased after induced OT-I TCR expression. 
There was a discrepancy between the measured TCR surface molecules by quantified TCR staining 
(Figure 13) and detected copy number of integrated vectors (Table 29). The 58+OT-I+P14tet cells 
showed less OT-I TCR surface expression but had a high copy number of 16 for the pLSN vector 
expressing the OT-I TCR. The 58+P14+OT-Itet cells had more P14 TCR surface expression but less 
integrated P14 TCR-pLSN vector (5). This might lead to the conclusion that the P14 TCR is easier 
expressed on the cell surface despite of less expressing integrated vectors as the OT-I TCR. 
Integration sites might have an influence on the vector expression, therefore it is not clear how many 
TCR molecules were really expressed and if, in the one case, just more TCR molecules came to the 
cell surface. But the lower copy number of the endogenous P14 TCR also would explain that the 
P14v2 chain was easily replaced by the OT-Iv2 chain, since the intracellular storage of TCR 
molecules was just less as for the endogenous OT-I TCR.  
The analysis of the functionality showed a loss or at least reduction of function of the endogenous 
TCRs in both cell clones. Although, by Labrecque et al. it was shown that 500-1000 TCR molecules are 
enough for T cell reactivity [16], in all analyzed cell clones the functionality of the endogenous TCRs 
was lost. The reduced TCR surface expression as measured by the MFI and the mispaired TCR dimers 
could explain this observation. But the observation is also restricted to the 58 cells and the kind of 
vectors used, since in primary OT-I cells the function was not lost when they were transduced with 
the P14 TCR, expressed by the strong retroviral MP71 vector. 
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5.1.3 TCR MISPAIRING 
In the clinical trial of Morgan et al. the detection of the transduced TCR in the patient’s blood by 
quantitative reverse-transcription PCR (26 %) did not correlate with the TCRv staining (8.1 %) and 
MART-1 tetramer staining (0.8 %) [85]. This discrepancy can be due to mispairing of transduced TCR 
chains with endogenous TCR chains. By Dossett et al. it was observed that P14 transgenic T cells 
transduced with a TCR specific for the gag antigen of Friend murine leukemia virus showed TCRv3 
expression on around 60 % of cells but TCRv12 on only 20 % cells depending on the transgene 
cassette used. These differences of cell surface expression hinted to a mispairing of the transferred 
TCRv3 chain with the endogenous P14v8 chain [95]. That TCR chain mispairing can indeed lead to 
autoreactivities was demonstrated by Bendle et al [123]. He transduced OT-I TCR, single OT-I TCR 
chains or other TCRs into C57BL/6 splenocytes and transferred them into recipient mice by 
employing a transfer protocol similar to human trials with total body irradiation and high-dose IL-2. 
Transduced cells induced GVHD by mispaired TCR dimers in this setting whereas transgenic OT-I 
splenocytes did not. For human TCRs the possible mispairing could be proven by van Loenen [124] by 
transducing T cell clones with TCRs and testing the transduced cells with autologous or allogeneic 
LCLs which elicited new reactivities. 
Also in nature T cells with mispaired TCRs occur. Due to failure of allelic exclusion it happens that T 
cells express a second TCR chain as seen for TCR in up to 10 % of peripheral T cells [184,185]. In 
animal models it was seen that these dual T cells are involved in alloreactivities [185] and might 
provide a link between viral and autoimmune diseases [186]. 
In the presented study, TCR mispairing was quantified by FRET. In the dual TCR T cell clones it was 
seen, that indeed mispairing occurred; to a lesser extend between the P14v2 chain and the OT-Iv5 
chain than between the OT-Iv2 chain with the P14v8 chain. Strikingly, the endogenous P14 TCR 
was reduced in its FRET efficiency when the OT-I TCR occurred on the cell surface which did not 
happen the other way around. This effect was mostly due to the displacement of the P14v2 chain 
by the OT-Iv2 chain, which was shown by analyzing cell clones with an endogenous P14 TCR and 
inducible single OT-I TCR chains. When the OT-Iv2 chain was induced the FRET efficiency of the P14 
TCR dropped vigorously, whereas it dropped only slightly when the OT-Iv5 chain was induced. This 
reduction of the endogenous TCR pairing was not seen for the OT-I TCR in 58+OT-I+P14tet cells. 
Probably, the available intracellular amount of the endogenous TCR plays a role since a higher copy 
number of 16 was measured for the endogenous OT-I TCR than only 5 of the endogenous P14 TCR. 
The copy number of the cell clone with one inducible OT-I chain were not determined but it cannot 
be excluded that this might influence the result. In conclusion, beside the provided protein amount 
also the intrinsic properties of the TCR chains determine the cell surface expression when competing 
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with other TCR chains. That the TCR chain determines its ability to associate with the CD3 complex 
was also shown by Heemskerk et al. [183] which in turn has an influence on the mispairing efficiency. 
In vivo Bendle et al. [123] saw a difference in GVHD induction between the usage of the OT-I TCR 
cassette with an IRES site linking the TCR chains and the OT-I TCR cassette with a 2A element linking 
the TCR chains and a second cysteine bridge. Also, in human TCRs it was shown that the second 
cysteine bridge has a benefit for the transgenic TCR-mediated functionality and surface expression 
[113]. In the presented work a second cysteine bridge was employed in the P14 TCR. The mispairing 
of the TCR chains could not be avoided and also not the reduction of the P14cys TCR FRET efficiency. 
Although, the reduction was different between the two analyzed cell clones. In cl. 7 the transgenic 
OT-I TCR was only inducible in 46 % of the cells, whereas in cl.9 in 90 % of the cells. The reduction of 
endogenous P14cys FRET efficiency was stronger in cl.9 than in cl.7. Here again, the copy number of 
integrated vectors could be a reason, since cl.7 had 11 P14 TCR vector copies whereas cl.9 had only 5. 
But more importantly, the second disulfide bond did not reduce the mispaired TCR formats. Also, the 
functionality loss of the endogenous TCRs could not be restored. Although in primary human 
lymphocytes it was shown that the second cysteine bridge improved the functionality of the 
transduced TCR [113]. When primary OT-I T cells were transduced with a P14 TCR with or without a 
second cysteine bridge, there was only a small difference seen in the FRET efficiencies for the P14 
TCR and no difference for the mispaired TCR dimer of P14v2 and OT-Iv5 chain. In conclusion, it can 
be that the there was no effect by the disulfide bond seen since only the combination of two TCRs 
were analyzed. The mentioned studies above were using polyclonal T cell populations. Therefore, 
analysis in wild-type cells was undertaken to determine the effect of the cysteine bridge in a 
polyclonal setting. Although a tendency of increasing FRET efficiencies between P14 TCR formats and 
for non-codon-optimized OT-I TCR formats with increasing optimization could be detected, these 
differences were not significant. The detection method by the FRET technology might not be 
sensitive enough. Differences might be better detectable with help of a sensitive in vivo model as 
used in the work of Bendle et al. [123]. 
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5.2 SAFETY ANALYSIS OF TCR-TRANSDUCED T CELLS 
The safety of gene therapy was questioned by trials where transduced HSCs were used as several 
patients in different trials treated with different -retroviral vectors and transgenes showed 
integration-related abnormal cell outgrowth (SCID, CGD, WAS). On the other side, trials treating ADA-
SCID in 30 patients worldwide since 2000 showed no adverse event so far, although developing T 
cells have a growth advantage in these patients [187,188]. As the rsik of gene-modified stem cells 
was shown, for T cells there has been no evidence so far. In human gene therapy trials using gene-
marked T cells malignancies were also not observed. The transfer of HSV-Tk transduced T cells for DLI 
to control GVHD was successful and safe [152,153,154,189]. Also the usage of the truncated NGF 
receptor (LNGFR) for gene marking studies with T cells in mice, rats and dogs and DLIs in humans 
were safe [155]. Also, there have been clinical studies involving HIV-infected patients which received 
gene-modifed T cells. Cells were transduced with a chimeric CD4 receptor fused to the signaling 
domain CD3 [190,191,192] or an HIV entry-inhibitory peptide [193] were transferred. Patients were 
followed up to one year and cells persisted. In none of the patients adverse events due to the T cell 
product were observed. 
The study of Newrzela et al. [156] showed that mature murine T cells do not transform even when 
transduced with known T cell oncogenes and transferred into lymphopenic RAG-1 mice. The chosen 
oncogenes LMO2 [194] and TrkA [195] are shown to be responsible for immature T cell leukemias 
and the oncogene Tcl-1 even for mature T cell leukemias in mice [196] and humans [197]. In another 
study [198], T cells transduced with a -retroviral vector expressing a chimeric T-Body, which was 
directed against the tumor-associated Lewis-Y antigen, were transferred into non-myeloablative 
irradiated mice which did not express the antigen. The T-Body consists of an extracellular single-
chain antibody and signaling regions of CD28 and CD3. Tumor incidence and types of tumors were 
comparable to a group without T cell transfer. None of the lymphomas arising were of donor T cell 
origin. The transferred T cells persisted with 1.9- 16.7 % of total spleen cells in most of the mice as 
measured upon death after around two years or earlier after tumor burden. The polyclonality of the 
transferred T cell population was confirmed by staining the TCRv repertoire, although two mice had 
an unusual high percentage of certain TCRv chains. Concluding these studies the researchers did not 
find malignancies derived from -retrovirally-transduced T cells. But in humans normally T cell 
leukemias and lymphomas arise in old age. It is difficult to extrapolate the life time of mice to 
humans, but for example showed a study with c-transduced HSC transfer into c-deficient mice that 
lymphomas already developed after 6-12 months [199] which took 3 years in humans [135] . Mice 
can develop many types of tumors in two years which occur only at old age in humans.  
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In vitro TCR-transduced primary T cell clones were shown to keep a stable phenotype and redirected 
functionality after 6 months in culture [200]. But, there is one study showing the possible 
transformation of T cells in vitro using the proto-oncogene LMO2 [157]. In the transformed T cell 
clone, the retroviral vector had integrated near the IL2RA and IL15RA genes. The up-regulation of 
these genes together with the transgenic LMO2 expression led to the transformation process 
although this T cell clone could not grow in vivo and was still IL-2-dependent. 
In the presented study no signs of malignancies due to the transfer of TCR-transduced T cells could 
be observed which goes in line with the studies mentioned above. Instead, the treatment with 
cyclophosphamide harbored a risk of toxicity. 
5.2.1 INFLUENCE OF PRECONDITIONING AND OF ENDOGENOUS T CELLS ON TRANSFERRED T 
CELLS 
Non-myeloablative treatment was used for a good T cell engraftment in recipient mice. The 
endogenous T cell pool was recovered after cyclophosphamide treatment of the mice in a short term 
view. The transfer of the high cell number probably influenced the T cell recovery due to competition 
for cytokines in the periphery. By day 200 after transfer, which corresponded to an age of around 10 
or 12 months of the recipient mice, the T cells (which derived from 5-6 months old donors) increased 
in percentage in the CD8 compartment. In the OT-I+P14 I group, the transferred T cells made up 60 % 
in the one unstimulated mouse on day 416, 44 ± 26 % in the gp33 tumor cell-stimulated group (two 
mice) on day 501, 31 ± 9 % in the gp33 peptide-stimulated group (three mice) and 39 % in the ova 
peptide-stimulated mouse on day 416. Similarly, in the OT-I+P14 II experiment in unstimulated mice 
28 ± 10 % and in tumor cell-stimulated mice 58 ± 18 % CD90.1-positive cells of CD8 T cells were found 
on day 365 after transfer. On day 450, transferred cells made up 28 ± 8 % of all CD8 T cells in the 
GFP-transduced T cell group. The increase of transferred T cells might be explained by the decreased 
T cell output of the thymus with age or also by late effects of cyclophosphamide treatment or the 
combination of both. The endogenous T cell repertoire declines with age and thymic involution, 
although the total number of T cells is maintained by homeostatic proliferation of peripheral memory 
T cells for some time [27,201]. In mice, the size of the thymus is already reduced by an age of 6 
weeks. Therefore, the recipient mice used in this work have already a diminished T cell output from 
the thymus. But until the age of 3 - 4 months, the murine thymus is still able to reconstitute the 
peripheral T cell pool after its ablation by chemotherapy or irradiation. In humans, it was shown that 
patients older than 30 years have a reduced thymic capacity for T cell recovery [27]. 
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The high cell number transferred into the mice might also have played a role. The endogenous T cell 
pool comprises 1-2 x 108 cells [201], transferred T cells made up 1/20 - 1/40 of the endogenous T cell 
pool upon transfer. 
Already in 1984, it was shown by Greenberg and Cheever [202] that cyclophosphamide treatment 
was beneficial for T cell transfer in the treatment of leukemia in a mouse model. Here, a high number 
of 2 x 107 antigen-activated T cells were transferred into sick mice pretreated with 180 mg/kg 
cyclophosphamide. Leukemic cells were cleared in 26 of 32 mice. The follow-up observation of 
treated mice showed that transferred T cells persisted and made up 5 % of spleen cells on day 60 and 
2 % on day 120. North et al. showed that tumor growth was delayed when mice were treated with 
160 mg/kg cyclophosphamide, but only slightly when tumor-bearing mice were irradiated. In 
combination with T cell transfer the positive effect could be even increased. In clinical trials the 
benefit of preconditioning on T cell transfer was already confirmed [80,119]. 
The toxicity seen in the OT-I+P14 I and OT-I+GFP experiment was due to the high concentration of 
cyclophosphamide (200 mg/kg) used. The concentration was chosen based on a publication stating 
this amount in combination with OT-I T cell transfer and peptide stimulation with poly (I:C) adjuvant 
[177]. This treatment led to an expansion of 22 % OT-I T cells in the peripheral blood of C57BL/6 
recipient mice on day 6. This approach seemed to be feasible for the experiments in this dissertation 
since a good stimulation and engraftment was required for the long-term observation of transferred 
cells in recipient mice. Salem and colleagues observed the mice only for a period of 21 days; 
therefore, they could not notice the toxicity occurring after day 50. In the second experiment, a 
lower dose of 100 mg/kg was chosen and 12 weeks old recipients were used. But also here, four mice 
probably died due to the cyclophosphamide. The lower dose of non-myeloablative treatment also led 
to an increase of transferred T cells in the CD8 T cell compartment of recipient mice. 
5.2.2 INFLUENCE OF STIMULATION ON TRANSFERRED T CELLS 
After adoptive transfer into patients, T cells encounter tumor antigens which should trigger T cell 
response and proliferation. In patients with recurring disease, T cells would be triggered several 
times. During proliferation mutations could be accumulated. Transferred T cells develop into 
memory T cells after transfer which have a moderate turnover of 1-2 division per month [203] or less 
independent on antigen encounter [204] whereas T cells responding to antigen divide several times 
per day [205,206]. The proliferative capacity is exhausted by the seventh decade in humans, which is 
due to telomere lengths and therefore the capacity to respond to antigens is reduced [27,201,207]. 
How often a T cell really divides during life time depends on subtype and surrounding conditions. 
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In this work, T cells were repetitively stimulated to provide mutations the opportunity to establish 
during cell division. In OT-I+P14 I mice, stimulation with gp33 tumor cells enriched the transferred T 
cells more than peptide stimulation, but the one unstimulated mouse also enriched the transferred T 
cells to a high amount. Tumor cell stimulation was a better choice than peptide stimulation with CpG 
ODN 1826 and IFA which probably induced activation induced cell death. The group of OT-I+P14 II 
mice, stimulated with gp33 tumor cells, had a higher percentage of transferred T cells than the 
unstimulated group at the end of the experiment. The differences between the unstimulated mice 
from OT-I+P14 I and II might be due to the different concentrations of cyclophosphamide used. Also, 
unstimulated mice showed that the increase of transferred T cells was not only due to the 
stimulation but also due to the preconditioning. 
The memory T cell pool for a certain antigen can increase in size overtime with secondary infection or 
heterologous boost stimulation [15,208]. This would go in line with the strong increase of cells in the 
tumor cell-stimulated group and to a lesser extend for the peptide-stimulated groups. In one study, it 
was shown that upon homologous boost stimulation (a recombinant virus expressing ova) T cells did 
not expand but upon heterologous boost (two different recombinant viruses expressing ova) [209] 
which was not the case using homologous Sendai virus reinfection [208]. In this presented work, 
homologous stimulation seemed to work since T cells proliferated upon second transfer and 
restimulation as shown by CFSE dilution. Nevertheless, the proliferative capacity is limited as older 
the T cells become. It was shown that T cell clones which arose two years after acute infection with 
Sendai virus in mice were mostly not as effective as young memory T cells against a second infection 
with Sendai virus [210]. In the mentioned study, a big cohort of 100 mice were observed for the 
occurrence of virus-specific T cell clones which was the case in most of the mice on day 780 as 
measured by virus-specific tetramer staining. These natural occurring T cell clones were not 
malignant. In the presented work 557 days after transfer of OT-I+P14 I or 365 days after transfer of 
OT-I+P14 II T cells did show proliferation when stimulated in secondary recipient. By others, it was 
also shown that nonspecifically activated and transduced T cells could respond to antigen 182 days 
after transfer [209] showing that at this time point the proliferative capacity is definitively not 
exhausted. 
The stimulation with peptides and adjuvant showed a stronger activation after first stimulation and a 
more dominant effector memory T cell phenotype after following stimulations, whereas the tumor 
cell-stimulated group contained transferred T cells of a more pronounced central memory T cell 
phenotype and down-regulation of CD62L was not as strong on peaks of responses. This is 
definitively due to the types of stimulations. Whereas in a model of Sendai virus infection, the central 
memory T cells dominated recall responses [208] effector memory T cells were more important in 
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another model with parainfluenza virus [211]. In adoptive transfer studies into macaques the central 
memory T cells showed a better performance in terms of persistence and functional response [212]. 
In the presented work, the tumor cell-stimulated group had the highest percentage of CD62L-positive 
transferred cells and the highest percentage of transferred cells over time. 
The vaccination with peptide in combination of CpG ODN and IFA was shown to be very effective in 
eliciting anti-tumor responses in mice [213] and triggering antigen-specific T cells in humans [214]. 
Long-term survival of transgenic T cells was seen five months after immunization [215]. Peptide and 
CpG ODN alone could also stimulate anti-viral response in mice [216]. Daily administration of 60 µg 
CpG ODN disturbed structure of lymphoid organs which led to a reduced primary humoral immune 
response and by day 20 liver necrosis and hemorrhagic ascites was observed [217]. Although the CpG 
ODN 1826 was not administered daily, it was given in total seven times over a period of more than 
one year. Indeed, mice which were killed at the end of the experiment had reduced liver size, spleen 
and lymph nodes. This might explain the lower level of transferred cells in the peptide-treated 
groups. 
5.2.3 VECTOR INTEGRATION PATTERNS IN T CELLS 
In studies with adoptive T cell transfer in mice, polyclonality of transduced T cells was confirmed by 
LM-PCR [156] or by TCR v repertoire staining [198]. In first case, at least oligoclonality to 
polyclonality was observed. Sequencing of integration sites revealed not more integrations near cell 
cycle genes and tumor-associated genes in TrkA-transduced cells than in GFP-transduced T cells, 
but near genes involved in signaling and chromatin folding and unfolding. In the second study, 
transferred T cells were stained for TCRv chains which showed polyclonality. Only in two mice, 
unusual high percentage were observed for two TCR chains [198]. In humans, gene-modified T cells 
were analyzed for integration sites of the retroviral vector by LAM-PCR. HSV-Tk-transduced T cells of 
two patients showed integration clusters within chromatin regions with epigenetic marks of active 
promoters and regulatory elements in a cell-specific fashion. No preferential survival of T cells with 
integrations in cell-specific gene categories was seen and clonal dominance of T cells was absent 
[154]. A similar integration profile was seen in a study comparing transduced T cells from ADA-SCID 
patients which received either transduced T cells [143] or transduced HSCs [144]. The retroviral 
vector used in both studies showed a different integration behavior in the two target cells. The 
epigenetic state and the expression profile of the target cell influenced the insertions. In T cells, 
integrations were seen near genes involved in the immune system and T cell function and in T cell 
DNase hypersensitive sites. Long-term, there was no vector-driven bias seen in transduced T cell 
populations in patients [218]. 
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In the presented experiment, LAM-PCR revealed polyclonality of the transferred T cells. Although 
stronger bands of integrations were observed for some time points, these disappeared again 
showing a dynamic behavior. Sequences of integrations sites were not analyzed yet, but will be in the 
future. 
In the study using T-Body transduced T cells, the transgene copy number was determined at the end 
of the experiment. Copy numbers were 4.2 x 103 to 5.9 x 105 per million cells. Interestingly, the 
higher copy numbers correlated with increasing age of mice. This pointed to a better survival of 
transduced cells with a higher copy number of the transgene [198]. In the presented work here, an 
end point analysis of copy number was not done, but will be included in the future 
In conclusion, in this work the transfer of TCR-transduced T cells in lymphodepleted mice showed 
long-term engraftment of transduced T cells which stayed polyclonal and functional over a period of 
one year and more. 
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6. OUTLOOK 
For TCR gene therapy some obstacles still have to be solved. The transgenic TCR expression must be 
strong enough to confer anti-tumor responses. This is achieved by an efficient expression vector and 
also by the chosen TCR molecule. As seen in this work, the chosen TCR can mediate mispairing with 
the endogenous TCR chains and that even a second disulfide bond does not necessarily prevent 
mispairing, although it is probably reduced in a polyclonal T cell population [113,123]. Therefore, 
other strategies have to be explored to further decrease the mispairing potential. One strategy which 
could be further analyzed is the usage of chimeric TCRs with the intracellular domain of CD3. FRET 
experiments showed that these TCR constructs only pair with its respective TCR chain and that the 
functionality of the endogenous TCR was not impaired while the transferred TCR gained function 
[116]. If such TCR constructs could confer a higher avidity remains to be analyzed. Another possibility 
would be the inversion of the constant region by mutating two residues which lead to a “hole-into-
knob”-configuration of the interface of c and c. These modified TCRs retain their avidity and TCR 
chains preferably pair with each other [108]. A similar approach is to minimally murinize the TCR 
constant regions [106,107]. Here, only few residues are mutated from human constant regions to 
murine ones. TCR construct show only slightly lower avidity than fully murinized TCRs and had a 
stronger association with the CD3 complex. Also, FRET efficiencies were higher for minimal murinized 
TCR than wt TCR [111]. The mispairing potential has to be analyzed not only for the TCR formats but 
also for the chosen TCR chains as it can be different from TCR to TCR. However, these strategies bear 
the risk to elicit immune responses as the transferred TCRs harbor mutations being foreign to the 
host. That indeed immune responses were seen in clinical trials was the case when murine TCRs 
specific for the human antigen p53 and gp100 were used. Antibodies directed against the variable 
regions of the murine TCRs were found in 23 % of the patients. The antibody detection did not 
correlate with persistence of transferred T cells and clinical outcome [219]. 
The ideal situation would be to have therapeutic T cells with only one TCR. This could be achieved by 
knocking down the endogenous TCR chains with small interference RNA vectors targeting the 
endogenous TCR chains [220,221]. Another possibility is the TCR transfer into HSCs and to 
differentiate these in vitro [222] or transfer them as a stem cell transplant [103,223,224]. The 
advantage would be that differentiated T cells only express the transgenic TCR. Therefore, mispairing 
problems would be avoided. But the potential risk of this technology would be insertional 
mutagenesis which was shown to occur in clinical trials with gene-modifed HSCs 
[135,136,138,142,150]. Another cell population which was tested for TCR gene transfer are  T cells. 
These cells were shown to be able to lyse tumor cells and leukemic cells and their TCR chains cannot 
form mixed dimers with TCR and  chains [225]. TCR and  transfer into these cells showed anti-
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leukemic reactivity in vitro [226] and proliferative capacity, persistence and recall responsiveness in 
vivo [227]. Disadvantage is that these cells are not available in a high number, as they only make up 
1-10 % of the peripheral T lymphocytes. Also, their functionality in vivo has to be further tested as it 
is still under debate. A reduction of possible mispairing combinations could be achieved when using T 
cell clones. This is an approach which was originally developed to confer a better survival of TCR-
transduced T cells in vivo due to activation of the endogenous TCR specific for viral antigens of latent 
viruses [228,229]. Although one can be sure that the endogenous TCR is not self-reactive, even here 
it can be that TCR chains mispair with each other which can lead to neoreactivites [124]. 
The safety of TCR gene therapy not only depends on the proper pairing of TCR chains and recognition 
of only malignant tissue, it also depends on the safety of the gene transfer system. In this work, a -
retroviral vector was used to transduce T cells which was shown to be safe so far. Nevertheless, -
retroviral vectors show an integration pattern which is not as safe as of lentiviral vectors [230]. The 
safety can be even increased by using SIN vectors [231]. The ideal situation would be a targeted 
integration. Eventually, this might be achievable with zinc finger nucleases. These are engineered 
sequence-specific endonucleases which cleave at a chosen target site. During repair of the double-
strand break gene insertion or targeted mutation can be done [232]. For TCR gene therapy the usage 
of zinc finger nucleases is under investigation. Another nonviral transfer technology is usage of DNA 
transposons. The Sleeping Beauty transposon system was shown to have a close-to-random insertion 
site pattern. DNA transposons function by a ‘cut and paste’ mechanism and were engineered for 
gene transfer, where the transgene is cut out of a donor plasmid and pasted into the cell DNA by the 
transposase enzyme which is provided on a separate plasmid [233]. The Sleeping Beauty transfer 
system was already employed for two TCRs which led to 16 % p53 pentamer and 33 % MART-1 
tetramer staining in PBLs [234]. 
A last option to increase the safety of TCR gene therapy is the usage of either additional selection 
markers like HSV-Tk, CD20 or apoptosis-inducing fusion genes or cytotoxic tetramers. But these 
“suicide genes” or agents harbor great disadvantages. For HSV-Tk or apoptosis-inducing caspase 9 it 
was shown that the expression was down-regulated [235,236] or the HSV-Tk transgene was even lost 
[235]. For HSV-Tk it was also shown that its solely expression was not enough to provide tumor 
rejection [237]. Also, the susceptibility to the suicide effect was different between tumor cells with 
HSV-Tk [238]. Elimination of T cells expressing transgenic CD20 with the specific antibody Rituximab 
depended on the expression level [239]. Another disadvantage of some of these strategies is the 
immunogenicity (HSV-Tk, Cytosine deaminase) and cytotoxic side effects for cytotoxic tetramers 
[240]. An intrinsic safe guard for TCR gene therapy was developed by the application of a small tag 
(Myc tag) added to the N-terminus of the TCRv chain. Transduced T cells could be eliminated with a 
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depleting anti-Myc tag antibody in two mouse models [123,241]. A drawback of this technology is 
the missing GMP-approved anti-Myc-antibody and that the additional Myc tag interferes with the 
function of some TCRs. Also, the tag would only be included in one of the TCR chain. Therefore, 
transduced T cells which down regulate the expression of this TCR chain would not be eliminated. 
Many investigations are on the way for a safe future TCR gene therapy. 
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Abbreviations 
ABC Antibody-binding capacity 
ADA-PEG Polyethylene glycol-modified bovine ADA 
ADA-SCID Adenosine deaminase-deficient SCID 
APC Antigen-presenting cell 
BAE Background antibody equivalent 
BM Bone marrow 
CEA Carcinoembryonic antigen 
CFSE Carboxyfluorescein diacetate, succinimidyl ester 
CDR Complementary determining region 
CGD Chronic granulomatous disease 
CMJ Corticomedullary junction 
CMV Cytomegalovirus 
CTL Cytotoxic T lymphocytes 
DC Dendritic cells 
dH2O Destilled water 
DP double-positive 
dNTPs Deoxynucleotides 
Dox Doxycycline 
EBV Epstein-Barr Virus 
ELISA Enzyme-linked immune-sorbent assay 
FACS Fluorescence activated cell sorting 
FCS Fetal calf serum 
FRET Fluorescence resonance energy transfer 
GVHD Graft-versus-host disease 
Hepes N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic-acid 
HIV Human immunodeficiency virus 
HPV Human papilloma virus 
HSC Hematopoietic stem cells 
HSV-Tk Herpes simplex thymidine kinase 
HTLV Human T cell lymphotropic virus 
H Hour/ hours 
IFA Freund’s adjuvant, incomplete  
IFN Interferon 
Ig Immunoglobulin 
IL Interleukine 
IRES Internal ribosomal entry site 
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ITAM Immunoreceptor tyrosine-based activation motif 
LAM Linear amplification-mediated 
LCL EBV-transformed lymphoblastoid cell line 
LN Lymphnodes 
LTR Long terminal repeat 
MHC Major histocompatibility complexes 
MFI Mean fluorescence intensity 
MLV Murine leukemia virus 
MOI Multiplicity of infection 
MPSV Myeloproliferative sarcoma virus 
MSCV Murine stem cell virus 
NADPH Nicotinamide dinucleotide phosphate 
Nt Nucleotides 
PBS Phosphate-buffered salines 
Pen/Strep Penicillin/ streptomycin 
Pgk Phosphoglycerate kinase 
PMT Photomultiplier tube 
PCR Polymerase chain reaction 
PMA Phorbol-12-myristate-13-acetate 
PRE Posttranscriptional regulatory element 
PTLD Post-transplant lymphoproliferative disease 
RAG Recombination-activating gene 
RN RetroNectin 
RT Room temperature 
SMAC Supramolecular adhesion complex 
SCID Severe combined immunodeficiency disease 
SCZ Subcapsular zone 
SIN Self-inactivating 
SP Single-positive 
SV Simian virus 
TAA Tumor-associated antigen 
T-ALL T cell acute lymphoblastic leukemia 
Tc Tetracycline 
TCR T cell receptor 
TEC Thymic epithelial cortical cells 
TEM Thymic medullary epithelilal cells 
TES Thymic subcapsular cells 
Tet Tetracycline-regulated 
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TetR Tet repressor protein 
tetO tet operator sequence 
TILs Tumor-infiltrating lymphocytes 
TNF Tumor necrosis factor 
TRE Tetracycline-responsive element 
tTA Tetracycline-controlled transactivator 
rTetR Reverse Tet repressor 
UV Ultraviolet light 
c gamma chain 
WAS/WASP Wiskott-Aldrich syndrome/ protein 
w/o Without 
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